<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Blood pressure‐lowering treatment for preventing recurrent stroke, major vascular events, and dementia in patients with a history of stroke or transient ischaemic attack - Zonneveld, TP - 2018 | Cochrane Library</title> <meta content="Blood pressure‐lowering treatment for preventing recurrent stroke, major vascular events, and dementia in patients with a history of stroke or transient ischaemic attack - Zonneveld, TP - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007858.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Blood pressure‐lowering treatment for preventing recurrent stroke, major vascular events, and dementia in patients with a history of stroke or transient ischaemic attack - Zonneveld, TP - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007858.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007858.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Blood pressure‐lowering treatment for preventing recurrent stroke, major vascular events, and dementia in patients with a history of stroke or transient ischaemic attack" name="citation_title"/> <meta content="Thomas P Zonneveld" name="citation_author"/> <meta content="Amsterdam UMC, University of Amsterdam" name="citation_author_institution"/> <meta content="t.p.zonneveld@amc.uva.nl" name="citation_author_email"/> <meta content="Edo Richard" name="citation_author"/> <meta content="Mervyn DI Vergouwen" name="citation_author"/> <meta content="University Medical Center Utrecht" name="citation_author_institution"/> <meta content="Paul J Nederkoorn" name="citation_author"/> <meta content="Amsterdam UMC, University of Amsterdam" name="citation_author_institution"/> <meta content="Rob J de Haan" name="citation_author"/> <meta content="Amsterdam UMC, University of Amsterdam" name="citation_author_institution"/> <meta content="Yvo BWEM Roos" name="citation_author"/> <meta content="Amsterdam UMC, University of Amsterdam" name="citation_author_institution"/> <meta content="Nyika D Kruyt" name="citation_author"/> <meta content="Leiden University Medical Center" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD007858.pub2" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/07/19" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007858.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007858.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007858.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Secondary Prevention; Angiotensin‐Converting Enzyme Inhibitors [therapeutic use]; Antihypertensive Agents [*therapeutic use]; Blood Pressure [drug effects]; Cardiovascular Diseases [prevention &amp; control]; Cause of Death; Dementia, Vascular [*prevention &amp; control]; Diuretics [therapeutic use]; Hypertension [complications, *drug therapy]; Ischemic Attack, Transient [*prevention &amp; control]; Primary Prevention; Randomized Controlled Trials as Topic; Recurrence; Stroke [etiology, *prevention &amp; control]; Systole; Time Factors" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007858.pub2&amp;doi=10.1002/14651858.CD007858.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007858.pub2&amp;doi=10.1002/14651858.CD007858.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007858.pub2&amp;doi=10.1002/14651858.CD007858.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007858.pub2&amp;doi=10.1002/14651858.CD007858.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007858.pub2&amp;doi=10.1002/14651858.CD007858.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007858.pub2&amp;doi=10.1002/14651858.CD007858.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007858.pub2&amp;doi=10.1002/14651858.CD007858.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007858.pub2&amp;doi=10.1002/14651858.CD007858.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007858.pub2&amp;doi=10.1002/14651858.CD007858.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007858.pub2&amp;doi=10.1002/14651858.CD007858.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007858.pub2&amp;doi=10.1002/14651858.CD007858.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007858.pub2&amp;doi=10.1002/14651858.CD007858.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007858.pub2&amp;doi=10.1002/14651858.CD007858.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007858.pub2&amp;doi=10.1002/14651858.CD007858.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007858.pub2&amp;doi=10.1002/14651858.CD007858.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007858.pub2&amp;doi=10.1002/14651858.CD007858.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007858.pub2&amp;doi=10.1002/14651858.CD007858.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007858.pub2&amp;doi=10.1002/14651858.CD007858.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007858.pub2&amp;doi=10.1002/14651858.CD007858.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007858.pub2&amp;doi=10.1002/14651858.CD007858.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007858.pub2&amp;doi=10.1002/14651858.CD007858.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007858.pub2&amp;doi=10.1002/14651858.CD007858.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007858.pub2&amp;doi=10.1002/14651858.CD007858.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="cdmLYOAV";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007858\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007858\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007858\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007858\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","ru","ms","pl","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007858.pub2",title:"Blood pressure\\u2010lowering treatment for preventing recurrent stroke, major vascular events, and dementia in patients with a history of stroke or transient ischaemic attack",firstPublishedDate:"Jul 19, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Stroke Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=cdmLYOAV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007858.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007858.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007858.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007858.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007858.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007858.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007858.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007858.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007858.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007858.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7511 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007858.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007858.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007858.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007858.pub2/full#CD007858-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007858.pub2/full#CD007858-sec-0108"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007858.pub2/full#CD007858-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007858.pub2/full#CD007858-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007858.pub2/full#CD007858-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007858.pub2/full#CD007858-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007858.pub2/full#CD007858-sec-0060"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007858.pub2/full#CD007858-sec-0100"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007858.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007858.pub2/appendices#CD007858-sec-0113"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007858.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007858.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/table_n/CD007858StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/table_n/CD007858StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007858.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007858.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007858.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007858.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007858.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007858.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Blood pressure‐lowering treatment for preventing recurrent stroke, major vascular events, and dementia in patients with a history of stroke or transient ischaemic attack </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007858.pub2/information#CD007858-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Thomas P Zonneveld</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007858.pub2/information#CD007858-cr-0003">Edo Richard</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007858.pub2/information#CD007858-cr-0004">Mervyn DI Vergouwen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007858.pub2/information#CD007858-cr-0005">Paul J Nederkoorn</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007858.pub2/information#CD007858-cr-0006">Rob J de Haan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007858.pub2/information#CD007858-cr-0007">Yvo BWEM Roos</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007858.pub2/information#CD007858-cr-0008">Nyika D Kruyt</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/information/en#CD007858-sec-0120">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 19 July 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007858.pub2">https://doi.org/10.1002/14651858.CD007858.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007858-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007858-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD007858-abs-0002">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD007858-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007858-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007858-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007858-abs-0001" lang="en"> <section id="CD007858-sec-0001"> <h3 class="title" id="CD007858-sec-0001">Background</h3> <p>Stroke is an important cause of death and disability worldwide. Since high blood pressure is an important risk factor for stroke and stroke recurrence, drugs that lower blood pressure might play an important role in secondary stroke prevention. </p> </section> <section id="CD007858-sec-0002"> <h3 class="title" id="CD007858-sec-0002">Objectives</h3> <p>To investigate whether blood pressure‐lowering drugs (BPLDs) started at least 48 hours after the index event are effective for the prevention of recurrent stroke, major vascular events, and dementia in people with stroke or transient ischaemic attack (TIA). Secondary objectives were to identify subgroups of people in which BPLDs are effective, and to investigate the optimum systolic blood pressure target after stroke or TIA for preventing recurrent stroke, major vascular events, and dementia. </p> </section> <section id="CD007858-sec-0003"> <h3 class="title" id="CD007858-sec-0003">Search methods</h3> <p>In August 2017, we searched the Trials Registers of the Cochrane Stroke Group and the Cochrane Hypertension Group, the Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 8), MEDLINE Ovid (1946 to August 2017), Embase Ovid (1974 to August 2017), ClinicalTrials.gov, the ISRCTN Registry, Stroke Trials Registry, Trials Central, and the World Health Organization (WHO) International Clinical Trials Registry Platform Portal. </p> </section> <section id="CD007858-sec-0004"> <h3 class="title" id="CD007858-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) of BPLDs started at least 48 hours after stroke or TIA. </p> </section> <section id="CD007858-sec-0005"> <h3 class="title" id="CD007858-sec-0005">Data collection and analysis</h3> <p>Two review authors independently screened all titles and abstracts, selected eligible trials, extracted the data, assessed risk of bias, and used GRADE to assess the quality of the evidence. If necessary, we contacted the principal investigators or corresponding authors for additional data. </p> </section> <section id="CD007858-sec-0006"> <h3 class="title" id="CD007858-sec-0006">Main results</h3> <p>We included 11 studies involving a total of 38,742 participants: eight studies compared BPLDs versus placebo or no treatment (35,110 participants), and three studies compared different systolic blood pressure targets (3632 participants). The risk of bias varied greatly between included studies. The pooled risk ratio (RR) of BPLDs for recurrent stroke was 0.81 (95% confidence interval (CI) 0.70 to 0.93; 8 RCTs; 35,110 participants; moderate‐quality evidence), for major vascular event 0.90 (95% CI 0.78 to 1.04; 4 RCTs; 28,630 participants; high‐quality evidence), and for dementia 0.88 (95% CI 0.73 to 1.06; 2 RCTs; 6671 participants; high‐quality evidence). We mainly observed a reduced risk of recurrent stroke in the subgroup of participants using an angiotensin‐converting enzyme (ACE) inhibitor or a diuretic (I<sup>2</sup> statistic for subgroup differences 72.1%; P = 0.006). The pooled RR of intensive blood pressure‐lowering for recurrent stroke was 0.80 (95% CI 0.63 to 1.00), and for major vascular event 0.58 (95% CI 0.23 to 1.46). </p> </section> <section id="CD007858-sec-0007"> <h3 class="title" id="CD007858-sec-0007">Authors' conclusions</h3> <p>Our results support the use of BPLDs in people with stroke or TIA for reducing the risk of recurrent stroke. Current evidence is primarily derived from trials studying an ACE inhibitor or a diuretic. No definite conclusions can be drawn from current evidence regarding an optimal systolic blood pressure target after stroke or TIA. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007858-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007858-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD007858-abs-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD007858-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007858-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD007858-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD007858-abs-0010">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD007858-abs-0008">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007858-abs-0007">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007858-abs-0005" lang="en"> <h3>Blood pressure drugs for preventing stroke and cardiovascular diseases in patients with a stroke or transient ischaemic attack (TIA) </h3> <p><b>Questions</b> </p> <p>Do blood pressure drugs prevent stroke, other blood vessel diseases, and dementia, in people with a stroke or transient ischaemic attack (TIA)? What blood pressure target is best for preventing stroke, other blood vessel diseases, and dementia, in people with a stroke or TIA? </p> <p><b>Background</b> </p> <p>Stroke, due to blocked or bleeding blood vessels in the brain affects about 14 million people worldwide each year. Stroke survivors are at increased risk of recurrent stroke, other blood vessel diseases, and dementia. High blood pressure is an important risk factor that can increase this risk. Blood pressure‐lowering drugs are known to prevent first ever stroke. However, in stroke survivors lowering the blood pressure too far (using blood pressure drugs) may be harmful especially early after the stroke. Therefore, we reviewed trials that tested blood pressure‐lowering drugs started at least 48 hours after the stroke or TIA. </p> <p><b>Study characteristics</b>: this review is up‐to‐date to August 2017. We included 11 trials involving 38,742 participants: eight trials assessed the effect of blood pressure drugs, and three trials compared different blood pressure targets. Ten studies were hospital‐based and one trial was performed in a general practitioner setting. Not all trials contributed information to all outcomes. </p> <p><b>Key results</b>: blood pressure drugs lowered the risk of recurrent stroke in patients with a stroke or TIA, whereas there is insufficient evidence to conclude whether they reduce the risk of other blood vessel diseases and dementia. There is also insufficient evidence to conclude which blood pressure target is best for patients with a stroke or TIA. </p> <p><b>Quality of the evidence</b>: overall, the quality of the trials in this review was moderate. However, we found similar results in an analysis using only high‐quality trials. More research is needed to investigate whether blood pressure drugs also prevent dementia, and what blood pressure targets are best for patients with a stroke or TIA. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007858-sec-0108" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007858-sec-0108">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007858-sec-0166">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007858-sec-0108"></div> <h3 class="title" id="CD007858-sec-0109">Implications for practice</h3> <section id="CD007858-sec-0109"> <p>Our results support the use of blood pressure‐lowering drugs (BPLDs) in secondary prevention after transient ischaemic attack (TIA) or stroke. Current evidence is primarily derived from trials of treatment with an angiotensin‐converting enzyme (ACE) inhibitor or diuretic. BPLDs appeared to be most effective in people with high baseline blood pressure (&gt; 140 mmHg); however, differences between these subgroups were not statistically significant. </p> <p>Only limited data comparing different systolic blood pressure targets were available. Therefore, no conclusions can be drawn from current evidence regarding an optimal systolic blood pressure target after TIA or stroke. </p> </section> <h3 class="title" id="CD007858-sec-0110">Implications for research</h3> <section id="CD007858-sec-0110"> <p>An individual participant data meta‐analysis could further identify specific subgroups of people who are likely to benefit from BPLDs after TIA or stroke. We recommend that future studies assess whether BPLDs lower the risk of dementia in TIA and stroke patients. </p> <p>Additional large randomised controlled trials (RCTs) are needed to investigate the optimal blood pressure target after TIA or stroke. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD007858-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD007858-sec-0029"></div> <div class="table" id="CD007858-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Blood pressure‐lowering drugs (BPLDs) compared to placebo or no treatment for preventing recurrent stroke, major vascular events, and dementia in patients with a history of TIA or stroke</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Blood pressure‐lowering drugs (BPLDs) compared to placebo or no treatment for preventing recurrent stroke, major vascular events, and dementia in patients with a history of TIA or stroke</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with a history of TIA or stroke </p> <p><b>Settings:</b> in hospital or community </p> <p><b>Intervention:</b> BPLDs </p> <p><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)<br/> Follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo or no treatment</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with BPLDs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrent stroke of any type</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>35,110<br/> (8 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.81<br/> (0.70 to 0.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 fewer per 1000<br/> (30 fewer to 7 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Time to recurrent stroke</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>26,889<br/> (3 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.82<br/> (0.65 to 1.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not available</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not available</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major vascular event (composite of non‐fatal stroke, non‐fatal myocardial infarction, or death from any vascular cause) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>28,630<br/> (4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.90<br/> (0.78 to 1.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>151 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 fewer per 1000<br/> (33 fewer to 6 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Myocardial infarction</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>34,747<br/> (6 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.90<br/> (0.72 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 fewer per 1000<br/> (6 fewer to 2 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Vascular death</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>34,747<br/> (6 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.85<br/> (0.76 to 0.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47 per 1.000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 fewer per 1000<br/> (11 fewer to 2 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Death by any cause</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>35,110<br/> (8 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.98<br/> (0.91 to 1.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 fewer per 1000<br/> (7 fewer to 4 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Dementia</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>6671<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.88<br/> (0.73 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 fewer per 1000<br/> (18 fewer to 4 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>BPLDs</b> : blood pressure‐lowering drugs; <b>CI:</b> confidence interval; <b>HR</b> : hazard ratio; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>We downgraded the quality of evidence for the outcomes 'recurrent stroke of any type', and 'death by any cause' because multiple studies with a high or unclear risk of bias were included for these outcomes. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007858-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007858-sec-0030">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007858-sec-0128">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD007858-sec-0030"></div> <section id="CD007858-sec-0031"> <h3 class="title" id="CD007858-sec-0031">Description of the condition</h3> <p>Stroke is the second most common cause of death and the second leading cause of disability‐adjusted life‐years (DALYs) lost worldwide (<a href="./references#CD007858-bbs2-0021" title="GBD 2016 DALYs and HALE Collaborators. Global, regional, and national disability‐adjusted life‐years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990‐2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet2017;390(10100):1260‐344. ">GBD 2016</a>). Despite improved prevention and management of stroke in high‐income countries, the numbers of worldwide incident strokes, prevalent stroke survivors, DALYs lost due to stroke, and stroke‐related deaths are still increasing. In 2016, an estimated 13.7 million incident strokes and 5.5 million stroke‐related deaths occurred, and 116 million DALYs were lost due to stroke (<a href="./references#CD007858-bbs2-0021" title="GBD 2016 DALYs and HALE Collaborators. Global, regional, and national disability‐adjusted life‐years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990‐2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet2017;390(10100):1260‐344. ">GBD 2016</a>). Stroke patients are at high risk of stroke recurrence, with cumulative risks increasing from 3% at 30 days to 40% at 10 years after their first stroke (<a href="./references#CD007858-bbs2-0028" title="MohanKM , WolfeCDA , RuddAG , HeuschmannPU , Kolominsky‐RabasPL , GrieveAP . Risk and cumulative risk of stroke recurrence: a systematic review and meta‐analysis. Stroke2011;42(5):1489‐94. ">Mohan 2011</a>). Patients with a transient ischaemic attack (TIA) are also at high risk for stroke recurrence, with reviews reporting a cumulative stroke risk of 3% at 30 days (<a href="./references#CD007858-bbs2-0034" title="VallsJ , Peiro‐ChamarroM , CambrayS , Molina‐SeguinJ , BenabdelhakI , PurroyF . A current estimation of the early risk of stroke after transient ischemic attack: a systematic review and meta‐analysis of recent intervention studies. Cerebrovascular Diseases2016;43:90‐8. ">Valls 2016</a>), and 18% at 10 years (<a href="./references#CD007858-bbs2-0035" title="vanWijkI , KappelleLJ , vanGijnJ , KoudstaalPJ , FrankeCL , VermeulenM , et al. Long‐term survival and vascular event risk after transient ischaemic attack or minor ischaemic stroke: a cohort study. Lancet2005;365:2098‐104. ">van Wijk 2005</a>). In addition, TIA patients have a cumulative 10‐year mortality risk of 34% and a cumulative 10‐year risk of major vascular event of 36% (<a href="./references#CD007858-bbs2-0035" title="vanWijkI , KappelleLJ , vanGijnJ , KoudstaalPJ , FrankeCL , VermeulenM , et al. Long‐term survival and vascular event risk after transient ischaemic attack or minor ischaemic stroke: a cohort study. Lancet2005;365:2098‐104. ">van Wijk 2005</a>). </p> </section> <section id="CD007858-sec-0032"> <h3 class="title" id="CD007858-sec-0032">Description of the intervention</h3> <p>Elevated blood pressure is a well‐known and modifiable risk factor for ischaemic and haemorrhagic stroke, as well as for myocardial infarction, major vascular events, and dementia (<a href="./references#CD007858-bbs2-0026" title="LewingtonS , ClarkeR , QizilbashN , PetoR , CollinsR , Prospective Studies Collaboration. Age‐specific relevance of usual blood pressure to vascular mortality: a meta‐analysis of individual data for one million adults in 61 prospective studies. Lancet2002;360:1903‐13. ">Lewington 2002</a>; <a href="./references#CD007858-bbs2-0030" title="QiuC , WinbladB , FratiglioniL . The age‐dependent relation of blood pressure to cognitive function and dementia. Lancet Neurology2005;4:487‐99. ">Qiu 2005</a>). There is overwhelming evidence that treatment with blood pressure‐lowering drugs (BPLDs) is effective for the primary prevention of strokes and major vascular events in patients with elevated blood pressure (<a href="./references#CD007858-bbs2-0018" title="TurnbullF , Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood‐pressure‐lowering regimens on major cardiovascular events results of prospectively‐designed overviews of randomised trials. Lancet2003;362(9395):1527‐35. ">BPLTTC 2003</a>; <a href="./references#CD007858-bbs2-0024" title="LacklandDT , RoccellaEJ , DeutschAF , FornageM , GeorgeMG , HowardG , et al. Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association. Stroke2014;45(1):315‐53. ">Lackland 2014</a>). However, there is still considerable debate on the effectiveness of BPLDs in secondary prevention of stroke (<a href="./references#CD007858-bbs2-0020" title="FeldsteinCA . Lowering blood pressure to prevent stroke recurrence: a systematic review of long‐term randomized trials. Journal of the American Society of Hypertension2014;8(7):503‐13. ">Feldstein 2014</a>). One reason why the effect of BPLDs after a first stroke is doubted, is the possible existence of a J‐ or U‐shaped curve representing the association between blood pressure levels and recurrent stroke (<a href="./references#CD007858-bbs2-0023" title="IrieK , YamaguchiT , MinematsuK , OmaeT . The J‐curve phenomenon in stroke recurrence. Stroke1993;24:1844‐9. ">Irie 1993</a>). If such an association indeed exists, lowering blood pressure below certain thresholds could increase the risk of recurrent stroke. Furthermore, there are concerns about a harmful decrease in cerebral perfusion as a result of decreased or disrupted autoregulation in patients with a history of stroke, especially in elderly patients (<a href="./references#CD007858-bbs2-0017" title="BirnsJ , MarkusH , KalraL . Blood pressure reduction for vascular risk: is there a price to be paid?. Stroke2005;36:1308‐13. ">Birns 2005</a>), which might be associated with an increased risk of dementia. </p> </section> <section id="CD007858-sec-0033"> <h3 class="title" id="CD007858-sec-0033">How the intervention might work</h3> <p>All BPLDs reduce blood pressure, which in turn decreases endothelial dysfunction and thereby the risk of atherosclerosis and small vessel disease. In addition, different BPLD classes have different sites and mechanisms of action, and therefore class‐specific effects. </p> </section> <section id="CD007858-sec-0034"> <h3 class="title" id="CD007858-sec-0034">Why it is important to do this review</h3> <p>Patients with a TIA or stroke are at risk for recurrence, major vascular events, and dementia. High blood pressure is a known and modifiable risk factor for these events. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007858-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007858-sec-0035">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007858-sec-0133">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007858-sec-0035"></div> <p>To investigate whether blood pressure‐lowering drugs (BPLDs) started at least 48 hours after the index event are effective for the prevention of recurrent stroke, major vascular events, and dementia in people with stroke or transient ischaemic attack (TIA). Secondary objectives were to identify subgroups of people in which BPLDs are effective, and to investigate the optimum systolic blood pressure target after stroke or TIA for preventing recurrent stroke, major vascular events, and dementia. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007858-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007858-sec-0036">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007858-sec-0134">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007858-sec-0036"></div> <section id="CD007858-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007858-sec-0038"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) only. We did not limit trials by any concomitant disease, baseline cardiovascular risk, or language. The effect must be estimated either in the main analysis or in a subgroup analysis. The effect must be estimated in an intention‐to‐treat analysis. We did not use individual participant data. </p> </section> <section id="CD007858-sec-0039"> <h4 class="title">Types of participants</h4> <p>Adult patients with an ischaemic stroke, haemorrhagic stroke or TIA, regardless of presence of elevated blood pressure. We defined haemorrhagic stroke as intracerebral haemorrhage, thus excluding subarachnoid haemorrhage. </p> </section> <section id="CD007858-sec-0040"> <h4 class="title">Types of interventions</h4> <p>We included trials comparing BPLDs (regardless of type, dosage or administration route) versus placebo or no treatment. We also included trials comparing intensive blood pressure lowering (defined as a blood pressure target &lt; 130/85 mmHg) with standard blood pressure lowering (defined as a blood pressure target &lt; 140 to 160/90 to 100 mmHg). The intervention was started at least 48 hours after the index event. We did not define a maximum time period for treatment initiation. We included trials with a factorial design if the investigators accounted for a possible interaction between the different interventions. </p> </section> <section id="CD007858-sec-0041"> <h4 class="title">Types of outcome measures</h4> <p>We included trials if they reported any of our outcome measures. All outcome measures are expressed as risk ratios (RRs), except for the secondary outcome measure 'time to recurrent stroke', which is time‐to‐event data. We only took into account composite endpoints (major vascular event and any stroke or death) if they were reported identically. </p> <section id="CD007858-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD007858-list-0001"> <li> <p>Recurrent stroke of any type (fatal and non‐fatal).</p> </li> </ul> </p> </section> <section id="CD007858-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD007858-list-0002"> <li> <p>Time to recurrent stroke</p> </li> <li> <p>Major vascular event (composite of non‐fatal stroke, non‐fatal myocardial infarction, or death from any vascular cause) </p> </li> <li> <p>Myocardial infarction</p> </li> <li> <p>Vascular death</p> </li> <li> <p>Death by any cause</p> </li> <li> <p>Dementia</p> </li> <li> <p>Ischaemic stroke</p> </li> <li> <p>Haemorrhagic stroke</p> </li> </ul> </p> </section> </section> </section> <section id="CD007858-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <p>See the 'Specialized register' section in the <a href="http://mrw.interscience.wiley.com/cochrane/clabout/articles/STROKE/frame.html" target="_blank">Cochrane Stroke Group</a> module. We did not impose any language restrictions and we arranged for the translation of articles where necessary. </p> <section id="CD007858-sec-0045"> <h4 class="title">Electronic searches</h4> <p>On 29 August 2017, we searched the Trials Registers of the Cochrane Stroke Group, the Cochrane Hypertension Group, the Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 8) in the Cochrane Library (<a href="./appendices#CD007858-sec-0114">Appendix 1</a>), MEDLINE Ovid (from 1946 to 29 August 2017) (<a href="./appendices#CD007858-sec-0115">Appendix 2</a>), and Embase Ovid (from 1974 to 29 August 2017) (<a href="./appendices#CD007858-sec-0116">Appendix 3</a>). </p> <p>We developed the MEDLINE search strategy with the help of the Cochrane Stroke Group Information Specialists Brenda Thomas and Joshua Cheyne (<a href="./appendices#CD007858-sec-0115">Appendix 2</a>), and they adapted it for the other databases. </p> <p>In August 2017, we searched for ongoing and unpublished trials in ClinicalTrials.gov (<a href="http://clinicaltrials.gov/" target="_blank">clinicaltrials.gov/</a>), the ISRCTN Registry (<a href="http://www.isrctn.com" target="_blank">www.isrctn.com</a>), Stroke Trials Registry (<a href="http://www.strokecenter.org/trials" target="_blank">www.strokecenter.org/trials</a>), Trials Central (<a href="http://www.trialscentral.org" target="_blank">www.trialscentral.org</a>), and WHO International Clinical Trials Registry Platform (ICTRP) Portal (<a href="./appendices#CD007858-sec-0117">Appendix 4</a>). </p> </section> <section id="CD007858-sec-0046"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of all relevant articles reporting studies selected for inclusion in this review retrieved from the above‐mentioned searches. When clarification was needed, we contacted the principal investigators or corresponding authors, or both, of the relevant studies. </p> </section> </section> <section id="CD007858-sec-0047"> <h3 class="title" id="CD007858-sec-0047">Data collection and analysis</h3> <section id="CD007858-sec-0048"> <h4 class="title">Selection of studies</h4> <p>Two review authors (TPZ and either NDK or ER) independently screened all titles, abstracts and keywords of publications identified by the searches to assess their eligibility. We obtained full‐texts of all possibly eligible manuscripts, and two review authors (TPZ and NDK) selected trials based on our inclusion criteria. Disagreements were resolved by discussion and, if necessary, by a third review author (ER). We included a PRISMA flowchart of our study selection (<a href="./references#CD007858-bbs2-0029" title="Moher , D , LiberatiA Fau ‐ Tetzlaff , Jennifer , TetzlaffJ Fau ‐ Altman , DouglasG , et al. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. Med, P. LoS2009. ">Moher 2009</a>). </p> </section> <section id="CD007858-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (TPZ and NDK) independently extracted the data. They resolved disagreements by discussion and, if necessary, by involving a third review author (ER). We used data reported in the published sources for analysis in this review. If reported data conflicted between two reports of the same study, we used the data of the most recent report. Where we needed additional data, we attempted to contact the principal investigator(s) or the corresponding author of the study or report. On a standardised data extraction form we recorded: </p> <p> <ul id="CD007858-list-0003"> <li> <p>general information: published/unpublished, title, authors, reference, country, language of publication, year of publication, duplicate publications, sponsor, setting; </p> </li> <li> <p>trial characteristics/methodology: design, inclusion and exclusion criteria, method of randomisation, sequence generation, allocation concealment, blinding (participants/personnel and outcome assessors) and analysis (intention‐to‐treat, per protocol), duration of follow‐up, presence of selective reporting, other types of bias; </p> </li> <li> <p>participant characteristics: number of participants randomised to each arm, age, sex, ethnicity, type of index event, presence of elevated blood pressure, level of blood pressure, compliance, duration of follow‐up; </p> </li> <li> <p>intervention characteristics: type, class and dose of BPLD, timing of treatment initiation, duration of treatment, additional interventions; </p> </li> <li> <p>outcomes: all specified primary and secondary outcomes, other reported outcomes, number of participants with complete follow‐up and reasons for loss to follow‐up. </p> </li> </ul> </p> </section> <section id="CD007858-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>To assess risk of bias in each included study, two review authors (TPZ and NDK) independently assessed the methodological quality using criteria described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007858-bbs2-0022" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011</a>). We created a 'Risk of bias' table per study, including a description and a judgement (low, high, or unclear risk of bias) for each of the seven types of possible bias. We considered studies with three or more entries of high or unclear risk of bias as being of low methodological quality. We summarised the risk of bias in a 'Risk of bias' graph and summary. </p> </section> <section id="CD007858-sec-0051"> <h4 class="title">Measures of treatment effect</h4> <p>We expressed the size of the treatment effect on the dichotomous outcome measures as pooled risk ratios (RRs) with 95% confidence intervals (CIs). We expressed the outcome 'time to recurrent stroke' as pooled log hazard ratio estimate with 95% CIs. </p> </section> <section id="CD007858-sec-0052"> <h4 class="title">Unit of analysis issues</h4> <p>For each study we considered whether participants were randomised individually or as a group and whether there were multiple observations for the same outcome. </p> </section> <section id="CD007858-sec-0053"> <h4 class="title">Dealing with missing data</h4> <p>We attempted to collect missing data by contacting (through multiple e‐mails) the principal investigators and corresponding authors of the studies in question. </p> </section> <section id="CD007858-sec-0054"> <h4 class="title">Assessment of heterogeneity</h4> <p>We calculated Tau<sup>2</sup>, Chi<sup>2</sup>, and I<sup>2</sup> to explore the between‐study variance. We considered I<sup>2</sup> statistic percentages greater than 50% as an indicator of substantial heterogeneity. </p> </section> <section id="CD007858-sec-0055"> <h4 class="title">Assessment of reporting biases</h4> <p>We did not create funnel plots to assess reporting biases, as the number of included studies per comparison (BPLD versus placebo or no treatment; intensive blood pressure‐lowering versus mild or standard blood pressure‐lowering) was lower than 10. </p> </section> <section id="CD007858-sec-0056"> <h4 class="title">Data synthesis</h4> <p>We processed data and performed quantitative analyses using Review Manager 5 (<a href="./references#CD007858-bbs2-0031" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). We used random‐effects models for all analyses, regardless of the statistical amount of heterogeneity, to take heterogeneous designs and participants into account. </p> </section> <section id="CD007858-sec-0057"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We defined the following subgroup analyses to investigate heterogeneous results for the primary outcome 'recurrent stroke of any type' and the secondary outcomes 'major vascular event' and 'dementia'. </p> <p> <ul id="CD007858-list-0004"> <li> <p>Subgroups based on baseline blood pressure, according to the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) classification (<a href="./references#CD007858-bbs2-0019" title="ChobanianAV , BakrisGL , BlackHR , CushmanWC , GreenLA , IzzoJLJr , et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA2003;289:2560‐72. ">Chobanian 2003</a>) (normal blood pressure, defined as a systolic blood pressure &lt; 120 mmHg and a diastolic blood pressure &lt; 80 mmHg; prehypertension, defined as a systolic blood pressure 120 to 139 mmHg or a diastolic blood pressure 80 to 89 mmHg; stage 1 hypertension, defined as a systolic blood pressure 140 to 159 mmHg or a diastolic blood pressure 90 to 99 mmHg; stage 2 hypertension, defined as a systolic blood pressure ≥ 160 mmHg or a diastolic blood pressure ≥ 100 mmHg). </p> </li> <li> <p>Subgroups based on class of BPLD (diuretics, angiotensin‐converting enzyme (ACE) inhibitors, calcium channel blockers, angiotensin II type 1 receptor blockers, adrenergic beta‐antagonists, other). </p> </li> <li> <p>Subgroups based on self‐reported ethnicity (Blacks, Whites, Hispanics, Asians, others).</p> </li> <li> <p>Subgroups based on prior history of hypertension (yes versus no).</p> </li> <li> <p>Subgroups based on age (&lt; 60 years, 60 to 79 years, 80 years or older).</p> </li> <li> <p>Subgroups based on index stroke event (TIA, ischaemic stroke, haemorrhagic stroke).</p> </li> <li> <p>Subgroups based on sex (men versus women).</p> </li> </ul> </p> </section> <section id="CD007858-sec-0058"> <h4 class="title">Sensitivity analysis</h4> <p>We planned the following sensitivity analyses.</p> <p> <ul id="CD007858-list-0005"> <li> <p>Methodological quality (0 to 2 entries of unclear or high risk versus 3 or more entries of unclear or high risk). </p> </li> <li> <p>Time of treatment initiation (within 2 weeks after stroke or TIA versus after 2 weeks following stroke or TIA). </p> </li> <li> <p>Duration of treatment and follow‐up (shorter versus longer than 1 year).</p> </li> <li> <p>Level of achieved systolic blood pressure‐lowering in comparison with baseline (&gt; 5 mmHg versus ≤ 5 mmHg). </p> </li> <li> <p>Level of achieved diastolic blood pressure‐lowering in comparison with baseline (&gt; 3 mmHg versus ≤ 3 mmHg). </p> </li> <li> <p>Contrast in achieved systolic blood pressure‐lowering between intervention and control group (&gt; 3 mmHg versus ≤ 3 mmHg). </p> </li> </ul> </p> <section id="CD007858-sec-0059"> <h5 class="title">GRADE assessment and 'Summary of findings' table</h5> <p>We used the GRADEpro Gudeline Development Tool to create a 'Summary of findings' table for the comparison of BPLDs versus placebo or no treatment (<a href="https://gradepro.org" target="_blank">GRADEpro GDT</a>; <a href="./full#CD007858-tbl-0001">summary of findings Table for the main comparison</a>). This table presents the results and the quality of the evidence of the main outcomes, using the GRADE system, which classifies the quality of evidence as high, moderate, low, and very low. The outcomes included are: recurrent stroke of any type, time to recurrent stroke, major vascular event (composite of non‐fatal stroke, non‐fatal myocardial infarction, or death from any vascular cause), myocardial infarction, vascular death, death by any cause, and dementia. The GRADE approach appraises the quality of the body of evidence according to the extent to which one can be confident that an estimate of effect or association reflects the item assessed. The quality of a body of evidence is based on within‐study risk of bias (methodological quality), directness of the evidence, heterogeneity of the data, precision of effect estimates, and risk of publication bias (<a href="./references#CD007858-bbs2-0032" title="SchünemannHJ , OxmanAD , VistGE , HigginsJP , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Schünemann 2011</a>). </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007858-sec-0060" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007858-sec-0060"></div> <section id="CD007858-sec-0061"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD007858-sec-0125" title="">Characteristics of included studies</a> and <a href="./references#CD007858-sec-0126" title="">Characteristics of excluded studies</a>. </p> <section id="CD007858-sec-0062"> <h4 class="title">Results of the search</h4> <p>The search strategy yielded 23,932 unique results, of which we excluded 23,093 after reading titles and abstracts (<a href="#CD007858-fig-0001">Figure 1</a>). We retrieved the remaining 839 records for detailed evaluation. Among these, we identified 13 randomised controlled trials (RCTs) eligible for inclusion. </p> <div class="figure" id="CD007858-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD007858-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>Two of the 13 trials that met our inclusion criteria are ongoing: The <a href="./references#CD007858-bbs2-0015" title="NCT01220622 . Efficacy and safety study of nimodipine to prevent mild cognitive impairment after acute ischemic strokes. https://ClinicalTrials.gov/show/NCT01220622 (first received 14 October 14 2010). WangP , WangY , FengT , ZhaoX , ZhouY , WangY , et al. Rationale and design of a double‐blind, placebo‐controlled, randomized trial to evaluate the safety and efficacy of nimodipine in preventing cognitive impairment in ischemic cerebrovascular events (NICE). BMC Neurology2012;12:88. ">NCT01220622</a> is investigating the effect of nimodipine started within seven days after ischaemic stroke on mortality at six months; the <a href="./references#CD007858-bbs2-0016" title="NCT01563731 . Optimal blood pressure and cholesterol targets for preventing recurrent stroke in hypertensives. https://ClinicalTrials.gov/show/NCT01563731 (first received 27 March 2012). ZanchettiA , LiuL , ManciaG , ParatiG , GrassiG , Stramba‐BadialeM , et al. Blood pressure and LDL‐cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient: design of the European Society of Hypertension‐Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trial. Journal of Hypertension2014;32(9):1888‐97. ZanchettiA , LiuL , ManciaG , ParatiG , GrassiG , Stramba‐BadialeM , et al. ESH‐CHL‐SHOT trial investigators. Continuation of the ESH‐CHL‐SHOT trial after publication of the SPRINT: Rationale for further study on blood pressure targets of antihypertensive treatment after stroke. Journal of Hypertension2016;34:393‐6. ">NCT01563731</a> trial studies the effect of three different systolic blood pressure targets (&lt; 145 to 135, &lt; 135 to 125, and &lt; 125 mmHg) on stroke and cardiovascular events in people with a transient ischaemic attack (TIA) or stroke (<a href="./references#CD007858-sec-0127" title="">Characteristics of ongoing studies</a>). </p> </section> <section id="CD007858-sec-0063"> <h4 class="title">Included studies</h4> <p>In total, we included 11 studies involving 38,742 participants (<a href="./references#CD007858-sec-0125" title="">Characteristics of included studies</a>); eight studies in the BPLD versus placebo or no treatment comparison, and three studies in the intensive blood pressure‐lowering versus mild or standard blood pressure‐lowering comparison. </p> <section id="CD007858-sec-0064"> <h5 class="title">Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment</h5> <p>Eight studies (35,110 participants) met the inclusion criteria for our primary and secondary objectives (<a href="./references#CD007858-bbs2-0001" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1:485‐9. ">Carter 1970</a>; <a href="./references#CD007858-bbs2-0002" title="BauerRB . Effect of antihypertensive treatment on stroke recurrence: results of the hypertension‐stroke cooperative study. Cerebral Vascular Diseases: Transactions of the Ninth Princeton Conference. 1975:137‐54. HooblerSW . Antihypertensive therapy for stroke patients. Hypertension and Stroke Control in the Community: Proceedings of a WHO Meeting, March 1974. 1976. Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. Journal of the American Medical Association1974;229:409‐18. ">Co‐operative Study 1975</a>; <a href="./references#CD007858-bbs2-0004" title="Marti MassoJF , LozanoR . Nicardipine in the prevention of cerebral infarction. Clinical Therapeutics1990;12:344‐51. ">Marti Masso 1990</a>; <a href="./references#CD007858-bbs2-0003" title="The Dutch TIA Study Group. The Dutch TIA trial: protective effects of low‐dose aspirin and atenolol in patients with transient ischemic attacks or nondisabling stroke. Stroke1988;19:512‐7. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. New England Journal of Medicine1991;325:1261‐6. The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke1993;24:543‐8. ">Dutch TIA Trial 1993</a>; <a href="./references#CD007858-bbs2-0006" title="LiuL , GongL , Guang WangJ . Blood pressure lowering in patients with cerebrovascular disease: results of the randomized Post‐stroke Antihypertensive Treatment Study (PATS). Journal of the American College of Cardiology1998;31 (Suppl 2A):211A. LiuL , WangZ , GongL , ZhangY , ThijsL , StaessenJA , et al. Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertension Research2009;32:1032‐40. PATS Collaborating Group. Post‐stroke antihypertensive treatment study. A preliminary result. Chinese Medical Journal1995;108:710‐7. ">PATS 1995</a>; <a href="./references#CD007858-bbs2-0009" title="ArimaH , AndersonC , OmaeT , LiuL , TzourioC , WoodwardM , et al. Perindopril‐based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial. Journal of Hypertension2010;28:395‐400. ArimaH , ChalmersJ , WoodwardM , AndersonC , RodgersA , DavisS , et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. Journal of Hypertension2006;24:1201‐8. ArimaH , TzourioC , AndersonC , WoodwardM , BousserMG , MacMahonS , et al. Effects of perindopril‐based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke2010;41:394‐6. ChapmanN , HuxleyR , AndersonC , BousserMG , ChalmersJ , ColmanS , et al. Effects of a perindopril‐based blood pressure‐lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke2004;35:116‐21. NealB , MacMahonS . The PROGRESS study: rationale and design. Journal of Hypertension1995;13:1869‐73. NinomiyaT , DonnanG , AndersonN , BladinC , ChambersB , GordonG , et al. Effects of the end point adjudication process on the results of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS). Stroke2009;40:2111‐5. PROGRESS Collaborative Group. Randomised trial of a perindopril‐based blood‐pressure‐lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet2001;358:1033‐41. PROGRESS Management Committee. PROGRESS: Perindopril pROtection aGainst REcurrent Stroke Study: status in March 1997. Journal of Human Hypertension1998;12:627‐9. Progress Management Committee. PROGRESS ‐ Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline. Journal of Hypertension1999;17:1647‐55. RodgersA , ChapmanN , WoodwardM , LiuLS , ColmanS , LeeA , et al. Perindopril‐based blood pressure lowering in individuals with cerebrovascular disease: consistency of benefits by age, sex and region. Journal of Hypertension2004;22:653‐9. TzourioC , AndersonC , ChapmanN , WoodwardM , NealB , MacMahonS , et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Archives of Internal Medicine2003;163:1069‐75. ">PROGRESS 2001</a>; <a href="./references#CD007858-bbs2-0008" title="BathPM , MartinRH , PaleschY , CottonD , YusufS , SaccoR , et al. Effect of telmisartan on functional outcome, recurrence, and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke2009;40:3541‐6. DienerHC , SaccoR , YusufS , Steering Committee, PRoFESS Study Group. Rationale, design and baseline data of a randomized, double‐blind, controlled trial comparing two antithrombotic regimens (a fixed‐dose combination of extended‐release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovascular Diseases2007;23:368‐80. DienerHC , SaccoRL , YusufS , CottonD , OunpuuS , LawtonWA , et al. Effects of aspirin plus extended‐release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double‐blind, active and placebo‐controlled study. Lancet Neurology2008;7:875‐84. YusufS , DienerHC , SaccoRL , CottonD , OunpuuS , LawtonWA , et al. Telmisartan to prevent recurrent stroke and cardiovascular events. New England Journal of Medicine2008;359:1225‐37. ">PRoFESS 2008</a>; <a href="./references#CD007858-bbs2-0011" title="ErikssonS , OlofssonBO , WesterPO , for the TEST study group. Atenolol in secondary prevention after stroke. Cerebrovascular Diseases1995;5:21‐5. ">TEST 1995</a>), the largest of which included 20,332 participants (<a href="./references#CD007858-bbs2-0008" title="BathPM , MartinRH , PaleschY , CottonD , YusufS , SaccoR , et al. Effect of telmisartan on functional outcome, recurrence, and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke2009;40:3541‐6. DienerHC , SaccoR , YusufS , Steering Committee, PRoFESS Study Group. Rationale, design and baseline data of a randomized, double‐blind, controlled trial comparing two antithrombotic regimens (a fixed‐dose combination of extended‐release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovascular Diseases2007;23:368‐80. DienerHC , SaccoRL , YusufS , CottonD , OunpuuS , LawtonWA , et al. Effects of aspirin plus extended‐release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double‐blind, active and placebo‐controlled study. Lancet Neurology2008;7:875‐84. YusufS , DienerHC , SaccoRL , CottonD , OunpuuS , LawtonWA , et al. Telmisartan to prevent recurrent stroke and cardiovascular events. New England Journal of Medicine2008;359:1225‐37. ">PRoFESS 2008</a>). </p> <section id="CD007858-sec-0065"> <h6 class="title">Type of intervention</h6> <p>Five studies (28,454 participants) compared a single BPLD with placebo (<a href="./references#CD007858-bbs2-0003" title="The Dutch TIA Study Group. The Dutch TIA trial: protective effects of low‐dose aspirin and atenolol in patients with transient ischemic attacks or nondisabling stroke. Stroke1988;19:512‐7. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. New England Journal of Medicine1991;325:1261‐6. The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke1993;24:543‐8. ">Dutch TIA Trial 1993</a>; <a href="./references#CD007858-bbs2-0006" title="LiuL , GongL , Guang WangJ . Blood pressure lowering in patients with cerebrovascular disease: results of the randomized Post‐stroke Antihypertensive Treatment Study (PATS). Journal of the American College of Cardiology1998;31 (Suppl 2A):211A. LiuL , WangZ , GongL , ZhangY , ThijsL , StaessenJA , et al. Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertension Research2009;32:1032‐40. PATS Collaborating Group. Post‐stroke antihypertensive treatment study. A preliminary result. Chinese Medical Journal1995;108:710‐7. ">PATS 1995</a>; <a href="./references#CD007858-bbs2-0008" title="BathPM , MartinRH , PaleschY , CottonD , YusufS , SaccoR , et al. Effect of telmisartan on functional outcome, recurrence, and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke2009;40:3541‐6. DienerHC , SaccoR , YusufS , Steering Committee, PRoFESS Study Group. Rationale, design and baseline data of a randomized, double‐blind, controlled trial comparing two antithrombotic regimens (a fixed‐dose combination of extended‐release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovascular Diseases2007;23:368‐80. DienerHC , SaccoRL , YusufS , CottonD , OunpuuS , LawtonWA , et al. Effects of aspirin plus extended‐release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double‐blind, active and placebo‐controlled study. Lancet Neurology2008;7:875‐84. YusufS , DienerHC , SaccoRL , CottonD , OunpuuS , LawtonWA , et al. Telmisartan to prevent recurrent stroke and cardiovascular events. New England Journal of Medicine2008;359:1225‐37. ">PRoFESS 2008</a>; <a href="./references#CD007858-bbs2-0011" title="ErikssonS , OlofssonBO , WesterPO , for the TEST study group. Atenolol in secondary prevention after stroke. Cerebrovascular Diseases1995;5:21‐5. ">TEST 1995</a>), or with no treatment (<a href="./references#CD007858-bbs2-0004" title="Marti MassoJF , LozanoR . Nicardipine in the prevention of cerebral infarction. Clinical Therapeutics1990;12:344‐51. ">Marti Masso 1990</a>), two trials investigated individually tailored regimens consisting of either one or two BPLDs versus placebo or no treatment (<a href="./references#CD007858-bbs2-0001" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1:485‐9. ">Carter 1970</a>; <a href="./references#CD007858-bbs2-0009" title="ArimaH , AndersonC , OmaeT , LiuL , TzourioC , WoodwardM , et al. Perindopril‐based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial. Journal of Hypertension2010;28:395‐400. ArimaH , ChalmersJ , WoodwardM , AndersonC , RodgersA , DavisS , et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. Journal of Hypertension2006;24:1201‐8. ArimaH , TzourioC , AndersonC , WoodwardM , BousserMG , MacMahonS , et al. Effects of perindopril‐based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke2010;41:394‐6. ChapmanN , HuxleyR , AndersonC , BousserMG , ChalmersJ , ColmanS , et al. Effects of a perindopril‐based blood pressure‐lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke2004;35:116‐21. NealB , MacMahonS . The PROGRESS study: rationale and design. Journal of Hypertension1995;13:1869‐73. NinomiyaT , DonnanG , AndersonN , BladinC , ChambersB , GordonG , et al. Effects of the end point adjudication process on the results of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS). Stroke2009;40:2111‐5. PROGRESS Collaborative Group. Randomised trial of a perindopril‐based blood‐pressure‐lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet2001;358:1033‐41. PROGRESS Management Committee. PROGRESS: Perindopril pROtection aGainst REcurrent Stroke Study: status in March 1997. Journal of Human Hypertension1998;12:627‐9. Progress Management Committee. PROGRESS ‐ Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline. Journal of Hypertension1999;17:1647‐55. RodgersA , ChapmanN , WoodwardM , LiuLS , ColmanS , LeeA , et al. Perindopril‐based blood pressure lowering in individuals with cerebrovascular disease: consistency of benefits by age, sex and region. Journal of Hypertension2004;22:653‐9. TzourioC , AndersonC , ChapmanN , WoodwardM , NealB , MacMahonS , et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Archives of Internal Medicine2003;163:1069‐75. ">PROGRESS 2001</a>), and one trial investigated a combined blood pressure‐lowering intervention versus placebo (<a href="./references#CD007858-bbs2-0002" title="BauerRB . Effect of antihypertensive treatment on stroke recurrence: results of the hypertension‐stroke cooperative study. Cerebral Vascular Diseases: Transactions of the Ninth Princeton Conference. 1975:137‐54. HooblerSW . Antihypertensive therapy for stroke patients. Hypertension and Stroke Control in the Community: Proceedings of a WHO Meeting, March 1974. 1976. Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. Journal of the American Medical Association1974;229:409‐18. ">Co‐operative Study 1975</a>). </p> <p>Five classes of BPLDs were evaluated; angiotensin‐converting enzyme (ACE) inhibitors (with individually tailored addition of diuretics, <a href="./references#CD007858-bbs2-0009" title="ArimaH , AndersonC , OmaeT , LiuL , TzourioC , WoodwardM , et al. Perindopril‐based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial. Journal of Hypertension2010;28:395‐400. ArimaH , ChalmersJ , WoodwardM , AndersonC , RodgersA , DavisS , et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. Journal of Hypertension2006;24:1201‐8. ArimaH , TzourioC , AndersonC , WoodwardM , BousserMG , MacMahonS , et al. Effects of perindopril‐based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke2010;41:394‐6. ChapmanN , HuxleyR , AndersonC , BousserMG , ChalmersJ , ColmanS , et al. Effects of a perindopril‐based blood pressure‐lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke2004;35:116‐21. NealB , MacMahonS . The PROGRESS study: rationale and design. Journal of Hypertension1995;13:1869‐73. NinomiyaT , DonnanG , AndersonN , BladinC , ChambersB , GordonG , et al. Effects of the end point adjudication process on the results of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS). Stroke2009;40:2111‐5. PROGRESS Collaborative Group. Randomised trial of a perindopril‐based blood‐pressure‐lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet2001;358:1033‐41. PROGRESS Management Committee. PROGRESS: Perindopril pROtection aGainst REcurrent Stroke Study: status in March 1997. Journal of Human Hypertension1998;12:627‐9. Progress Management Committee. PROGRESS ‐ Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline. Journal of Hypertension1999;17:1647‐55. RodgersA , ChapmanN , WoodwardM , LiuLS , ColmanS , LeeA , et al. Perindopril‐based blood pressure lowering in individuals with cerebrovascular disease: consistency of benefits by age, sex and region. Journal of Hypertension2004;22:653‐9. TzourioC , AndersonC , ChapmanN , WoodwardM , NealB , MacMahonS , et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Archives of Internal Medicine2003;163:1069‐75. ">PROGRESS 2001</a>), beta‐blockers (<a href="./references#CD007858-bbs2-0003" title="The Dutch TIA Study Group. The Dutch TIA trial: protective effects of low‐dose aspirin and atenolol in patients with transient ischemic attacks or nondisabling stroke. Stroke1988;19:512‐7. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. New England Journal of Medicine1991;325:1261‐6. The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke1993;24:543‐8. ">Dutch TIA Trial 1993</a>; <a href="./references#CD007858-bbs2-0011" title="ErikssonS , OlofssonBO , WesterPO , for the TEST study group. Atenolol in secondary prevention after stroke. Cerebrovascular Diseases1995;5:21‐5. ">TEST 1995</a>), angiotensin II receptor antagonists (<a href="./references#CD007858-bbs2-0008" title="BathPM , MartinRH , PaleschY , CottonD , YusufS , SaccoR , et al. Effect of telmisartan on functional outcome, recurrence, and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke2009;40:3541‐6. DienerHC , SaccoR , YusufS , Steering Committee, PRoFESS Study Group. Rationale, design and baseline data of a randomized, double‐blind, controlled trial comparing two antithrombotic regimens (a fixed‐dose combination of extended‐release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovascular Diseases2007;23:368‐80. DienerHC , SaccoRL , YusufS , CottonD , OunpuuS , LawtonWA , et al. Effects of aspirin plus extended‐release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double‐blind, active and placebo‐controlled study. Lancet Neurology2008;7:875‐84. YusufS , DienerHC , SaccoRL , CottonD , OunpuuS , LawtonWA , et al. Telmisartan to prevent recurrent stroke and cardiovascular events. New England Journal of Medicine2008;359:1225‐37. ">PRoFESS 2008</a>), diuretics (<a href="./references#CD007858-bbs2-0002" title="BauerRB . Effect of antihypertensive treatment on stroke recurrence: results of the hypertension‐stroke cooperative study. Cerebral Vascular Diseases: Transactions of the Ninth Princeton Conference. 1975:137‐54. HooblerSW . Antihypertensive therapy for stroke patients. Hypertension and Stroke Control in the Community: Proceedings of a WHO Meeting, March 1974. 1976. Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. Journal of the American Medical Association1974;229:409‐18. ">Co‐operative Study 1975</a>: a combination of two diuretic drugs; <a href="./references#CD007858-bbs2-0006" title="LiuL , GongL , Guang WangJ . Blood pressure lowering in patients with cerebrovascular disease: results of the randomized Post‐stroke Antihypertensive Treatment Study (PATS). Journal of the American College of Cardiology1998;31 (Suppl 2A):211A. LiuL , WangZ , GongL , ZhangY , ThijsL , StaessenJA , et al. Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertension Research2009;32:1032‐40. PATS Collaborating Group. Post‐stroke antihypertensive treatment study. A preliminary result. Chinese Medical Journal1995;108:710‐7. ">PATS 1995</a>), calcium channel blockers (<a href="./references#CD007858-bbs2-0004" title="Marti MassoJF , LozanoR . Nicardipine in the prevention of cerebral infarction. Clinical Therapeutics1990;12:344‐51. ">Marti Masso 1990</a>), and an individually tailored regimen of diuretics and centrally acting BPLDs (<a href="./references#CD007858-bbs2-0001" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1:485‐9. ">Carter 1970</a>). Two trials had a 2x2 factorial design (<a href="./references#CD007858-bbs2-0003" title="The Dutch TIA Study Group. The Dutch TIA trial: protective effects of low‐dose aspirin and atenolol in patients with transient ischemic attacks or nondisabling stroke. Stroke1988;19:512‐7. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. New England Journal of Medicine1991;325:1261‐6. The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke1993;24:543‐8. ">Dutch TIA Trial 1993</a>; <a href="./references#CD007858-bbs2-0008" title="BathPM , MartinRH , PaleschY , CottonD , YusufS , SaccoR , et al. Effect of telmisartan on functional outcome, recurrence, and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke2009;40:3541‐6. DienerHC , SaccoR , YusufS , Steering Committee, PRoFESS Study Group. Rationale, design and baseline data of a randomized, double‐blind, controlled trial comparing two antithrombotic regimens (a fixed‐dose combination of extended‐release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovascular Diseases2007;23:368‐80. DienerHC , SaccoRL , YusufS , CottonD , OunpuuS , LawtonWA , et al. Effects of aspirin plus extended‐release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double‐blind, active and placebo‐controlled study. Lancet Neurology2008;7:875‐84. YusufS , DienerHC , SaccoRL , CottonD , OunpuuS , LawtonWA , et al. Telmisartan to prevent recurrent stroke and cardiovascular events. New England Journal of Medicine2008;359:1225‐37. ">PRoFESS 2008</a>), both also comparing different antithrombotic regimens. </p> </section> <section id="CD007858-sec-0066"> <h6 class="title">Index event</h6> <p>In four studies, the qualifying event could either be a TIA, ischaemic stroke, or haemorrhagic stroke (<a href="./references#CD007858-bbs2-0002" title="BauerRB . Effect of antihypertensive treatment on stroke recurrence: results of the hypertension‐stroke cooperative study. Cerebral Vascular Diseases: Transactions of the Ninth Princeton Conference. 1975:137‐54. HooblerSW . Antihypertensive therapy for stroke patients. Hypertension and Stroke Control in the Community: Proceedings of a WHO Meeting, March 1974. 1976. Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. Journal of the American Medical Association1974;229:409‐18. ">Co‐operative Study 1975</a>; <a href="./references#CD007858-bbs2-0006" title="LiuL , GongL , Guang WangJ . Blood pressure lowering in patients with cerebrovascular disease: results of the randomized Post‐stroke Antihypertensive Treatment Study (PATS). Journal of the American College of Cardiology1998;31 (Suppl 2A):211A. LiuL , WangZ , GongL , ZhangY , ThijsL , StaessenJA , et al. Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertension Research2009;32:1032‐40. PATS Collaborating Group. Post‐stroke antihypertensive treatment study. A preliminary result. Chinese Medical Journal1995;108:710‐7. ">PATS 1995</a>; <a href="./references#CD007858-bbs2-0009" title="ArimaH , AndersonC , OmaeT , LiuL , TzourioC , WoodwardM , et al. Perindopril‐based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial. Journal of Hypertension2010;28:395‐400. ArimaH , ChalmersJ , WoodwardM , AndersonC , RodgersA , DavisS , et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. Journal of Hypertension2006;24:1201‐8. ArimaH , TzourioC , AndersonC , WoodwardM , BousserMG , MacMahonS , et al. Effects of perindopril‐based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke2010;41:394‐6. ChapmanN , HuxleyR , AndersonC , BousserMG , ChalmersJ , ColmanS , et al. Effects of a perindopril‐based blood pressure‐lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke2004;35:116‐21. NealB , MacMahonS . The PROGRESS study: rationale and design. Journal of Hypertension1995;13:1869‐73. NinomiyaT , DonnanG , AndersonN , BladinC , ChambersB , GordonG , et al. Effects of the end point adjudication process on the results of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS). Stroke2009;40:2111‐5. PROGRESS Collaborative Group. Randomised trial of a perindopril‐based blood‐pressure‐lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet2001;358:1033‐41. PROGRESS Management Committee. PROGRESS: Perindopril pROtection aGainst REcurrent Stroke Study: status in March 1997. Journal of Human Hypertension1998;12:627‐9. Progress Management Committee. PROGRESS ‐ Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline. Journal of Hypertension1999;17:1647‐55. RodgersA , ChapmanN , WoodwardM , LiuLS , ColmanS , LeeA , et al. Perindopril‐based blood pressure lowering in individuals with cerebrovascular disease: consistency of benefits by age, sex and region. Journal of Hypertension2004;22:653‐9. TzourioC , AndersonC , ChapmanN , WoodwardM , NealB , MacMahonS , et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Archives of Internal Medicine2003;163:1069‐75. ">PROGRESS 2001</a>; <a href="./references#CD007858-bbs2-0011" title="ErikssonS , OlofssonBO , WesterPO , for the TEST study group. Atenolol in secondary prevention after stroke. Cerebrovascular Diseases1995;5:21‐5. ">TEST 1995</a>). One of these studies also included people with a subarachnoid haemorrhage (112 of 5665 participants (2.0%), <a href="./references#CD007858-bbs2-0006" title="LiuL , GongL , Guang WangJ . Blood pressure lowering in patients with cerebrovascular disease: results of the randomized Post‐stroke Antihypertensive Treatment Study (PATS). Journal of the American College of Cardiology1998;31 (Suppl 2A):211A. LiuL , WangZ , GongL , ZhangY , ThijsL , StaessenJA , et al. Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertension Research2009;32:1032‐40. PATS Collaborating Group. Post‐stroke antihypertensive treatment study. A preliminary result. Chinese Medical Journal1995;108:710‐7. ">PATS 1995</a>), and one study did not require a specific qualifying event but a prior history of TIA or stroke (<a href="./references#CD007858-bbs2-0009" title="ArimaH , AndersonC , OmaeT , LiuL , TzourioC , WoodwardM , et al. Perindopril‐based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial. Journal of Hypertension2010;28:395‐400. ArimaH , ChalmersJ , WoodwardM , AndersonC , RodgersA , DavisS , et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. Journal of Hypertension2006;24:1201‐8. ArimaH , TzourioC , AndersonC , WoodwardM , BousserMG , MacMahonS , et al. Effects of perindopril‐based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke2010;41:394‐6. ChapmanN , HuxleyR , AndersonC , BousserMG , ChalmersJ , ColmanS , et al. Effects of a perindopril‐based blood pressure‐lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke2004;35:116‐21. NealB , MacMahonS . The PROGRESS study: rationale and design. Journal of Hypertension1995;13:1869‐73. NinomiyaT , DonnanG , AndersonN , BladinC , ChambersB , GordonG , et al. Effects of the end point adjudication process on the results of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS). Stroke2009;40:2111‐5. PROGRESS Collaborative Group. Randomised trial of a perindopril‐based blood‐pressure‐lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet2001;358:1033‐41. PROGRESS Management Committee. PROGRESS: Perindopril pROtection aGainst REcurrent Stroke Study: status in March 1997. Journal of Human Hypertension1998;12:627‐9. Progress Management Committee. PROGRESS ‐ Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline. Journal of Hypertension1999;17:1647‐55. RodgersA , ChapmanN , WoodwardM , LiuLS , ColmanS , LeeA , et al. Perindopril‐based blood pressure lowering in individuals with cerebrovascular disease: consistency of benefits by age, sex and region. Journal of Hypertension2004;22:653‐9. TzourioC , AndersonC , ChapmanN , WoodwardM , NealB , MacMahonS , et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Archives of Internal Medicine2003;163:1069‐75. ">PROGRESS 2001</a>). Three studies included people with a TIA or ischaemic stroke (<a href="./references#CD007858-bbs2-0003" title="The Dutch TIA Study Group. The Dutch TIA trial: protective effects of low‐dose aspirin and atenolol in patients with transient ischemic attacks or nondisabling stroke. Stroke1988;19:512‐7. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. New England Journal of Medicine1991;325:1261‐6. The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke1993;24:543‐8. ">Dutch TIA Trial 1993</a>; <a href="./references#CD007858-bbs2-0004" title="Marti MassoJF , LozanoR . Nicardipine in the prevention of cerebral infarction. Clinical Therapeutics1990;12:344‐51. ">Marti Masso 1990</a>; <a href="./references#CD007858-bbs2-0008" title="BathPM , MartinRH , PaleschY , CottonD , YusufS , SaccoR , et al. Effect of telmisartan on functional outcome, recurrence, and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke2009;40:3541‐6. DienerHC , SaccoR , YusufS , Steering Committee, PRoFESS Study Group. Rationale, design and baseline data of a randomized, double‐blind, controlled trial comparing two antithrombotic regimens (a fixed‐dose combination of extended‐release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovascular Diseases2007;23:368‐80. DienerHC , SaccoRL , YusufS , CottonD , OunpuuS , LawtonWA , et al. Effects of aspirin plus extended‐release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double‐blind, active and placebo‐controlled study. Lancet Neurology2008;7:875‐84. YusufS , DienerHC , SaccoRL , CottonD , OunpuuS , LawtonWA , et al. Telmisartan to prevent recurrent stroke and cardiovascular events. New England Journal of Medicine2008;359:1225‐37. ">PRoFESS 2008</a>). One study only included people with an ischaemic stroke (<a href="./references#CD007858-bbs2-0001" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1:485‐9. ">Carter 1970</a>). However, this diagnosis was based on a lumbar puncture negative for blood, as computerised tomography (CT) scanners were not yet available to reliably distinguish between ischaemic and haemorrhagic stroke. Six out of the seven studies, including TIA participants, based inclusion on the clinical syndrome only, whereas one study required confirmatory brain imaging (CT or magnetic resonance imaging (MRI), <a href="./references#CD007858-bbs2-0008" title="BathPM , MartinRH , PaleschY , CottonD , YusufS , SaccoR , et al. Effect of telmisartan on functional outcome, recurrence, and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke2009;40:3541‐6. DienerHC , SaccoR , YusufS , Steering Committee, PRoFESS Study Group. Rationale, design and baseline data of a randomized, double‐blind, controlled trial comparing two antithrombotic regimens (a fixed‐dose combination of extended‐release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovascular Diseases2007;23:368‐80. DienerHC , SaccoRL , YusufS , CottonD , OunpuuS , LawtonWA , et al. Effects of aspirin plus extended‐release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double‐blind, active and placebo‐controlled study. Lancet Neurology2008;7:875‐84. YusufS , DienerHC , SaccoRL , CottonD , OunpuuS , LawtonWA , et al. Telmisartan to prevent recurrent stroke and cardiovascular events. New England Journal of Medicine2008;359:1225‐37. ">PRoFESS 2008</a>). </p> </section> <section id="CD007858-sec-0067"> <h6 class="title">Time window for inclusion</h6> <p>Five trials included participants within a limited period after the index event: three weeks (<a href="./references#CD007858-bbs2-0011" title="ErikssonS , OlofssonBO , WesterPO , for the TEST study group. Atenolol in secondary prevention after stroke. Cerebrovascular Diseases1995;5:21‐5. ">TEST 1995</a>), three months (<a href="./references#CD007858-bbs2-0003" title="The Dutch TIA Study Group. The Dutch TIA trial: protective effects of low‐dose aspirin and atenolol in patients with transient ischemic attacks or nondisabling stroke. Stroke1988;19:512‐7. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. New England Journal of Medicine1991;325:1261‐6. The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke1993;24:543‐8. ">Dutch TIA Trial 1993</a>; <a href="./references#CD007858-bbs2-0008" title="BathPM , MartinRH , PaleschY , CottonD , YusufS , SaccoR , et al. Effect of telmisartan on functional outcome, recurrence, and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke2009;40:3541‐6. DienerHC , SaccoR , YusufS , Steering Committee, PRoFESS Study Group. Rationale, design and baseline data of a randomized, double‐blind, controlled trial comparing two antithrombotic regimens (a fixed‐dose combination of extended‐release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovascular Diseases2007;23:368‐80. DienerHC , SaccoRL , YusufS , CottonD , OunpuuS , LawtonWA , et al. Effects of aspirin plus extended‐release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double‐blind, active and placebo‐controlled study. Lancet Neurology2008;7:875‐84. YusufS , DienerHC , SaccoRL , CottonD , OunpuuS , LawtonWA , et al. Telmisartan to prevent recurrent stroke and cardiovascular events. New England Journal of Medicine2008;359:1225‐37. ">PRoFESS 2008</a>), one year (<a href="./references#CD007858-bbs2-0002" title="BauerRB . Effect of antihypertensive treatment on stroke recurrence: results of the hypertension‐stroke cooperative study. Cerebral Vascular Diseases: Transactions of the Ninth Princeton Conference. 1975:137‐54. HooblerSW . Antihypertensive therapy for stroke patients. Hypertension and Stroke Control in the Community: Proceedings of a WHO Meeting, March 1974. 1976. Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. Journal of the American Medical Association1974;229:409‐18. ">Co‐operative Study 1975</a>), and five years (<a href="./references#CD007858-bbs2-0009" title="ArimaH , AndersonC , OmaeT , LiuL , TzourioC , WoodwardM , et al. Perindopril‐based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial. Journal of Hypertension2010;28:395‐400. ArimaH , ChalmersJ , WoodwardM , AndersonC , RodgersA , DavisS , et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. Journal of Hypertension2006;24:1201‐8. ArimaH , TzourioC , AndersonC , WoodwardM , BousserMG , MacMahonS , et al. Effects of perindopril‐based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke2010;41:394‐6. ChapmanN , HuxleyR , AndersonC , BousserMG , ChalmersJ , ColmanS , et al. Effects of a perindopril‐based blood pressure‐lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke2004;35:116‐21. NealB , MacMahonS . The PROGRESS study: rationale and design. Journal of Hypertension1995;13:1869‐73. NinomiyaT , DonnanG , AndersonN , BladinC , ChambersB , GordonG , et al. Effects of the end point adjudication process on the results of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS). Stroke2009;40:2111‐5. PROGRESS Collaborative Group. Randomised trial of a perindopril‐based blood‐pressure‐lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet2001;358:1033‐41. PROGRESS Management Committee. PROGRESS: Perindopril pROtection aGainst REcurrent Stroke Study: status in March 1997. Journal of Human Hypertension1998;12:627‐9. Progress Management Committee. PROGRESS ‐ Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline. Journal of Hypertension1999;17:1647‐55. RodgersA , ChapmanN , WoodwardM , LiuLS , ColmanS , LeeA , et al. Perindopril‐based blood pressure lowering in individuals with cerebrovascular disease: consistency of benefits by age, sex and region. Journal of Hypertension2004;22:653‐9. TzourioC , AndersonC , ChapmanN , WoodwardM , NealB , MacMahonS , et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Archives of Internal Medicine2003;163:1069‐75. ">PROGRESS 2001</a>). One of these studies recommended participants to be stable two weeks after the index event (<a href="./references#CD007858-bbs2-0009" title="ArimaH , AndersonC , OmaeT , LiuL , TzourioC , WoodwardM , et al. Perindopril‐based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial. Journal of Hypertension2010;28:395‐400. ArimaH , ChalmersJ , WoodwardM , AndersonC , RodgersA , DavisS , et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. Journal of Hypertension2006;24:1201‐8. ArimaH , TzourioC , AndersonC , WoodwardM , BousserMG , MacMahonS , et al. Effects of perindopril‐based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke2010;41:394‐6. ChapmanN , HuxleyR , AndersonC , BousserMG , ChalmersJ , ColmanS , et al. Effects of a perindopril‐based blood pressure‐lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke2004;35:116‐21. NealB , MacMahonS . The PROGRESS study: rationale and design. Journal of Hypertension1995;13:1869‐73. NinomiyaT , DonnanG , AndersonN , BladinC , ChambersB , GordonG , et al. Effects of the end point adjudication process on the results of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS). Stroke2009;40:2111‐5. PROGRESS Collaborative Group. Randomised trial of a perindopril‐based blood‐pressure‐lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet2001;358:1033‐41. PROGRESS Management Committee. PROGRESS: Perindopril pROtection aGainst REcurrent Stroke Study: status in March 1997. Journal of Human Hypertension1998;12:627‐9. Progress Management Committee. PROGRESS ‐ Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline. Journal of Hypertension1999;17:1647‐55. RodgersA , ChapmanN , WoodwardM , LiuLS , ColmanS , LeeA , et al. Perindopril‐based blood pressure lowering in individuals with cerebrovascular disease: consistency of benefits by age, sex and region. Journal of Hypertension2004;22:653‐9. TzourioC , AndersonC , ChapmanN , WoodwardM , NealB , MacMahonS , et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Archives of Internal Medicine2003;163:1069‐75. ">PROGRESS 2001</a>), and one used a six‐week run‐in period before participants were randomised (<a href="./references#CD007858-bbs2-0002" title="BauerRB . Effect of antihypertensive treatment on stroke recurrence: results of the hypertension‐stroke cooperative study. Cerebral Vascular Diseases: Transactions of the Ninth Princeton Conference. 1975:137‐54. HooblerSW . Antihypertensive therapy for stroke patients. Hypertension and Stroke Control in the Community: Proceedings of a WHO Meeting, March 1974. 1976. Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. Journal of the American Medical Association1974;229:409‐18. ">Co‐operative Study 1975</a>). Median time from index event to randomisation was reported in two of these trials; 15 days (<a href="./references#CD007858-bbs2-0008" title="BathPM , MartinRH , PaleschY , CottonD , YusufS , SaccoR , et al. Effect of telmisartan on functional outcome, recurrence, and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke2009;40:3541‐6. DienerHC , SaccoR , YusufS , Steering Committee, PRoFESS Study Group. Rationale, design and baseline data of a randomized, double‐blind, controlled trial comparing two antithrombotic regimens (a fixed‐dose combination of extended‐release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovascular Diseases2007;23:368‐80. DienerHC , SaccoRL , YusufS , CottonD , OunpuuS , LawtonWA , et al. Effects of aspirin plus extended‐release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double‐blind, active and placebo‐controlled study. Lancet Neurology2008;7:875‐84. YusufS , DienerHC , SaccoRL , CottonD , OunpuuS , LawtonWA , et al. Telmisartan to prevent recurrent stroke and cardiovascular events. New England Journal of Medicine2008;359:1225‐37. ">PRoFESS 2008</a>), and eight months (<a href="./references#CD007858-bbs2-0009" title="ArimaH , AndersonC , OmaeT , LiuL , TzourioC , WoodwardM , et al. Perindopril‐based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial. Journal of Hypertension2010;28:395‐400. ArimaH , ChalmersJ , WoodwardM , AndersonC , RodgersA , DavisS , et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. Journal of Hypertension2006;24:1201‐8. ArimaH , TzourioC , AndersonC , WoodwardM , BousserMG , MacMahonS , et al. Effects of perindopril‐based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke2010;41:394‐6. ChapmanN , HuxleyR , AndersonC , BousserMG , ChalmersJ , ColmanS , et al. Effects of a perindopril‐based blood pressure‐lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke2004;35:116‐21. NealB , MacMahonS . The PROGRESS study: rationale and design. Journal of Hypertension1995;13:1869‐73. NinomiyaT , DonnanG , AndersonN , BladinC , ChambersB , GordonG , et al. Effects of the end point adjudication process on the results of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS). Stroke2009;40:2111‐5. PROGRESS Collaborative Group. Randomised trial of a perindopril‐based blood‐pressure‐lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet2001;358:1033‐41. PROGRESS Management Committee. PROGRESS: Perindopril pROtection aGainst REcurrent Stroke Study: status in March 1997. Journal of Human Hypertension1998;12:627‐9. Progress Management Committee. PROGRESS ‐ Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline. Journal of Hypertension1999;17:1647‐55. RodgersA , ChapmanN , WoodwardM , LiuLS , ColmanS , LeeA , et al. Perindopril‐based blood pressure lowering in individuals with cerebrovascular disease: consistency of benefits by age, sex and region. Journal of Hypertension2004;22:653‐9. TzourioC , AndersonC , ChapmanN , WoodwardM , NealB , MacMahonS , et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Archives of Internal Medicine2003;163:1069‐75. ">PROGRESS 2001</a>). One study reported that 22% of participants were randomised within one week from index event (<a href="./references#CD007858-bbs2-0003" title="The Dutch TIA Study Group. The Dutch TIA trial: protective effects of low‐dose aspirin and atenolol in patients with transient ischemic attacks or nondisabling stroke. Stroke1988;19:512‐7. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. New England Journal of Medicine1991;325:1261‐6. The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke1993;24:543‐8. ">Dutch TIA Trial 1993</a>). One study did not report data on time between index event and start of treatment (<a href="./references#CD007858-bbs2-0011" title="ErikssonS , OlofssonBO , WesterPO , for the TEST study group. Atenolol in secondary prevention after stroke. Cerebrovascular Diseases1995;5:21‐5. ">TEST 1995</a>). </p> <p>Three trials included participants after a minimum time period after the index event; two weeks (<a href="./references#CD007858-bbs2-0001" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1:485‐9. ">Carter 1970</a>), four weeks (<a href="./references#CD007858-bbs2-0006" title="LiuL , GongL , Guang WangJ . Blood pressure lowering in patients with cerebrovascular disease: results of the randomized Post‐stroke Antihypertensive Treatment Study (PATS). Journal of the American College of Cardiology1998;31 (Suppl 2A):211A. LiuL , WangZ , GongL , ZhangY , ThijsL , StaessenJA , et al. Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertension Research2009;32:1032‐40. PATS Collaborating Group. Post‐stroke antihypertensive treatment study. A preliminary result. Chinese Medical Journal1995;108:710‐7. ">PATS 1995</a>), and one year (<a href="./references#CD007858-bbs2-0004" title="Marti MassoJF , LozanoR . Nicardipine in the prevention of cerebral infarction. Clinical Therapeutics1990;12:344‐51. ">Marti Masso 1990</a>). Two of these studies did not report median time from index event to intervention, whereas one study reported a median of 31 months (<a href="./references#CD007858-bbs2-0006" title="LiuL , GongL , Guang WangJ . Blood pressure lowering in patients with cerebrovascular disease: results of the randomized Post‐stroke Antihypertensive Treatment Study (PATS). Journal of the American College of Cardiology1998;31 (Suppl 2A):211A. LiuL , WangZ , GongL , ZhangY , ThijsL , StaessenJA , et al. Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertension Research2009;32:1032‐40. PATS Collaborating Group. Post‐stroke antihypertensive treatment study. A preliminary result. Chinese Medical Journal1995;108:710‐7. ">PATS 1995</a>). </p> </section> <section id="CD007858-sec-0068"> <h6 class="title">Blood pressure at baseline</h6> <p>Increased blood pressure at baseline was not part of our inclusion criteria. Overall mean blood pressure at baseline was not different between participants randomised to blood pressure‐lowering or to placebo or no treatment (<a href="./references#CD007858-fig-0013" title="">Analysis 1.10</a>; <a href="./references#CD007858-fig-0014" title="">Analysis 1.11</a>). </p> </section> <section id="CD007858-sec-0069"> <h6 class="title">Follow‐up</h6> <p>Median overall follow‐up duration was reported in six studies, and ranged from 12 to 47 months. Seven trials reported (recurrent) stroke as the primary outcome measure (<a href="./references#CD007858-bbs2-0001" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1:485‐9. ">Carter 1970</a>; <a href="./references#CD007858-bbs2-0002" title="BauerRB . Effect of antihypertensive treatment on stroke recurrence: results of the hypertension‐stroke cooperative study. Cerebral Vascular Diseases: Transactions of the Ninth Princeton Conference. 1975:137‐54. HooblerSW . Antihypertensive therapy for stroke patients. Hypertension and Stroke Control in the Community: Proceedings of a WHO Meeting, March 1974. 1976. Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. Journal of the American Medical Association1974;229:409‐18. ">Co‐operative Study 1975</a>; <a href="./references#CD007858-bbs2-0004" title="Marti MassoJF , LozanoR . Nicardipine in the prevention of cerebral infarction. Clinical Therapeutics1990;12:344‐51. ">Marti Masso 1990</a>; <a href="./references#CD007858-bbs2-0006" title="LiuL , GongL , Guang WangJ . Blood pressure lowering in patients with cerebrovascular disease: results of the randomized Post‐stroke Antihypertensive Treatment Study (PATS). Journal of the American College of Cardiology1998;31 (Suppl 2A):211A. LiuL , WangZ , GongL , ZhangY , ThijsL , StaessenJA , et al. Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertension Research2009;32:1032‐40. PATS Collaborating Group. Post‐stroke antihypertensive treatment study. A preliminary result. Chinese Medical Journal1995;108:710‐7. ">PATS 1995</a>; <a href="./references#CD007858-bbs2-0008" title="BathPM , MartinRH , PaleschY , CottonD , YusufS , SaccoR , et al. Effect of telmisartan on functional outcome, recurrence, and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke2009;40:3541‐6. DienerHC , SaccoR , YusufS , Steering Committee, PRoFESS Study Group. Rationale, design and baseline data of a randomized, double‐blind, controlled trial comparing two antithrombotic regimens (a fixed‐dose combination of extended‐release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovascular Diseases2007;23:368‐80. DienerHC , SaccoRL , YusufS , CottonD , OunpuuS , LawtonWA , et al. Effects of aspirin plus extended‐release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double‐blind, active and placebo‐controlled study. Lancet Neurology2008;7:875‐84. YusufS , DienerHC , SaccoRL , CottonD , OunpuuS , LawtonWA , et al. Telmisartan to prevent recurrent stroke and cardiovascular events. New England Journal of Medicine2008;359:1225‐37. ">PRoFESS 2008</a>; <a href="./references#CD007858-bbs2-0009" title="ArimaH , AndersonC , OmaeT , LiuL , TzourioC , WoodwardM , et al. Perindopril‐based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial. Journal of Hypertension2010;28:395‐400. ArimaH , ChalmersJ , WoodwardM , AndersonC , RodgersA , DavisS , et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. Journal of Hypertension2006;24:1201‐8. ArimaH , TzourioC , AndersonC , WoodwardM , BousserMG , MacMahonS , et al. Effects of perindopril‐based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke2010;41:394‐6. ChapmanN , HuxleyR , AndersonC , BousserMG , ChalmersJ , ColmanS , et al. Effects of a perindopril‐based blood pressure‐lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke2004;35:116‐21. NealB , MacMahonS . The PROGRESS study: rationale and design. Journal of Hypertension1995;13:1869‐73. NinomiyaT , DonnanG , AndersonN , BladinC , ChambersB , GordonG , et al. Effects of the end point adjudication process on the results of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS). Stroke2009;40:2111‐5. PROGRESS Collaborative Group. Randomised trial of a perindopril‐based blood‐pressure‐lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet2001;358:1033‐41. PROGRESS Management Committee. PROGRESS: Perindopril pROtection aGainst REcurrent Stroke Study: status in March 1997. Journal of Human Hypertension1998;12:627‐9. Progress Management Committee. PROGRESS ‐ Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline. Journal of Hypertension1999;17:1647‐55. RodgersA , ChapmanN , WoodwardM , LiuLS , ColmanS , LeeA , et al. Perindopril‐based blood pressure lowering in individuals with cerebrovascular disease: consistency of benefits by age, sex and region. Journal of Hypertension2004;22:653‐9. TzourioC , AndersonC , ChapmanN , WoodwardM , NealB , MacMahonS , et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Archives of Internal Medicine2003;163:1069‐75. ">PROGRESS 2001</a>; <a href="./references#CD007858-bbs2-0011" title="ErikssonS , OlofssonBO , WesterPO , for the TEST study group. Atenolol in secondary prevention after stroke. Cerebrovascular Diseases1995;5:21‐5. ">TEST 1995</a>), whereas one trial primarily reported a composite endpoint of major vascular events (<a href="./references#CD007858-bbs2-0003" title="The Dutch TIA Study Group. The Dutch TIA trial: protective effects of low‐dose aspirin and atenolol in patients with transient ischemic attacks or nondisabling stroke. Stroke1988;19:512‐7. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. New England Journal of Medicine1991;325:1261‐6. The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke1993;24:543‐8. ">Dutch TIA Trial 1993</a>). </p> </section> </section> <section id="CD007858-sec-0070"> <h5 class="title">Intensive versus standard blood pressure‐lowering</h5> <p>Three trials (3632 participants) met the inclusion criteria for our second comparison, intensive blood pressure‐lowering versus mild or standard blood pressure‐lowering (<a href="./references#CD007858-bbs2-0005" title="FletcherK , MantJ , McManusR , CampbellS , BettsJ , TaylorC , et al. Protocol for Past BP: a randomised controlled trial of different blood pressure targets for people with a history of stroke or transient ischaemic attack (TIA) in primary care. BMC Cardiovascular Disorders2010;10:37. MantJ , McManusRJ , RoalfeA , FletcherK , TaylorCJ , MartinU , et al. Different systolic blood pressure targets for people with history of stroke or transient ischaemic attack: PAST‐BP (Prevention After Stroke‐Blood Pressure) randomised controlled trial. BMJ2016;352:i708. ">PAST‐BP 2016</a>; <a href="./references#CD007858-bbs2-0007" title="BlackburnDJ , KrishnanK , FoxL , BallardC , BurnsA , FordGA , et al. Prevention Of Decline in Cognition After Stroke Trial (PODCAST): a study protocol for a factorial randomised controlled trial of intensive versus guideline lowering of blood pressure and lipids. Trials2013;14:401. ">PODCAST 2017</a>; <a href="./references#CD007858-bbs2-0010" title="BenaventeOR , WhiteCL , PearceL , PergolaP , RoldanA , BenaventeMF , et al. The Secondary Prevention of Small Subcortical Strokes (SPS3) study. International Journal of Stroke2011;6:164‐75. The SPS3 Study Group. Blood‐pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet2013;382:507‐15. WhiteCL , SzychowskiJM , RoldanA , BenaventeMF , PretellEJ , DelBruttoOH , et al. Clinical features and racial/ethnic differences among the 3020 participants in the Secondary Prevention of Small Subcortical Strokes (SPS3) trial. Journal of Stroke and Cerebrovascular Diseases2013;22:764‐74. ">SPS3 2013</a>). All three trials compared a lower versus a higher systolic blood pressure target, although with slightly different targets (&lt; 130 mmHg versus 130 to 149 mmHg (<a href="./references#CD007858-bbs2-0010" title="BenaventeOR , WhiteCL , PearceL , PergolaP , RoldanA , BenaventeMF , et al. The Secondary Prevention of Small Subcortical Strokes (SPS3) study. International Journal of Stroke2011;6:164‐75. The SPS3 Study Group. Blood‐pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet2013;382:507‐15. WhiteCL , SzychowskiJM , RoldanA , BenaventeMF , PretellEJ , DelBruttoOH , et al. Clinical features and racial/ethnic differences among the 3020 participants in the Secondary Prevention of Small Subcortical Strokes (SPS3) trial. Journal of Stroke and Cerebrovascular Diseases2013;22:764‐74. ">SPS3 2013</a>); &lt; 130 mmHg or a reduction of 10 mmHg if systolic blood pressure was between 125 mmHg and 140 mmHg at randomisation versus &lt; 140 mmHg (<a href="./references#CD007858-bbs2-0005" title="FletcherK , MantJ , McManusR , CampbellS , BettsJ , TaylorC , et al. Protocol for Past BP: a randomised controlled trial of different blood pressure targets for people with a history of stroke or transient ischaemic attack (TIA) in primary care. BMC Cardiovascular Disorders2010;10:37. MantJ , McManusRJ , RoalfeA , FletcherK , TaylorCJ , MartinU , et al. Different systolic blood pressure targets for people with history of stroke or transient ischaemic attack: PAST‐BP (Prevention After Stroke‐Blood Pressure) randomised controlled trial. BMJ2016;352:i708. ">PAST‐BP 2016</a>), &lt; 125 mmHg versus &lt; 140 mmHg (<a href="./references#CD007858-bbs2-0007" title="BlackburnDJ , KrishnanK , FoxL , BallardC , BurnsA , FordGA , et al. Prevention Of Decline in Cognition After Stroke Trial (PODCAST): a study protocol for a factorial randomised controlled trial of intensive versus guideline lowering of blood pressure and lipids. Trials2013;14:401. ">PODCAST 2017</a>). The qualifying event was TIA or stroke in one trial (<a href="./references#CD007858-bbs2-0005" title="FletcherK , MantJ , McManusR , CampbellS , BettsJ , TaylorC , et al. Protocol for Past BP: a randomised controlled trial of different blood pressure targets for people with a history of stroke or transient ischaemic attack (TIA) in primary care. BMC Cardiovascular Disorders2010;10:37. MantJ , McManusRJ , RoalfeA , FletcherK , TaylorCJ , MartinU , et al. Different systolic blood pressure targets for people with history of stroke or transient ischaemic attack: PAST‐BP (Prevention After Stroke‐Blood Pressure) randomised controlled trial. BMJ2016;352:i708. ">PAST‐BP 2016</a>), stroke in one trial (<a href="./references#CD007858-bbs2-0007" title="BlackburnDJ , KrishnanK , FoxL , BallardC , BurnsA , FordGA , et al. Prevention Of Decline in Cognition After Stroke Trial (PODCAST): a study protocol for a factorial randomised controlled trial of intensive versus guideline lowering of blood pressure and lipids. Trials2013;14:401. ">PODCAST 2017</a>), and lacunar stroke only in one trial (<a href="./references#CD007858-bbs2-0010" title="BenaventeOR , WhiteCL , PearceL , PergolaP , RoldanA , BenaventeMF , et al. The Secondary Prevention of Small Subcortical Strokes (SPS3) study. International Journal of Stroke2011;6:164‐75. The SPS3 Study Group. Blood‐pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet2013;382:507‐15. WhiteCL , SzychowskiJM , RoldanA , BenaventeMF , PretellEJ , DelBruttoOH , et al. Clinical features and racial/ethnic differences among the 3020 participants in the Secondary Prevention of Small Subcortical Strokes (SPS3) trial. Journal of Stroke and Cerebrovascular Diseases2013;22:764‐74. ">SPS3 2013</a>). Participants were randomised between two weeks and seven months after the qualifying event, with a median 62 days in one trial (<a href="./references#CD007858-bbs2-0010" title="BenaventeOR , WhiteCL , PearceL , PergolaP , RoldanA , BenaventeMF , et al. The Secondary Prevention of Small Subcortical Strokes (SPS3) study. International Journal of Stroke2011;6:164‐75. The SPS3 Study Group. Blood‐pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet2013;382:507‐15. WhiteCL , SzychowskiJM , RoldanA , BenaventeMF , PretellEJ , DelBruttoOH , et al. Clinical features and racial/ethnic differences among the 3020 participants in the Secondary Prevention of Small Subcortical Strokes (SPS3) trial. Journal of Stroke and Cerebrovascular Diseases2013;22:764‐74. ">SPS3 2013</a>), a median 4.5 months in one trial (<a href="./references#CD007858-bbs2-0007" title="BlackburnDJ , KrishnanK , FoxL , BallardC , BurnsA , FordGA , et al. Prevention Of Decline in Cognition After Stroke Trial (PODCAST): a study protocol for a factorial randomised controlled trial of intensive versus guideline lowering of blood pressure and lipids. Trials2013;14:401. ">PODCAST 2017</a>), and unknown median time in one trial (<a href="./references#CD007858-bbs2-0005" title="FletcherK , MantJ , McManusR , CampbellS , BettsJ , TaylorC , et al. Protocol for Past BP: a randomised controlled trial of different blood pressure targets for people with a history of stroke or transient ischaemic attack (TIA) in primary care. BMC Cardiovascular Disorders2010;10:37. MantJ , McManusRJ , RoalfeA , FletcherK , TaylorCJ , MartinU , et al. Different systolic blood pressure targets for people with history of stroke or transient ischaemic attack: PAST‐BP (Prevention After Stroke‐Blood Pressure) randomised controlled trial. BMJ2016;352:i708. ">PAST‐BP 2016</a>). Median overall follow‐up was 12 months (<a href="./references#CD007858-bbs2-0005" title="FletcherK , MantJ , McManusR , CampbellS , BettsJ , TaylorC , et al. Protocol for Past BP: a randomised controlled trial of different blood pressure targets for people with a history of stroke or transient ischaemic attack (TIA) in primary care. BMC Cardiovascular Disorders2010;10:37. MantJ , McManusRJ , RoalfeA , FletcherK , TaylorCJ , MartinU , et al. Different systolic blood pressure targets for people with history of stroke or transient ischaemic attack: PAST‐BP (Prevention After Stroke‐Blood Pressure) randomised controlled trial. BMJ2016;352:i708. ">PAST‐BP 2016</a>), 24 months (<a href="./references#CD007858-bbs2-0007" title="BlackburnDJ , KrishnanK , FoxL , BallardC , BurnsA , FordGA , et al. Prevention Of Decline in Cognition After Stroke Trial (PODCAST): a study protocol for a factorial randomised controlled trial of intensive versus guideline lowering of blood pressure and lipids. Trials2013;14:401. ">PODCAST 2017</a>), and 44 months (<a href="./references#CD007858-bbs2-0010" title="BenaventeOR , WhiteCL , PearceL , PergolaP , RoldanA , BenaventeMF , et al. The Secondary Prevention of Small Subcortical Strokes (SPS3) study. International Journal of Stroke2011;6:164‐75. The SPS3 Study Group. Blood‐pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet2013;382:507‐15. WhiteCL , SzychowskiJM , RoldanA , BenaventeMF , PretellEJ , DelBruttoOH , et al. Clinical features and racial/ethnic differences among the 3020 participants in the Secondary Prevention of Small Subcortical Strokes (SPS3) trial. Journal of Stroke and Cerebrovascular Diseases2013;22:764‐74. ">SPS3 2013</a>). One trial had a 2x2 factorial design, also comparing different antithrombotic regimens (<a href="./references#CD007858-bbs2-0010" title="BenaventeOR , WhiteCL , PearceL , PergolaP , RoldanA , BenaventeMF , et al. The Secondary Prevention of Small Subcortical Strokes (SPS3) study. International Journal of Stroke2011;6:164‐75. The SPS3 Study Group. Blood‐pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet2013;382:507‐15. WhiteCL , SzychowskiJM , RoldanA , BenaventeMF , PretellEJ , DelBruttoOH , et al. Clinical features and racial/ethnic differences among the 3020 participants in the Secondary Prevention of Small Subcortical Strokes (SPS3) trial. Journal of Stroke and Cerebrovascular Diseases2013;22:764‐74. ">SPS3 2013</a>). One trial primarily reported recurrent stroke (<a href="./references#CD007858-bbs2-0010" title="BenaventeOR , WhiteCL , PearceL , PergolaP , RoldanA , BenaventeMF , et al. The Secondary Prevention of Small Subcortical Strokes (SPS3) study. International Journal of Stroke2011;6:164‐75. The SPS3 Study Group. Blood‐pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet2013;382:507‐15. WhiteCL , SzychowskiJM , RoldanA , BenaventeMF , PretellEJ , DelBruttoOH , et al. Clinical features and racial/ethnic differences among the 3020 participants in the Secondary Prevention of Small Subcortical Strokes (SPS3) trial. Journal of Stroke and Cerebrovascular Diseases2013;22:764‐74. ">SPS3 2013</a>), whereas the other trials primarily reported change in systolic blood pressure (<a href="./references#CD007858-bbs2-0005" title="FletcherK , MantJ , McManusR , CampbellS , BettsJ , TaylorC , et al. Protocol for Past BP: a randomised controlled trial of different blood pressure targets for people with a history of stroke or transient ischaemic attack (TIA) in primary care. BMC Cardiovascular Disorders2010;10:37. MantJ , McManusRJ , RoalfeA , FletcherK , TaylorCJ , MartinU , et al. Different systolic blood pressure targets for people with history of stroke or transient ischaemic attack: PAST‐BP (Prevention After Stroke‐Blood Pressure) randomised controlled trial. BMJ2016;352:i708. ">PAST‐BP 2016</a>), and Addenbrooke's Cognitive Examination‐Revised score (<a href="./references#CD007858-bbs2-0007" title="BlackburnDJ , KrishnanK , FoxL , BallardC , BurnsA , FordGA , et al. Prevention Of Decline in Cognition After Stroke Trial (PODCAST): a study protocol for a factorial randomised controlled trial of intensive versus guideline lowering of blood pressure and lipids. Trials2013;14:401. ">PODCAST 2017</a>). </p> </section> </section> <section id="CD007858-sec-0071"> <h4 class="title">Excluded studies</h4> <p>We excluded three studies after discussing their eligibility with the third review author. We excluded two trials because of the large proportion of participants in the control group in whom BPLDs were started during follow‐up, resulting in a lack of contrast between the two treatment arms (<a href="./references#CD007858-bbs2-0013" title="LithellH , HanssonL , SkoogI , ElmfeldtD , HofmanA , OlofssonB , et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double‐blind intervention trial. Journal of Hypertension2003;21(5):875‐86. ">Lithell 2003</a>; <a href="./references#CD007858-bbs2-0014" title="SchraderJ , LüdersS , KulschewskiA , BergerJ , ZidekW , TreibJ , et al. Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke2003;34(7):1699‐703. ">Schrader 2003</a>). One trial did not report baseline characteristics for the intention‐to‐treat population, and a small subset of participants did not have an index TIA or stroke (<a href="./references#CD007858-bbs2-0012" title="LeeJSW , ChuiPY , MaHM , AuyeungTW , KngC , LawT , et al. Does low dose angiotensin converting enzyme inhibitor prevent pneumonia in older people with neurologic dysphagia ‐ a randomized placebo‐controlled trial. Journal of the American Medical Directors Association2015;16(8):702‐7. ">Lee 2015</a>). </p> </section> </section> <section id="CD007858-sec-0072"> <h3 class="title">Risk of bias in included studies</h3> <p>In all included studies, we assessed the risk of selection bias, performance bias, attrition bias, detection bias and reporting bias. We used the 'Risk of bias' tool in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> to classify the seven described domains as 'low risk', 'high risk' or 'unclear risk' (<a href="./references#CD007858-bbs2-0022" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011</a>). An overview is given in the 'Risk of bias summary' (<a href="#CD007858-fig-0002">Figure 2</a>), and the 'Risk of bias graph' (<a href="#CD007858-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD007858-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD007858-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD007858-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD007858-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD007858-sec-0073"> <h4 class="title">Allocation</h4> <p>Two studies did not describe their methods of allocation concealment (<a href="./references#CD007858-bbs2-0001" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1:485‐9. ">Carter 1970</a>; <a href="./references#CD007858-bbs2-0004" title="Marti MassoJF , LozanoR . Nicardipine in the prevention of cerebral infarction. Clinical Therapeutics1990;12:344‐51. ">Marti Masso 1990</a>); we assessed these to have an unclear risk of bias. One study did not describe their method of sequence generation (<a href="./references#CD007858-bbs2-0004" title="Marti MassoJF , LozanoR . Nicardipine in the prevention of cerebral infarction. Clinical Therapeutics1990;12:344‐51. ">Marti Masso 1990</a>); we assessed this as an unclear risk of bias. We assessed the remaining studies as having a low risk of selection bias. </p> </section> <section id="CD007858-sec-0074"> <h4 class="title">Blinding</h4> <p>Two studies did not describe their methods of blinding (<a href="./references#CD007858-bbs2-0001" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1:485‐9. ">Carter 1970</a>; <a href="./references#CD007858-bbs2-0004" title="Marti MassoJF , LozanoR . Nicardipine in the prevention of cerebral infarction. Clinical Therapeutics1990;12:344‐51. ">Marti Masso 1990</a>); we assessed these to have a high risk of bias. Two studies only reported their blinding of participants and personnel as being "double‐blind" (<a href="./references#CD007858-bbs2-0003" title="The Dutch TIA Study Group. The Dutch TIA trial: protective effects of low‐dose aspirin and atenolol in patients with transient ischemic attacks or nondisabling stroke. Stroke1988;19:512‐7. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. New England Journal of Medicine1991;325:1261‐6. The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke1993;24:543‐8. ">Dutch TIA Trial 1993</a>; <a href="./references#CD007858-bbs2-0011" title="ErikssonS , OlofssonBO , WesterPO , for the TEST study group. Atenolol in secondary prevention after stroke. Cerebrovascular Diseases1995;5:21‐5. ">TEST 1995</a>); we assessed these to have an unclear risk of bias. We assessed the remaining studies as having a low risk of performance bias and detection bias. </p> </section> <section id="CD007858-sec-0075"> <h4 class="title">Incomplete outcome data</h4> <p>All trials were analysed according to the intention‐to‐treat principle. One study used a per protocol analysis for their primary outcome measure (blood pressure reduction), and intention‐to‐treat analyses for the clinical outcome events (<a href="./references#CD007858-bbs2-0005" title="FletcherK , MantJ , McManusR , CampbellS , BettsJ , TaylorC , et al. Protocol for Past BP: a randomised controlled trial of different blood pressure targets for people with a history of stroke or transient ischaemic attack (TIA) in primary care. BMC Cardiovascular Disorders2010;10:37. MantJ , McManusRJ , RoalfeA , FletcherK , TaylorCJ , MartinU , et al. Different systolic blood pressure targets for people with history of stroke or transient ischaemic attack: PAST‐BP (Prevention After Stroke‐Blood Pressure) randomised controlled trial. BMJ2016;352:i708. ">PAST‐BP 2016</a>); as we did not use their primary outcome measure, we assessed this study as having a low risk of bias. One study did not address loss to follow‐up (<a href="./references#CD007858-bbs2-0004" title="Marti MassoJF , LozanoR . Nicardipine in the prevention of cerebral infarction. Clinical Therapeutics1990;12:344‐51. ">Marti Masso 1990</a>), and one study only reported overall (reasons for) loss to follow‐up (<a href="./references#CD007858-bbs2-0010" title="BenaventeOR , WhiteCL , PearceL , PergolaP , RoldanA , BenaventeMF , et al. The Secondary Prevention of Small Subcortical Strokes (SPS3) study. International Journal of Stroke2011;6:164‐75. The SPS3 Study Group. Blood‐pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet2013;382:507‐15. WhiteCL , SzychowskiJM , RoldanA , BenaventeMF , PretellEJ , DelBruttoOH , et al. Clinical features and racial/ethnic differences among the 3020 participants in the Secondary Prevention of Small Subcortical Strokes (SPS3) trial. Journal of Stroke and Cerebrovascular Diseases2013;22:764‐74. ">SPS3 2013</a>); we assessed these studies as having an unclear risk of bias. One study reported 28% loss to follow‐up without further explanation (<a href="./references#CD007858-bbs2-0006" title="LiuL , GongL , Guang WangJ . Blood pressure lowering in patients with cerebrovascular disease: results of the randomized Post‐stroke Antihypertensive Treatment Study (PATS). Journal of the American College of Cardiology1998;31 (Suppl 2A):211A. LiuL , WangZ , GongL , ZhangY , ThijsL , StaessenJA , et al. Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertension Research2009;32:1032‐40. PATS Collaborating Group. Post‐stroke antihypertensive treatment study. A preliminary result. Chinese Medical Journal1995;108:710‐7. ">PATS 1995</a>); we assessed this study to be at high risk of bias. We assessed the remaining studies as having low risk of attrition bias. </p> </section> <section id="CD007858-sec-0076"> <h4 class="title">Selective reporting</h4> <p>One study was designed to report functional outcome at three months, but primarily reported major vascular events instead (<a href="./references#CD007858-bbs2-0003" title="The Dutch TIA Study Group. The Dutch TIA trial: protective effects of low‐dose aspirin and atenolol in patients with transient ischemic attacks or nondisabling stroke. Stroke1988;19:512‐7. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. New England Journal of Medicine1991;325:1261‐6. The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke1993;24:543‐8. ">Dutch TIA Trial 1993</a>); we assessed this study as having a high risk of bias. Because there was no study protocol available or published, we assessed five studies as having an unclear risk of bias (<a href="./references#CD007858-bbs2-0001" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1:485‐9. ">Carter 1970</a>; <a href="./references#CD007858-bbs2-0002" title="BauerRB . Effect of antihypertensive treatment on stroke recurrence: results of the hypertension‐stroke cooperative study. Cerebral Vascular Diseases: Transactions of the Ninth Princeton Conference. 1975:137‐54. HooblerSW . Antihypertensive therapy for stroke patients. Hypertension and Stroke Control in the Community: Proceedings of a WHO Meeting, March 1974. 1976. Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. Journal of the American Medical Association1974;229:409‐18. ">Co‐operative Study 1975</a>; <a href="./references#CD007858-bbs2-0004" title="Marti MassoJF , LozanoR . Nicardipine in the prevention of cerebral infarction. Clinical Therapeutics1990;12:344‐51. ">Marti Masso 1990</a>; <a href="./references#CD007858-bbs2-0006" title="LiuL , GongL , Guang WangJ . Blood pressure lowering in patients with cerebrovascular disease: results of the randomized Post‐stroke Antihypertensive Treatment Study (PATS). Journal of the American College of Cardiology1998;31 (Suppl 2A):211A. LiuL , WangZ , GongL , ZhangY , ThijsL , StaessenJA , et al. Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertension Research2009;32:1032‐40. PATS Collaborating Group. Post‐stroke antihypertensive treatment study. A preliminary result. Chinese Medical Journal1995;108:710‐7. ">PATS 1995</a>; <a href="./references#CD007858-bbs2-0011" title="ErikssonS , OlofssonBO , WesterPO , for the TEST study group. Atenolol in secondary prevention after stroke. Cerebrovascular Diseases1995;5:21‐5. ">TEST 1995</a>), whereas the remaining studies were assessed as having a low risk of reporting bias (<a href="./references#CD007858-bbs2-0005" title="FletcherK , MantJ , McManusR , CampbellS , BettsJ , TaylorC , et al. Protocol for Past BP: a randomised controlled trial of different blood pressure targets for people with a history of stroke or transient ischaemic attack (TIA) in primary care. BMC Cardiovascular Disorders2010;10:37. MantJ , McManusRJ , RoalfeA , FletcherK , TaylorCJ , MartinU , et al. Different systolic blood pressure targets for people with history of stroke or transient ischaemic attack: PAST‐BP (Prevention After Stroke‐Blood Pressure) randomised controlled trial. BMJ2016;352:i708. ">PAST‐BP 2016</a>; <a href="./references#CD007858-bbs2-0007" title="BlackburnDJ , KrishnanK , FoxL , BallardC , BurnsA , FordGA , et al. Prevention Of Decline in Cognition After Stroke Trial (PODCAST): a study protocol for a factorial randomised controlled trial of intensive versus guideline lowering of blood pressure and lipids. Trials2013;14:401. ">PODCAST 2017</a>; <a href="./references#CD007858-bbs2-0008" title="BathPM , MartinRH , PaleschY , CottonD , YusufS , SaccoR , et al. Effect of telmisartan on functional outcome, recurrence, and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke2009;40:3541‐6. DienerHC , SaccoR , YusufS , Steering Committee, PRoFESS Study Group. Rationale, design and baseline data of a randomized, double‐blind, controlled trial comparing two antithrombotic regimens (a fixed‐dose combination of extended‐release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovascular Diseases2007;23:368‐80. DienerHC , SaccoRL , YusufS , CottonD , OunpuuS , LawtonWA , et al. Effects of aspirin plus extended‐release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double‐blind, active and placebo‐controlled study. Lancet Neurology2008;7:875‐84. YusufS , DienerHC , SaccoRL , CottonD , OunpuuS , LawtonWA , et al. Telmisartan to prevent recurrent stroke and cardiovascular events. New England Journal of Medicine2008;359:1225‐37. ">PRoFESS 2008</a>; <a href="./references#CD007858-bbs2-0009" title="ArimaH , AndersonC , OmaeT , LiuL , TzourioC , WoodwardM , et al. Perindopril‐based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial. Journal of Hypertension2010;28:395‐400. ArimaH , ChalmersJ , WoodwardM , AndersonC , RodgersA , DavisS , et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. Journal of Hypertension2006;24:1201‐8. ArimaH , TzourioC , AndersonC , WoodwardM , BousserMG , MacMahonS , et al. Effects of perindopril‐based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke2010;41:394‐6. ChapmanN , HuxleyR , AndersonC , BousserMG , ChalmersJ , ColmanS , et al. Effects of a perindopril‐based blood pressure‐lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke2004;35:116‐21. NealB , MacMahonS . The PROGRESS study: rationale and design. Journal of Hypertension1995;13:1869‐73. NinomiyaT , DonnanG , AndersonN , BladinC , ChambersB , GordonG , et al. Effects of the end point adjudication process on the results of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS). Stroke2009;40:2111‐5. PROGRESS Collaborative Group. Randomised trial of a perindopril‐based blood‐pressure‐lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet2001;358:1033‐41. PROGRESS Management Committee. PROGRESS: Perindopril pROtection aGainst REcurrent Stroke Study: status in March 1997. Journal of Human Hypertension1998;12:627‐9. Progress Management Committee. PROGRESS ‐ Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline. Journal of Hypertension1999;17:1647‐55. RodgersA , ChapmanN , WoodwardM , LiuLS , ColmanS , LeeA , et al. Perindopril‐based blood pressure lowering in individuals with cerebrovascular disease: consistency of benefits by age, sex and region. Journal of Hypertension2004;22:653‐9. TzourioC , AndersonC , ChapmanN , WoodwardM , NealB , MacMahonS , et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Archives of Internal Medicine2003;163:1069‐75. ">PROGRESS 2001</a>; <a href="./references#CD007858-bbs2-0010" title="BenaventeOR , WhiteCL , PearceL , PergolaP , RoldanA , BenaventeMF , et al. The Secondary Prevention of Small Subcortical Strokes (SPS3) study. International Journal of Stroke2011;6:164‐75. The SPS3 Study Group. Blood‐pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet2013;382:507‐15. WhiteCL , SzychowskiJM , RoldanA , BenaventeMF , PretellEJ , DelBruttoOH , et al. Clinical features and racial/ethnic differences among the 3020 participants in the Secondary Prevention of Small Subcortical Strokes (SPS3) trial. Journal of Stroke and Cerebrovascular Diseases2013;22:764‐74. ">SPS3 2013</a>). </p> </section> <section id="CD007858-sec-0077"> <h4 class="title">Other potential sources of bias</h4> <p>One study was performed by a single‐investigator, and did not report a definition of the primary endpoint (<a href="./references#CD007858-bbs2-0001" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1:485‐9. ">Carter 1970</a>). In another study, both the number of participants per treatment group and the number of outcome events differed between subsequent reports (<a href="./references#CD007858-bbs2-0006" title="LiuL , GongL , Guang WangJ . Blood pressure lowering in patients with cerebrovascular disease: results of the randomized Post‐stroke Antihypertensive Treatment Study (PATS). Journal of the American College of Cardiology1998;31 (Suppl 2A):211A. LiuL , WangZ , GongL , ZhangY , ThijsL , StaessenJA , et al. Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertension Research2009;32:1032‐40. PATS Collaborating Group. Post‐stroke antihypertensive treatment study. A preliminary result. Chinese Medical Journal1995;108:710‐7. ">PATS 1995</a>); based on these findings we assessed these studies as having a high risk of bias. We did not identify any potential sources of bias in the remaining studies. </p> </section> </section> <section id="CD007858-sec-0078"> <h3 class="title" id="CD007858-sec-0078">Effects of interventions</h3> <p>See: <a href="./full#CD007858-tbl-0001"><b>Summary of findings for the main comparison</b> Blood pressure‐lowering drugs (BPLDs) compared to placebo or no treatment for preventing recurrent stroke, major vascular events, and dementia in patients with a history of TIA or stroke</a> </p> <p>See <a href="./references#CD007858-sec-0112" title="">Data and analyses</a>. </p> <section id="CD007858-sec-0079"> <h4 class="title">Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment</h4> <p>See <a href="./full#CD007858-tbl-0001">summary of findings Table for the main comparison</a> </p> <section id="CD007858-sec-0080"> <h5 class="title">Recurrent stroke of any type</h5> <p>Data from eight trials (35,110 participants) were available for our primary analysis (<a href="./references#CD007858-bbs2-0001" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1:485‐9. ">Carter 1970</a>; <a href="./references#CD007858-bbs2-0002" title="BauerRB . Effect of antihypertensive treatment on stroke recurrence: results of the hypertension‐stroke cooperative study. Cerebral Vascular Diseases: Transactions of the Ninth Princeton Conference. 1975:137‐54. HooblerSW . Antihypertensive therapy for stroke patients. Hypertension and Stroke Control in the Community: Proceedings of a WHO Meeting, March 1974. 1976. Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. Journal of the American Medical Association1974;229:409‐18. ">Co‐operative Study 1975</a>; <a href="./references#CD007858-bbs2-0003" title="The Dutch TIA Study Group. The Dutch TIA trial: protective effects of low‐dose aspirin and atenolol in patients with transient ischemic attacks or nondisabling stroke. Stroke1988;19:512‐7. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. New England Journal of Medicine1991;325:1261‐6. The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke1993;24:543‐8. ">Dutch TIA Trial 1993</a>; <a href="./references#CD007858-bbs2-0004" title="Marti MassoJF , LozanoR . Nicardipine in the prevention of cerebral infarction. Clinical Therapeutics1990;12:344‐51. ">Marti Masso 1990</a>; <a href="./references#CD007858-bbs2-0006" title="LiuL , GongL , Guang WangJ . Blood pressure lowering in patients with cerebrovascular disease: results of the randomized Post‐stroke Antihypertensive Treatment Study (PATS). Journal of the American College of Cardiology1998;31 (Suppl 2A):211A. LiuL , WangZ , GongL , ZhangY , ThijsL , StaessenJA , et al. Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertension Research2009;32:1032‐40. PATS Collaborating Group. Post‐stroke antihypertensive treatment study. A preliminary result. Chinese Medical Journal1995;108:710‐7. ">PATS 1995</a>; <a href="./references#CD007858-bbs2-0009" title="ArimaH , AndersonC , OmaeT , LiuL , TzourioC , WoodwardM , et al. Perindopril‐based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial. Journal of Hypertension2010;28:395‐400. ArimaH , ChalmersJ , WoodwardM , AndersonC , RodgersA , DavisS , et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. Journal of Hypertension2006;24:1201‐8. ArimaH , TzourioC , AndersonC , WoodwardM , BousserMG , MacMahonS , et al. Effects of perindopril‐based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke2010;41:394‐6. ChapmanN , HuxleyR , AndersonC , BousserMG , ChalmersJ , ColmanS , et al. Effects of a perindopril‐based blood pressure‐lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke2004;35:116‐21. NealB , MacMahonS . The PROGRESS study: rationale and design. Journal of Hypertension1995;13:1869‐73. NinomiyaT , DonnanG , AndersonN , BladinC , ChambersB , GordonG , et al. Effects of the end point adjudication process on the results of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS). Stroke2009;40:2111‐5. PROGRESS Collaborative Group. Randomised trial of a perindopril‐based blood‐pressure‐lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet2001;358:1033‐41. PROGRESS Management Committee. PROGRESS: Perindopril pROtection aGainst REcurrent Stroke Study: status in March 1997. Journal of Human Hypertension1998;12:627‐9. Progress Management Committee. PROGRESS ‐ Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline. Journal of Hypertension1999;17:1647‐55. RodgersA , ChapmanN , WoodwardM , LiuLS , ColmanS , LeeA , et al. Perindopril‐based blood pressure lowering in individuals with cerebrovascular disease: consistency of benefits by age, sex and region. Journal of Hypertension2004;22:653‐9. TzourioC , AndersonC , ChapmanN , WoodwardM , NealB , MacMahonS , et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Archives of Internal Medicine2003;163:1069‐75. ">PROGRESS 2001</a>; <a href="./references#CD007858-bbs2-0008" title="BathPM , MartinRH , PaleschY , CottonD , YusufS , SaccoR , et al. Effect of telmisartan on functional outcome, recurrence, and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke2009;40:3541‐6. DienerHC , SaccoR , YusufS , Steering Committee, PRoFESS Study Group. Rationale, design and baseline data of a randomized, double‐blind, controlled trial comparing two antithrombotic regimens (a fixed‐dose combination of extended‐release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovascular Diseases2007;23:368‐80. DienerHC , SaccoRL , YusufS , CottonD , OunpuuS , LawtonWA , et al. Effects of aspirin plus extended‐release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double‐blind, active and placebo‐controlled study. Lancet Neurology2008;7:875‐84. YusufS , DienerHC , SaccoRL , CottonD , OunpuuS , LawtonWA , et al. Telmisartan to prevent recurrent stroke and cardiovascular events. New England Journal of Medicine2008;359:1225‐37. ">PRoFESS 2008</a>; <a href="./references#CD007858-bbs2-0011" title="ErikssonS , OlofssonBO , WesterPO , for the TEST study group. Atenolol in secondary prevention after stroke. Cerebrovascular Diseases1995;5:21‐5. ">TEST 1995</a>). The pooled risk ratio (RR) of BPLDs for recurrent stroke was 0.81 (95% confidence interval (CI) 0.70 to 0.93; moderate‐quality evidence; <a href="./references#CD007858-fig-0004" title="">Analysis 1.1</a>). To explore the substantial heterogeneity (I<sup>2</sup> = 61%), we performed subgroup analyses. </p> <section id="CD007858-sec-0081"> <h6 class="title">Subgroup analyses</h6> <section id="CD007858-sec-0082"> <p><b>Recurrent stroke of any type by baseline systolic blood pressure</b></p> <p>Data from three trials (6656 participants) were available (<a href="./references#CD007858-bbs2-0001" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1:485‐9. ">Carter 1970</a>; <a href="./references#CD007858-bbs2-0002" title="BauerRB . Effect of antihypertensive treatment on stroke recurrence: results of the hypertension‐stroke cooperative study. Cerebral Vascular Diseases: Transactions of the Ninth Princeton Conference. 1975:137‐54. HooblerSW . Antihypertensive therapy for stroke patients. Hypertension and Stroke Control in the Community: Proceedings of a WHO Meeting, March 1974. 1976. Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. Journal of the American Medical Association1974;229:409‐18. ">Co‐operative Study 1975</a>; <a href="./references#CD007858-bbs2-0009" title="ArimaH , AndersonC , OmaeT , LiuL , TzourioC , WoodwardM , et al. Perindopril‐based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial. Journal of Hypertension2010;28:395‐400. ArimaH , ChalmersJ , WoodwardM , AndersonC , RodgersA , DavisS , et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. Journal of Hypertension2006;24:1201‐8. ArimaH , TzourioC , AndersonC , WoodwardM , BousserMG , MacMahonS , et al. Effects of perindopril‐based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke2010;41:394‐6. ChapmanN , HuxleyR , AndersonC , BousserMG , ChalmersJ , ColmanS , et al. Effects of a perindopril‐based blood pressure‐lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke2004;35:116‐21. NealB , MacMahonS . The PROGRESS study: rationale and design. Journal of Hypertension1995;13:1869‐73. NinomiyaT , DonnanG , AndersonN , BladinC , ChambersB , GordonG , et al. Effects of the end point adjudication process on the results of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS). Stroke2009;40:2111‐5. PROGRESS Collaborative Group. Randomised trial of a perindopril‐based blood‐pressure‐lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet2001;358:1033‐41. PROGRESS Management Committee. PROGRESS: Perindopril pROtection aGainst REcurrent Stroke Study: status in March 1997. Journal of Human Hypertension1998;12:627‐9. Progress Management Committee. PROGRESS ‐ Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline. Journal of Hypertension1999;17:1647‐55. RodgersA , ChapmanN , WoodwardM , LiuLS , ColmanS , LeeA , et al. Perindopril‐based blood pressure lowering in individuals with cerebrovascular disease: consistency of benefits by age, sex and region. Journal of Hypertension2004;22:653‐9. TzourioC , AndersonC , ChapmanN , WoodwardM , NealB , MacMahonS , et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Archives of Internal Medicine2003;163:1069‐75. ">PROGRESS 2001</a>). The pooled RRs of BPLDs for recurrent stroke were 0.65 (95% CI 0.51 to 0.83) in participants with a baseline systolic blood pressure of 160 mmHg or above, and 0.71 (95% CI 0.57 to 0.89) in those with a baseline systolic blood pressure between 140 and 160 mmHg. The RRs of BPLDs for recurrent stroke were 0.86 (95% CI 0.67 to 1.12) in participants with a baseline systolic blood pressure between 120 and 140 mmHg, and 1.01 (95% CI 0.47 to 2.19) in those with a baseline systolic blood pressure below 120 mmHg (<a href="./references#CD007858-fig-0015" title="">Analysis 2.1</a>). The I<sup>2</sup> statistic for subgroup differences was 5.3% (P = 0.37). </p> </section> <section id="CD007858-sec-0083"> <p><b>Recurrent stroke of any type by intervention</b></p> <p>Data from eight trials (35,110 participants) were available (<a href="./references#CD007858-bbs2-0001" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1:485‐9. ">Carter 1970</a>; <a href="./references#CD007858-bbs2-0002" title="BauerRB . Effect of antihypertensive treatment on stroke recurrence: results of the hypertension‐stroke cooperative study. Cerebral Vascular Diseases: Transactions of the Ninth Princeton Conference. 1975:137‐54. HooblerSW . Antihypertensive therapy for stroke patients. Hypertension and Stroke Control in the Community: Proceedings of a WHO Meeting, March 1974. 1976. Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. Journal of the American Medical Association1974;229:409‐18. ">Co‐operative Study 1975</a>; <a href="./references#CD007858-bbs2-0004" title="Marti MassoJF , LozanoR . Nicardipine in the prevention of cerebral infarction. Clinical Therapeutics1990;12:344‐51. ">Marti Masso 1990</a>; <a href="./references#CD007858-bbs2-0003" title="The Dutch TIA Study Group. The Dutch TIA trial: protective effects of low‐dose aspirin and atenolol in patients with transient ischemic attacks or nondisabling stroke. Stroke1988;19:512‐7. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. New England Journal of Medicine1991;325:1261‐6. The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke1993;24:543‐8. ">Dutch TIA Trial 1993</a>; <a href="./references#CD007858-bbs2-0006" title="LiuL , GongL , Guang WangJ . Blood pressure lowering in patients with cerebrovascular disease: results of the randomized Post‐stroke Antihypertensive Treatment Study (PATS). Journal of the American College of Cardiology1998;31 (Suppl 2A):211A. LiuL , WangZ , GongL , ZhangY , ThijsL , StaessenJA , et al. Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertension Research2009;32:1032‐40. PATS Collaborating Group. Post‐stroke antihypertensive treatment study. A preliminary result. Chinese Medical Journal1995;108:710‐7. ">PATS 1995</a>; <a href="./references#CD007858-bbs2-0009" title="ArimaH , AndersonC , OmaeT , LiuL , TzourioC , WoodwardM , et al. Perindopril‐based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial. Journal of Hypertension2010;28:395‐400. ArimaH , ChalmersJ , WoodwardM , AndersonC , RodgersA , DavisS , et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. Journal of Hypertension2006;24:1201‐8. ArimaH , TzourioC , AndersonC , WoodwardM , BousserMG , MacMahonS , et al. Effects of perindopril‐based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke2010;41:394‐6. ChapmanN , HuxleyR , AndersonC , BousserMG , ChalmersJ , ColmanS , et al. Effects of a perindopril‐based blood pressure‐lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke2004;35:116‐21. NealB , MacMahonS . The PROGRESS study: rationale and design. Journal of Hypertension1995;13:1869‐73. NinomiyaT , DonnanG , AndersonN , BladinC , ChambersB , GordonG , et al. Effects of the end point adjudication process on the results of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS). Stroke2009;40:2111‐5. PROGRESS Collaborative Group. Randomised trial of a perindopril‐based blood‐pressure‐lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet2001;358:1033‐41. PROGRESS Management Committee. PROGRESS: Perindopril pROtection aGainst REcurrent Stroke Study: status in March 1997. Journal of Human Hypertension1998;12:627‐9. Progress Management Committee. PROGRESS ‐ Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline. Journal of Hypertension1999;17:1647‐55. RodgersA , ChapmanN , WoodwardM , LiuLS , ColmanS , LeeA , et al. Perindopril‐based blood pressure lowering in individuals with cerebrovascular disease: consistency of benefits by age, sex and region. Journal of Hypertension2004;22:653‐9. TzourioC , AndersonC , ChapmanN , WoodwardM , NealB , MacMahonS , et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Archives of Internal Medicine2003;163:1069‐75. ">PROGRESS 2001</a>; <a href="./references#CD007858-bbs2-0008" title="BathPM , MartinRH , PaleschY , CottonD , YusufS , SaccoR , et al. Effect of telmisartan on functional outcome, recurrence, and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke2009;40:3541‐6. DienerHC , SaccoR , YusufS , Steering Committee, PRoFESS Study Group. Rationale, design and baseline data of a randomized, double‐blind, controlled trial comparing two antithrombotic regimens (a fixed‐dose combination of extended‐release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovascular Diseases2007;23:368‐80. DienerHC , SaccoRL , YusufS , CottonD , OunpuuS , LawtonWA , et al. Effects of aspirin plus extended‐release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double‐blind, active and placebo‐controlled study. Lancet Neurology2008;7:875‐84. YusufS , DienerHC , SaccoRL , CottonD , OunpuuS , LawtonWA , et al. Telmisartan to prevent recurrent stroke and cardiovascular events. New England Journal of Medicine2008;359:1225‐37. ">PRoFESS 2008</a>; <a href="./references#CD007858-bbs2-0011" title="ErikssonS , OlofssonBO , WesterPO , for the TEST study group. Atenolol in secondary prevention after stroke. Cerebrovascular Diseases1995;5:21‐5. ">TEST 1995</a>). The pooled RRs of BPLDs for recurrent stroke were 0.73 (95% CI 0.64 to 0.84) in participants using ACE inhibitors, 0.72 (95% CI 0.59 to 0.87) in those using diuretics, and 0.94 (95% CI 0.75 to 1.18) in those using beta‐blockers. The RRs of BPLDs for recurrent stroke were 0.95 (95% CI 0.87 to 1.03) in participants using angiotensin receptor blockers, and 0.55 (95% CI 0.18 to 1.67) in those using calcium channel blockers (<a href="./references#CD007858-fig-0016" title="">Analysis 2.2</a>). The I<sup>2</sup> statistic for subgroup differences was 72.1% (P = 0.006). </p> </section> <section id="CD007858-sec-0084"> <p><b>Recurrent stroke of any type by type of index event</b></p> <p>Data from one trial (5854 participants) were available (<a href="./references#CD007858-bbs2-0009" title="ArimaH , AndersonC , OmaeT , LiuL , TzourioC , WoodwardM , et al. Perindopril‐based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial. Journal of Hypertension2010;28:395‐400. ArimaH , ChalmersJ , WoodwardM , AndersonC , RodgersA , DavisS , et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. Journal of Hypertension2006;24:1201‐8. ArimaH , TzourioC , AndersonC , WoodwardM , BousserMG , MacMahonS , et al. Effects of perindopril‐based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke2010;41:394‐6. ChapmanN , HuxleyR , AndersonC , BousserMG , ChalmersJ , ColmanS , et al. Effects of a perindopril‐based blood pressure‐lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke2004;35:116‐21. NealB , MacMahonS . The PROGRESS study: rationale and design. Journal of Hypertension1995;13:1869‐73. NinomiyaT , DonnanG , AndersonN , BladinC , ChambersB , GordonG , et al. Effects of the end point adjudication process on the results of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS). Stroke2009;40:2111‐5. PROGRESS Collaborative Group. Randomised trial of a perindopril‐based blood‐pressure‐lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet2001;358:1033‐41. PROGRESS Management Committee. PROGRESS: Perindopril pROtection aGainst REcurrent Stroke Study: status in March 1997. Journal of Human Hypertension1998;12:627‐9. Progress Management Committee. PROGRESS ‐ Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline. Journal of Hypertension1999;17:1647‐55. RodgersA , ChapmanN , WoodwardM , LiuLS , ColmanS , LeeA , et al. Perindopril‐based blood pressure lowering in individuals with cerebrovascular disease: consistency of benefits by age, sex and region. Journal of Hypertension2004;22:653‐9. TzourioC , AndersonC , ChapmanN , WoodwardM , NealB , MacMahonS , et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Archives of Internal Medicine2003;163:1069‐75. ">PROGRESS 2001</a>). The RRs of BPLDs for recurrent stroke were 0.76 (95% CI 0.64 to 0.89) in participants with an ischaemic index stroke, 0.59 (95% CI 0.39 to 0.89) in those with an haemorrhagic index stroke, and 0.77 (95% CI 0.50 to 1.18) in those with an index TIA (<a href="./references#CD007858-fig-0017" title="">Analysis 2.3</a>). The I<sup>2</sup> statistic for subgroup differences was 0% (P = 0.53). </p> </section> </section> <section id="CD007858-sec-0085"> <h6 class="title">Sensitivity analyses</h6> <section id="CD007858-sec-0086"> <p><b>Recurrent stroke of any type, methodological quality</b></p> <p>Five trials (29,082 participants) were of high methodological quality (<a href="./references#CD007858-bbs2-0002" title="BauerRB . Effect of antihypertensive treatment on stroke recurrence: results of the hypertension‐stroke cooperative study. Cerebral Vascular Diseases: Transactions of the Ninth Princeton Conference. 1975:137‐54. HooblerSW . Antihypertensive therapy for stroke patients. Hypertension and Stroke Control in the Community: Proceedings of a WHO Meeting, March 1974. 1976. Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. Journal of the American Medical Association1974;229:409‐18. ">Co‐operative Study 1975</a>; <a href="./references#CD007858-bbs2-0003" title="The Dutch TIA Study Group. The Dutch TIA trial: protective effects of low‐dose aspirin and atenolol in patients with transient ischemic attacks or nondisabling stroke. Stroke1988;19:512‐7. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. New England Journal of Medicine1991;325:1261‐6. The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke1993;24:543‐8. ">Dutch TIA Trial 1993</a>; <a href="./references#CD007858-bbs2-0009" title="ArimaH , AndersonC , OmaeT , LiuL , TzourioC , WoodwardM , et al. Perindopril‐based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial. Journal of Hypertension2010;28:395‐400. ArimaH , ChalmersJ , WoodwardM , AndersonC , RodgersA , DavisS , et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. Journal of Hypertension2006;24:1201‐8. ArimaH , TzourioC , AndersonC , WoodwardM , BousserMG , MacMahonS , et al. Effects of perindopril‐based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke2010;41:394‐6. ChapmanN , HuxleyR , AndersonC , BousserMG , ChalmersJ , ColmanS , et al. Effects of a perindopril‐based blood pressure‐lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke2004;35:116‐21. NealB , MacMahonS . The PROGRESS study: rationale and design. Journal of Hypertension1995;13:1869‐73. NinomiyaT , DonnanG , AndersonN , BladinC , ChambersB , GordonG , et al. Effects of the end point adjudication process on the results of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS). Stroke2009;40:2111‐5. PROGRESS Collaborative Group. Randomised trial of a perindopril‐based blood‐pressure‐lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet2001;358:1033‐41. PROGRESS Management Committee. PROGRESS: Perindopril pROtection aGainst REcurrent Stroke Study: status in March 1997. Journal of Human Hypertension1998;12:627‐9. Progress Management Committee. PROGRESS ‐ Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline. Journal of Hypertension1999;17:1647‐55. RodgersA , ChapmanN , WoodwardM , LiuLS , ColmanS , LeeA , et al. Perindopril‐based blood pressure lowering in individuals with cerebrovascular disease: consistency of benefits by age, sex and region. Journal of Hypertension2004;22:653‐9. TzourioC , AndersonC , ChapmanN , WoodwardM , NealB , MacMahonS , et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Archives of Internal Medicine2003;163:1069‐75. ">PROGRESS 2001</a>; <a href="./references#CD007858-bbs2-0008" title="BathPM , MartinRH , PaleschY , CottonD , YusufS , SaccoR , et al. Effect of telmisartan on functional outcome, recurrence, and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke2009;40:3541‐6. DienerHC , SaccoR , YusufS , Steering Committee, PRoFESS Study Group. Rationale, design and baseline data of a randomized, double‐blind, controlled trial comparing two antithrombotic regimens (a fixed‐dose combination of extended‐release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovascular Diseases2007;23:368‐80. DienerHC , SaccoRL , YusufS , CottonD , OunpuuS , LawtonWA , et al. Effects of aspirin plus extended‐release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double‐blind, active and placebo‐controlled study. Lancet Neurology2008;7:875‐84. YusufS , DienerHC , SaccoRL , CottonD , OunpuuS , LawtonWA , et al. Telmisartan to prevent recurrent stroke and cardiovascular events. New England Journal of Medicine2008;359:1225‐37. ">PRoFESS 2008</a>; <a href="./references#CD007858-bbs2-0011" title="ErikssonS , OlofssonBO , WesterPO , for the TEST study group. Atenolol in secondary prevention after stroke. Cerebrovascular Diseases1995;5:21‐5. ">TEST 1995</a>). The pooled RR of BPLDs for recurrent stroke was 0.86 (95% CI 0.75 to 1.00; <a href="./references#CD007858-fig-0019" title="">Analysis 3.1</a>). </p> <p><i>Recurrent stroke of any type, minimum 5 mmHg systolic blood pressure reduction</i> </p> <p>Four trials (33,575 participants) achieved a minimum systolic blood pressure reduction of 5 mmHg at the end of the observation period (<a href="./references#CD007858-bbs2-0003" title="The Dutch TIA Study Group. The Dutch TIA trial: protective effects of low‐dose aspirin and atenolol in patients with transient ischemic attacks or nondisabling stroke. Stroke1988;19:512‐7. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. New England Journal of Medicine1991;325:1261‐6. The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke1993;24:543‐8. ">Dutch TIA Trial 1993</a>; <a href="./references#CD007858-bbs2-0006" title="LiuL , GongL , Guang WangJ . Blood pressure lowering in patients with cerebrovascular disease: results of the randomized Post‐stroke Antihypertensive Treatment Study (PATS). Journal of the American College of Cardiology1998;31 (Suppl 2A):211A. LiuL , WangZ , GongL , ZhangY , ThijsL , StaessenJA , et al. Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertension Research2009;32:1032‐40. PATS Collaborating Group. Post‐stroke antihypertensive treatment study. A preliminary result. Chinese Medical Journal1995;108:710‐7. ">PATS 1995</a>; <a href="./references#CD007858-bbs2-0009" title="ArimaH , AndersonC , OmaeT , LiuL , TzourioC , WoodwardM , et al. Perindopril‐based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial. Journal of Hypertension2010;28:395‐400. ArimaH , ChalmersJ , WoodwardM , AndersonC , RodgersA , DavisS , et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. Journal of Hypertension2006;24:1201‐8. ArimaH , TzourioC , AndersonC , WoodwardM , BousserMG , MacMahonS , et al. Effects of perindopril‐based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke2010;41:394‐6. ChapmanN , HuxleyR , AndersonC , BousserMG , ChalmersJ , ColmanS , et al. Effects of a perindopril‐based blood pressure‐lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke2004;35:116‐21. NealB , MacMahonS . The PROGRESS study: rationale and design. Journal of Hypertension1995;13:1869‐73. NinomiyaT , DonnanG , AndersonN , BladinC , ChambersB , GordonG , et al. Effects of the end point adjudication process on the results of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS). Stroke2009;40:2111‐5. PROGRESS Collaborative Group. Randomised trial of a perindopril‐based blood‐pressure‐lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet2001;358:1033‐41. PROGRESS Management Committee. PROGRESS: Perindopril pROtection aGainst REcurrent Stroke Study: status in March 1997. Journal of Human Hypertension1998;12:627‐9. Progress Management Committee. PROGRESS ‐ Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline. Journal of Hypertension1999;17:1647‐55. RodgersA , ChapmanN , WoodwardM , LiuLS , ColmanS , LeeA , et al. Perindopril‐based blood pressure lowering in individuals with cerebrovascular disease: consistency of benefits by age, sex and region. Journal of Hypertension2004;22:653‐9. TzourioC , AndersonC , ChapmanN , WoodwardM , NealB , MacMahonS , et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Archives of Internal Medicine2003;163:1069‐75. ">PROGRESS 2001</a>; <a href="./references#CD007858-bbs2-0008" title="BathPM , MartinRH , PaleschY , CottonD , YusufS , SaccoR , et al. Effect of telmisartan on functional outcome, recurrence, and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke2009;40:3541‐6. DienerHC , SaccoR , YusufS , Steering Committee, PRoFESS Study Group. Rationale, design and baseline data of a randomized, double‐blind, controlled trial comparing two antithrombotic regimens (a fixed‐dose combination of extended‐release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovascular Diseases2007;23:368‐80. DienerHC , SaccoRL , YusufS , CottonD , OunpuuS , LawtonWA , et al. Effects of aspirin plus extended‐release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double‐blind, active and placebo‐controlled study. Lancet Neurology2008;7:875‐84. YusufS , DienerHC , SaccoRL , CottonD , OunpuuS , LawtonWA , et al. Telmisartan to prevent recurrent stroke and cardiovascular events. New England Journal of Medicine2008;359:1225‐37. ">PRoFESS 2008</a>). The pooled RR of BPLDs for recurrent stroke was 0.81 (95% CI 0.68 to 0.96; <a href="./references#CD007858-fig-0020" title="">Analysis 3.2</a>). </p> </section> <section id="CD007858-sec-0087"> <p><b>Recurrent stroke of any type, minimum 3 mmHg diastolic blood pressure reduction</b></p> <p>Five trials (34,295 participants) achieved a minimum systolic blood pressure reduction of 3 mmHg at the end of the observation period (<a href="./references#CD007858-bbs2-0003" title="The Dutch TIA Study Group. The Dutch TIA trial: protective effects of low‐dose aspirin and atenolol in patients with transient ischemic attacks or nondisabling stroke. Stroke1988;19:512‐7. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. New England Journal of Medicine1991;325:1261‐6. The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke1993;24:543‐8. ">Dutch TIA Trial 1993</a>; <a href="./references#CD007858-bbs2-0006" title="LiuL , GongL , Guang WangJ . Blood pressure lowering in patients with cerebrovascular disease: results of the randomized Post‐stroke Antihypertensive Treatment Study (PATS). Journal of the American College of Cardiology1998;31 (Suppl 2A):211A. LiuL , WangZ , GongL , ZhangY , ThijsL , StaessenJA , et al. Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertension Research2009;32:1032‐40. PATS Collaborating Group. Post‐stroke antihypertensive treatment study. A preliminary result. Chinese Medical Journal1995;108:710‐7. ">PATS 1995</a>; <a href="./references#CD007858-bbs2-0009" title="ArimaH , AndersonC , OmaeT , LiuL , TzourioC , WoodwardM , et al. Perindopril‐based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial. Journal of Hypertension2010;28:395‐400. ArimaH , ChalmersJ , WoodwardM , AndersonC , RodgersA , DavisS , et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. Journal of Hypertension2006;24:1201‐8. ArimaH , TzourioC , AndersonC , WoodwardM , BousserMG , MacMahonS , et al. Effects of perindopril‐based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke2010;41:394‐6. ChapmanN , HuxleyR , AndersonC , BousserMG , ChalmersJ , ColmanS , et al. Effects of a perindopril‐based blood pressure‐lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke2004;35:116‐21. NealB , MacMahonS . The PROGRESS study: rationale and design. Journal of Hypertension1995;13:1869‐73. NinomiyaT , DonnanG , AndersonN , BladinC , ChambersB , GordonG , et al. Effects of the end point adjudication process on the results of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS). Stroke2009;40:2111‐5. PROGRESS Collaborative Group. Randomised trial of a perindopril‐based blood‐pressure‐lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet2001;358:1033‐41. PROGRESS Management Committee. PROGRESS: Perindopril pROtection aGainst REcurrent Stroke Study: status in March 1997. Journal of Human Hypertension1998;12:627‐9. Progress Management Committee. PROGRESS ‐ Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline. Journal of Hypertension1999;17:1647‐55. RodgersA , ChapmanN , WoodwardM , LiuLS , ColmanS , LeeA , et al. Perindopril‐based blood pressure lowering in individuals with cerebrovascular disease: consistency of benefits by age, sex and region. Journal of Hypertension2004;22:653‐9. TzourioC , AndersonC , ChapmanN , WoodwardM , NealB , MacMahonS , et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Archives of Internal Medicine2003;163:1069‐75. ">PROGRESS 2001</a>; <a href="./references#CD007858-bbs2-0008" title="BathPM , MartinRH , PaleschY , CottonD , YusufS , SaccoR , et al. Effect of telmisartan on functional outcome, recurrence, and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke2009;40:3541‐6. DienerHC , SaccoR , YusufS , Steering Committee, PRoFESS Study Group. Rationale, design and baseline data of a randomized, double‐blind, controlled trial comparing two antithrombotic regimens (a fixed‐dose combination of extended‐release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovascular Diseases2007;23:368‐80. DienerHC , SaccoRL , YusufS , CottonD , OunpuuS , LawtonWA , et al. Effects of aspirin plus extended‐release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double‐blind, active and placebo‐controlled study. Lancet Neurology2008;7:875‐84. YusufS , DienerHC , SaccoRL , CottonD , OunpuuS , LawtonWA , et al. Telmisartan to prevent recurrent stroke and cardiovascular events. New England Journal of Medicine2008;359:1225‐37. ">PRoFESS 2008</a>; <a href="./references#CD007858-bbs2-0011" title="ErikssonS , OlofssonBO , WesterPO , for the TEST study group. Atenolol in secondary prevention after stroke. Cerebrovascular Diseases1995;5:21‐5. ">TEST 1995</a>). The pooled RR of BPLDs for recurrent stroke was 0.84 (95% CI 0.72 to 0.97; <a href="./references#CD007858-fig-0021" title="">Analysis 3.3</a>). </p> </section> <section id="CD007858-sec-0088"> <p><b>Recurrent stroke of any type, excluding patients with subarachnoid haemorrhage as possible index event</b></p> <p>One trial not only included participants with an ischaemic of haemorrhagic stroke, but also with subarachnoid haemorrhage (<a href="./references#CD007858-bbs2-0006" title="LiuL , GongL , Guang WangJ . Blood pressure lowering in patients with cerebrovascular disease: results of the randomized Post‐stroke Antihypertensive Treatment Study (PATS). Journal of the American College of Cardiology1998;31 (Suppl 2A):211A. LiuL , WangZ , GongL , ZhangY , ThijsL , StaessenJA , et al. Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertension Research2009;32:1032‐40. PATS Collaborating Group. Post‐stroke antihypertensive treatment study. A preliminary result. Chinese Medical Journal1995;108:710‐7. ">PATS 1995</a>). Recurrent stroke was reported separately for participants with an ischaemic stroke as index event and a haemorrhagic stroke as index event (comprising both intracerebral and subarachnoid haemorrhage). Therefore, we performed this additional sensitivity analysis, excluding the participants from this trial with a haemorrhagic stroke as index event. </p> <p>Data from eight trials (33,690 participants) were available (<a href="./references#CD007858-bbs2-0001" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1:485‐9. ">Carter 1970</a>; <a href="./references#CD007858-bbs2-0002" title="BauerRB . Effect of antihypertensive treatment on stroke recurrence: results of the hypertension‐stroke cooperative study. Cerebral Vascular Diseases: Transactions of the Ninth Princeton Conference. 1975:137‐54. HooblerSW . Antihypertensive therapy for stroke patients. Hypertension and Stroke Control in the Community: Proceedings of a WHO Meeting, March 1974. 1976. Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. Journal of the American Medical Association1974;229:409‐18. ">Co‐operative Study 1975</a>; <a href="./references#CD007858-bbs2-0003" title="The Dutch TIA Study Group. The Dutch TIA trial: protective effects of low‐dose aspirin and atenolol in patients with transient ischemic attacks or nondisabling stroke. Stroke1988;19:512‐7. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. New England Journal of Medicine1991;325:1261‐6. The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke1993;24:543‐8. ">Dutch TIA Trial 1993</a>; <a href="./references#CD007858-bbs2-0004" title="Marti MassoJF , LozanoR . Nicardipine in the prevention of cerebral infarction. Clinical Therapeutics1990;12:344‐51. ">Marti Masso 1990</a>; <a href="./references#CD007858-bbs2-0006" title="LiuL , GongL , Guang WangJ . Blood pressure lowering in patients with cerebrovascular disease: results of the randomized Post‐stroke Antihypertensive Treatment Study (PATS). Journal of the American College of Cardiology1998;31 (Suppl 2A):211A. LiuL , WangZ , GongL , ZhangY , ThijsL , StaessenJA , et al. Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertension Research2009;32:1032‐40. PATS Collaborating Group. Post‐stroke antihypertensive treatment study. A preliminary result. Chinese Medical Journal1995;108:710‐7. ">PATS 1995</a>; <a href="./references#CD007858-bbs2-0009" title="ArimaH , AndersonC , OmaeT , LiuL , TzourioC , WoodwardM , et al. Perindopril‐based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial. Journal of Hypertension2010;28:395‐400. ArimaH , ChalmersJ , WoodwardM , AndersonC , RodgersA , DavisS , et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. Journal of Hypertension2006;24:1201‐8. ArimaH , TzourioC , AndersonC , WoodwardM , BousserMG , MacMahonS , et al. Effects of perindopril‐based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke2010;41:394‐6. ChapmanN , HuxleyR , AndersonC , BousserMG , ChalmersJ , ColmanS , et al. Effects of a perindopril‐based blood pressure‐lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke2004;35:116‐21. NealB , MacMahonS . The PROGRESS study: rationale and design. Journal of Hypertension1995;13:1869‐73. NinomiyaT , DonnanG , AndersonN , BladinC , ChambersB , GordonG , et al. Effects of the end point adjudication process on the results of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS). Stroke2009;40:2111‐5. PROGRESS Collaborative Group. Randomised trial of a perindopril‐based blood‐pressure‐lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet2001;358:1033‐41. PROGRESS Management Committee. PROGRESS: Perindopril pROtection aGainst REcurrent Stroke Study: status in March 1997. Journal of Human Hypertension1998;12:627‐9. Progress Management Committee. PROGRESS ‐ Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline. Journal of Hypertension1999;17:1647‐55. RodgersA , ChapmanN , WoodwardM , LiuLS , ColmanS , LeeA , et al. Perindopril‐based blood pressure lowering in individuals with cerebrovascular disease: consistency of benefits by age, sex and region. Journal of Hypertension2004;22:653‐9. TzourioC , AndersonC , ChapmanN , WoodwardM , NealB , MacMahonS , et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Archives of Internal Medicine2003;163:1069‐75. ">PROGRESS 2001</a>; <a href="./references#CD007858-bbs2-0008" title="BathPM , MartinRH , PaleschY , CottonD , YusufS , SaccoR , et al. Effect of telmisartan on functional outcome, recurrence, and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke2009;40:3541‐6. DienerHC , SaccoR , YusufS , Steering Committee, PRoFESS Study Group. Rationale, design and baseline data of a randomized, double‐blind, controlled trial comparing two antithrombotic regimens (a fixed‐dose combination of extended‐release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovascular Diseases2007;23:368‐80. DienerHC , SaccoRL , YusufS , CottonD , OunpuuS , LawtonWA , et al. Effects of aspirin plus extended‐release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double‐blind, active and placebo‐controlled study. Lancet Neurology2008;7:875‐84. YusufS , DienerHC , SaccoRL , CottonD , OunpuuS , LawtonWA , et al. Telmisartan to prevent recurrent stroke and cardiovascular events. New England Journal of Medicine2008;359:1225‐37. ">PRoFESS 2008</a>; <a href="./references#CD007858-bbs2-0011" title="ErikssonS , OlofssonBO , WesterPO , for the TEST study group. Atenolol in secondary prevention after stroke. Cerebrovascular Diseases1995;5:21‐5. ">TEST 1995</a>). The pooled RR of BPLDs for recurrent stroke was 0.81 (95% CI 0.70 to 0.93; <a href="./references#CD007858-fig-0022" title="">Analysis 3.4</a>). </p> <p>We did not perform subgroup analyses based on self‐reported ethnicity, prior history of hypertension, age, and sex because of insufficient studies reporting estimates for these subgroups. We did not perform sensitivity analyses based on time of treatment initiation, duration of treatment and follow‐up, or the achieved contrast in systolic blood pressure‐lowering between intervention and control. All studies treated and followed participants for at least one year, and studies did not uniformly report time of treatment initiation or the contrast in systolic blood pressure‐lowering at the end of the observation period. </p> </section> </section> </section> <section id="CD007858-sec-0089"> <h5 class="title">Time to recurrent stroke</h5> <p>We transformed tabular data for the <a href="./references#CD007858-bbs2-0002" title="BauerRB . Effect of antihypertensive treatment on stroke recurrence: results of the hypertension‐stroke cooperative study. Cerebral Vascular Diseases: Transactions of the Ninth Princeton Conference. 1975:137‐54. HooblerSW . Antihypertensive therapy for stroke patients. Hypertension and Stroke Control in the Community: Proceedings of a WHO Meeting, March 1974. 1976. Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. Journal of the American Medical Association1974;229:409‐18. ">Co‐operative Study 1975</a> into a hazard ratio using spreadsheets developed by Tierney et al (<a href="./references#CD007858-bbs2-0033" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials2007;8:16. ">Tierney 2007</a>; <a href="./references#CD007858-bbs2-0036" title="WangYu , ZengTingting . Response to: Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials2013;14:391. ">Wang 2013</a>). </p> <p>Data from three trials (26,889 participants) were available (<a href="./references#CD007858-bbs2-0002" title="BauerRB . Effect of antihypertensive treatment on stroke recurrence: results of the hypertension‐stroke cooperative study. Cerebral Vascular Diseases: Transactions of the Ninth Princeton Conference. 1975:137‐54. HooblerSW . Antihypertensive therapy for stroke patients. Hypertension and Stroke Control in the Community: Proceedings of a WHO Meeting, March 1974. 1976. Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. Journal of the American Medical Association1974;229:409‐18. ">Co‐operative Study 1975</a>; <a href="./references#CD007858-bbs2-0009" title="ArimaH , AndersonC , OmaeT , LiuL , TzourioC , WoodwardM , et al. Perindopril‐based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial. Journal of Hypertension2010;28:395‐400. ArimaH , ChalmersJ , WoodwardM , AndersonC , RodgersA , DavisS , et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. Journal of Hypertension2006;24:1201‐8. ArimaH , TzourioC , AndersonC , WoodwardM , BousserMG , MacMahonS , et al. Effects of perindopril‐based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke2010;41:394‐6. ChapmanN , HuxleyR , AndersonC , BousserMG , ChalmersJ , ColmanS , et al. Effects of a perindopril‐based blood pressure‐lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke2004;35:116‐21. NealB , MacMahonS . The PROGRESS study: rationale and design. Journal of Hypertension1995;13:1869‐73. NinomiyaT , DonnanG , AndersonN , BladinC , ChambersB , GordonG , et al. Effects of the end point adjudication process on the results of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS). Stroke2009;40:2111‐5. PROGRESS Collaborative Group. Randomised trial of a perindopril‐based blood‐pressure‐lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet2001;358:1033‐41. PROGRESS Management Committee. PROGRESS: Perindopril pROtection aGainst REcurrent Stroke Study: status in March 1997. Journal of Human Hypertension1998;12:627‐9. Progress Management Committee. PROGRESS ‐ Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline. Journal of Hypertension1999;17:1647‐55. RodgersA , ChapmanN , WoodwardM , LiuLS , ColmanS , LeeA , et al. Perindopril‐based blood pressure lowering in individuals with cerebrovascular disease: consistency of benefits by age, sex and region. Journal of Hypertension2004;22:653‐9. TzourioC , AndersonC , ChapmanN , WoodwardM , NealB , MacMahonS , et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Archives of Internal Medicine2003;163:1069‐75. ">PROGRESS 2001</a>; <a href="./references#CD007858-bbs2-0008" title="BathPM , MartinRH , PaleschY , CottonD , YusufS , SaccoR , et al. Effect of telmisartan on functional outcome, recurrence, and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke2009;40:3541‐6. DienerHC , SaccoR , YusufS , Steering Committee, PRoFESS Study Group. Rationale, design and baseline data of a randomized, double‐blind, controlled trial comparing two antithrombotic regimens (a fixed‐dose combination of extended‐release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovascular Diseases2007;23:368‐80. DienerHC , SaccoRL , YusufS , CottonD , OunpuuS , LawtonWA , et al. Effects of aspirin plus extended‐release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double‐blind, active and placebo‐controlled study. Lancet Neurology2008;7:875‐84. YusufS , DienerHC , SaccoRL , CottonD , OunpuuS , LawtonWA , et al. Telmisartan to prevent recurrent stroke and cardiovascular events. New England Journal of Medicine2008;359:1225‐37. ">PRoFESS 2008</a>). The pooled hazard ratio of BPLDs for time to recurrent stroke was 0.82 (95% CI 0.65 to 1.03; high‐quality evidence; <a href="./references#CD007858-fig-0005" title="">Analysis 1.2</a>). </p> </section> <section id="CD007858-sec-0090"> <h5 class="title">Major vascular event (composite of non‐fatal stroke, non‐fatal myocardial infarction, or death from any vascular cause) </h5> <p>Data from four trials (28,630 participants) were available (<a href="./references#CD007858-bbs2-0003" title="The Dutch TIA Study Group. The Dutch TIA trial: protective effects of low‐dose aspirin and atenolol in patients with transient ischemic attacks or nondisabling stroke. Stroke1988;19:512‐7. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. New England Journal of Medicine1991;325:1261‐6. The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke1993;24:543‐8. ">Dutch TIA Trial 1993</a>; <a href="./references#CD007858-bbs2-0009" title="ArimaH , AndersonC , OmaeT , LiuL , TzourioC , WoodwardM , et al. Perindopril‐based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial. Journal of Hypertension2010;28:395‐400. ArimaH , ChalmersJ , WoodwardM , AndersonC , RodgersA , DavisS , et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. Journal of Hypertension2006;24:1201‐8. ArimaH , TzourioC , AndersonC , WoodwardM , BousserMG , MacMahonS , et al. Effects of perindopril‐based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke2010;41:394‐6. ChapmanN , HuxleyR , AndersonC , BousserMG , ChalmersJ , ColmanS , et al. Effects of a perindopril‐based blood pressure‐lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke2004;35:116‐21. NealB , MacMahonS . The PROGRESS study: rationale and design. Journal of Hypertension1995;13:1869‐73. NinomiyaT , DonnanG , AndersonN , BladinC , ChambersB , GordonG , et al. Effects of the end point adjudication process on the results of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS). Stroke2009;40:2111‐5. PROGRESS Collaborative Group. Randomised trial of a perindopril‐based blood‐pressure‐lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet2001;358:1033‐41. PROGRESS Management Committee. PROGRESS: Perindopril pROtection aGainst REcurrent Stroke Study: status in March 1997. Journal of Human Hypertension1998;12:627‐9. Progress Management Committee. PROGRESS ‐ Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline. Journal of Hypertension1999;17:1647‐55. RodgersA , ChapmanN , WoodwardM , LiuLS , ColmanS , LeeA , et al. Perindopril‐based blood pressure lowering in individuals with cerebrovascular disease: consistency of benefits by age, sex and region. Journal of Hypertension2004;22:653‐9. TzourioC , AndersonC , ChapmanN , WoodwardM , NealB , MacMahonS , et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Archives of Internal Medicine2003;163:1069‐75. ">PROGRESS 2001</a>; <a href="./references#CD007858-bbs2-0008" title="BathPM , MartinRH , PaleschY , CottonD , YusufS , SaccoR , et al. Effect of telmisartan on functional outcome, recurrence, and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke2009;40:3541‐6. DienerHC , SaccoR , YusufS , Steering Committee, PRoFESS Study Group. Rationale, design and baseline data of a randomized, double‐blind, controlled trial comparing two antithrombotic regimens (a fixed‐dose combination of extended‐release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovascular Diseases2007;23:368‐80. DienerHC , SaccoRL , YusufS , CottonD , OunpuuS , LawtonWA , et al. Effects of aspirin plus extended‐release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double‐blind, active and placebo‐controlled study. Lancet Neurology2008;7:875‐84. YusufS , DienerHC , SaccoRL , CottonD , OunpuuS , LawtonWA , et al. Telmisartan to prevent recurrent stroke and cardiovascular events. New England Journal of Medicine2008;359:1225‐37. ">PRoFESS 2008</a>; <a href="./references#CD007858-bbs2-0011" title="ErikssonS , OlofssonBO , WesterPO , for the TEST study group. Atenolol in secondary prevention after stroke. Cerebrovascular Diseases1995;5:21‐5. ">TEST 1995</a>). The pooled RR of BPLDs for major vascular event was 0.90 (95% CI 0.78 to 1.04; high‐quality evidence; <a href="./references#CD007858-fig-0006" title="">Analysis 1.3</a>). To explore the substantial heterogeneity (I<sup>2</sup> = 75%), we performed a subgroup analysis. </p> <section id="CD007858-sec-0091"> <h6 class="title">Subgroup analyses</h6> <section id="CD007858-sec-0092"> <p><b>Major vascular event by intervention</b></p> <p>Data from four trials (28,630 participants) were available (<a href="./references#CD007858-bbs2-0003" title="The Dutch TIA Study Group. The Dutch TIA trial: protective effects of low‐dose aspirin and atenolol in patients with transient ischemic attacks or nondisabling stroke. Stroke1988;19:512‐7. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. New England Journal of Medicine1991;325:1261‐6. The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke1993;24:543‐8. ">Dutch TIA Trial 1993</a>; <a href="./references#CD007858-bbs2-0009" title="ArimaH , AndersonC , OmaeT , LiuL , TzourioC , WoodwardM , et al. Perindopril‐based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial. Journal of Hypertension2010;28:395‐400. ArimaH , ChalmersJ , WoodwardM , AndersonC , RodgersA , DavisS , et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. Journal of Hypertension2006;24:1201‐8. ArimaH , TzourioC , AndersonC , WoodwardM , BousserMG , MacMahonS , et al. Effects of perindopril‐based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke2010;41:394‐6. ChapmanN , HuxleyR , AndersonC , BousserMG , ChalmersJ , ColmanS , et al. Effects of a perindopril‐based blood pressure‐lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke2004;35:116‐21. NealB , MacMahonS . The PROGRESS study: rationale and design. Journal of Hypertension1995;13:1869‐73. NinomiyaT , DonnanG , AndersonN , BladinC , ChambersB , GordonG , et al. Effects of the end point adjudication process on the results of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS). Stroke2009;40:2111‐5. PROGRESS Collaborative Group. Randomised trial of a perindopril‐based blood‐pressure‐lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet2001;358:1033‐41. PROGRESS Management Committee. PROGRESS: Perindopril pROtection aGainst REcurrent Stroke Study: status in March 1997. Journal of Human Hypertension1998;12:627‐9. Progress Management Committee. PROGRESS ‐ Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline. Journal of Hypertension1999;17:1647‐55. RodgersA , ChapmanN , WoodwardM , LiuLS , ColmanS , LeeA , et al. Perindopril‐based blood pressure lowering in individuals with cerebrovascular disease: consistency of benefits by age, sex and region. Journal of Hypertension2004;22:653‐9. TzourioC , AndersonC , ChapmanN , WoodwardM , NealB , MacMahonS , et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Archives of Internal Medicine2003;163:1069‐75. ">PROGRESS 2001</a>; <a href="./references#CD007858-bbs2-0008" title="BathPM , MartinRH , PaleschY , CottonD , YusufS , SaccoR , et al. Effect of telmisartan on functional outcome, recurrence, and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke2009;40:3541‐6. DienerHC , SaccoR , YusufS , Steering Committee, PRoFESS Study Group. Rationale, design and baseline data of a randomized, double‐blind, controlled trial comparing two antithrombotic regimens (a fixed‐dose combination of extended‐release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovascular Diseases2007;23:368‐80. DienerHC , SaccoRL , YusufS , CottonD , OunpuuS , LawtonWA , et al. Effects of aspirin plus extended‐release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double‐blind, active and placebo‐controlled study. Lancet Neurology2008;7:875‐84. YusufS , DienerHC , SaccoRL , CottonD , OunpuuS , LawtonWA , et al. Telmisartan to prevent recurrent stroke and cardiovascular events. New England Journal of Medicine2008;359:1225‐37. ">PRoFESS 2008</a>; <a href="./references#CD007858-bbs2-0011" title="ErikssonS , OlofssonBO , WesterPO , for the TEST study group. Atenolol in secondary prevention after stroke. Cerebrovascular Diseases1995;5:21‐5. ">TEST 1995</a>). The RRs of BPLDs for major vascular event were 0.76 (95% CI 0.68 to 0.85) in participants using ACE inhibitors, and 0.94 (95% CI 0.88 to 1.01) in those using angiotensin receptor blockers. The pooled RR of BPLDs for major vascular event was 1.01 (95% CI 0.84 to 1.21) in participants using beta‐blockers (<a href="./references#CD007858-fig-0018" title="">Analysis 2.4</a>). </p> <p>We did not perform subgroup analyses based on baseline blood pressure, self‐reported ethnicity, prior history of hypertension, age, index stroke event and sex because of insufficient studies reporting estimates for these subgroups. </p> </section> </section> </section> <section id="CD007858-sec-0093"> <h5 class="title">Ischaemic stroke</h5> <p>Data from three trials (26,701 participants) were available (<a href="./references#CD007858-bbs2-0004" title="Marti MassoJF , LozanoR . Nicardipine in the prevention of cerebral infarction. Clinical Therapeutics1990;12:344‐51. ">Marti Masso 1990</a>; <a href="./references#CD007858-bbs2-0009" title="ArimaH , AndersonC , OmaeT , LiuL , TzourioC , WoodwardM , et al. Perindopril‐based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial. Journal of Hypertension2010;28:395‐400. ArimaH , ChalmersJ , WoodwardM , AndersonC , RodgersA , DavisS , et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. Journal of Hypertension2006;24:1201‐8. ArimaH , TzourioC , AndersonC , WoodwardM , BousserMG , MacMahonS , et al. Effects of perindopril‐based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke2010;41:394‐6. ChapmanN , HuxleyR , AndersonC , BousserMG , ChalmersJ , ColmanS , et al. Effects of a perindopril‐based blood pressure‐lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke2004;35:116‐21. NealB , MacMahonS . The PROGRESS study: rationale and design. Journal of Hypertension1995;13:1869‐73. NinomiyaT , DonnanG , AndersonN , BladinC , ChambersB , GordonG , et al. Effects of the end point adjudication process on the results of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS). Stroke2009;40:2111‐5. PROGRESS Collaborative Group. Randomised trial of a perindopril‐based blood‐pressure‐lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet2001;358:1033‐41. PROGRESS Management Committee. PROGRESS: Perindopril pROtection aGainst REcurrent Stroke Study: status in March 1997. Journal of Human Hypertension1998;12:627‐9. Progress Management Committee. PROGRESS ‐ Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline. Journal of Hypertension1999;17:1647‐55. RodgersA , ChapmanN , WoodwardM , LiuLS , ColmanS , LeeA , et al. Perindopril‐based blood pressure lowering in individuals with cerebrovascular disease: consistency of benefits by age, sex and region. Journal of Hypertension2004;22:653‐9. TzourioC , AndersonC , ChapmanN , WoodwardM , NealB , MacMahonS , et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Archives of Internal Medicine2003;163:1069‐75. ">PROGRESS 2001</a>; <a href="./references#CD007858-bbs2-0008" title="BathPM , MartinRH , PaleschY , CottonD , YusufS , SaccoR , et al. Effect of telmisartan on functional outcome, recurrence, and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke2009;40:3541‐6. DienerHC , SaccoR , YusufS , Steering Committee, PRoFESS Study Group. Rationale, design and baseline data of a randomized, double‐blind, controlled trial comparing two antithrombotic regimens (a fixed‐dose combination of extended‐release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovascular Diseases2007;23:368‐80. DienerHC , SaccoRL , YusufS , CottonD , OunpuuS , LawtonWA , et al. Effects of aspirin plus extended‐release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double‐blind, active and placebo‐controlled study. Lancet Neurology2008;7:875‐84. YusufS , DienerHC , SaccoRL , CottonD , OunpuuS , LawtonWA , et al. Telmisartan to prevent recurrent stroke and cardiovascular events. New England Journal of Medicine2008;359:1225‐37. ">PRoFESS 2008</a>). The pooled RR of BPLDs for ischaemic stroke was 0.86 (95% CI 0.70 to 1.05; <a href="./references#CD007858-fig-0007" title="">Analysis 1.4</a>). </p> </section> <section id="CD007858-sec-0094"> <h5 class="title">Haemorrhagic stroke</h5> <p>Data from two trials (26,437 participants) were available (<a href="./references#CD007858-bbs2-0009" title="ArimaH , AndersonC , OmaeT , LiuL , TzourioC , WoodwardM , et al. Perindopril‐based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial. Journal of Hypertension2010;28:395‐400. ArimaH , ChalmersJ , WoodwardM , AndersonC , RodgersA , DavisS , et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. Journal of Hypertension2006;24:1201‐8. ArimaH , TzourioC , AndersonC , WoodwardM , BousserMG , MacMahonS , et al. Effects of perindopril‐based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke2010;41:394‐6. ChapmanN , HuxleyR , AndersonC , BousserMG , ChalmersJ , ColmanS , et al. Effects of a perindopril‐based blood pressure‐lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke2004;35:116‐21. NealB , MacMahonS . The PROGRESS study: rationale and design. Journal of Hypertension1995;13:1869‐73. NinomiyaT , DonnanG , AndersonN , BladinC , ChambersB , GordonG , et al. Effects of the end point adjudication process on the results of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS). Stroke2009;40:2111‐5. PROGRESS Collaborative Group. Randomised trial of a perindopril‐based blood‐pressure‐lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet2001;358:1033‐41. PROGRESS Management Committee. PROGRESS: Perindopril pROtection aGainst REcurrent Stroke Study: status in March 1997. Journal of Human Hypertension1998;12:627‐9. Progress Management Committee. PROGRESS ‐ Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline. Journal of Hypertension1999;17:1647‐55. RodgersA , ChapmanN , WoodwardM , LiuLS , ColmanS , LeeA , et al. Perindopril‐based blood pressure lowering in individuals with cerebrovascular disease: consistency of benefits by age, sex and region. Journal of Hypertension2004;22:653‐9. TzourioC , AndersonC , ChapmanN , WoodwardM , NealB , MacMahonS , et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Archives of Internal Medicine2003;163:1069‐75. ">PROGRESS 2001</a>; <a href="./references#CD007858-bbs2-0008" title="BathPM , MartinRH , PaleschY , CottonD , YusufS , SaccoR , et al. Effect of telmisartan on functional outcome, recurrence, and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke2009;40:3541‐6. DienerHC , SaccoR , YusufS , Steering Committee, PRoFESS Study Group. Rationale, design and baseline data of a randomized, double‐blind, controlled trial comparing two antithrombotic regimens (a fixed‐dose combination of extended‐release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovascular Diseases2007;23:368‐80. DienerHC , SaccoRL , YusufS , CottonD , OunpuuS , LawtonWA , et al. Effects of aspirin plus extended‐release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double‐blind, active and placebo‐controlled study. Lancet Neurology2008;7:875‐84. YusufS , DienerHC , SaccoRL , CottonD , OunpuuS , LawtonWA , et al. Telmisartan to prevent recurrent stroke and cardiovascular events. New England Journal of Medicine2008;359:1225‐37. ">PRoFESS 2008</a>). The pooled RR of BPLDs for haemorrhagic stroke was 0.66 (95% CI 0.39 to 1.12; <a href="./references#CD007858-fig-0008" title="">Analysis 1.5</a>). </p> </section> <section id="CD007858-sec-0095"> <h5 class="title">Myocardial infarction</h5> <p>Data from six trials (34,747 participants) were available (<a href="./references#CD007858-bbs2-0002" title="BauerRB . Effect of antihypertensive treatment on stroke recurrence: results of the hypertension‐stroke cooperative study. Cerebral Vascular Diseases: Transactions of the Ninth Princeton Conference. 1975:137‐54. HooblerSW . Antihypertensive therapy for stroke patients. Hypertension and Stroke Control in the Community: Proceedings of a WHO Meeting, March 1974. 1976. Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. Journal of the American Medical Association1974;229:409‐18. ">Co‐operative Study 1975</a>; <a href="./references#CD007858-bbs2-0003" title="The Dutch TIA Study Group. The Dutch TIA trial: protective effects of low‐dose aspirin and atenolol in patients with transient ischemic attacks or nondisabling stroke. Stroke1988;19:512‐7. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. New England Journal of Medicine1991;325:1261‐6. The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke1993;24:543‐8. ">Dutch TIA Trial 1993</a>; <a href="./references#CD007858-bbs2-0006" title="LiuL , GongL , Guang WangJ . Blood pressure lowering in patients with cerebrovascular disease: results of the randomized Post‐stroke Antihypertensive Treatment Study (PATS). Journal of the American College of Cardiology1998;31 (Suppl 2A):211A. LiuL , WangZ , GongL , ZhangY , ThijsL , StaessenJA , et al. Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertension Research2009;32:1032‐40. PATS Collaborating Group. Post‐stroke antihypertensive treatment study. A preliminary result. Chinese Medical Journal1995;108:710‐7. ">PATS 1995</a>; <a href="./references#CD007858-bbs2-0009" title="ArimaH , AndersonC , OmaeT , LiuL , TzourioC , WoodwardM , et al. Perindopril‐based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial. Journal of Hypertension2010;28:395‐400. ArimaH , ChalmersJ , WoodwardM , AndersonC , RodgersA , DavisS , et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. Journal of Hypertension2006;24:1201‐8. ArimaH , TzourioC , AndersonC , WoodwardM , BousserMG , MacMahonS , et al. Effects of perindopril‐based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke2010;41:394‐6. ChapmanN , HuxleyR , AndersonC , BousserMG , ChalmersJ , ColmanS , et al. Effects of a perindopril‐based blood pressure‐lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke2004;35:116‐21. NealB , MacMahonS . The PROGRESS study: rationale and design. Journal of Hypertension1995;13:1869‐73. NinomiyaT , DonnanG , AndersonN , BladinC , ChambersB , GordonG , et al. Effects of the end point adjudication process on the results of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS). Stroke2009;40:2111‐5. PROGRESS Collaborative Group. Randomised trial of a perindopril‐based blood‐pressure‐lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet2001;358:1033‐41. PROGRESS Management Committee. PROGRESS: Perindopril pROtection aGainst REcurrent Stroke Study: status in March 1997. Journal of Human Hypertension1998;12:627‐9. Progress Management Committee. PROGRESS ‐ Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline. Journal of Hypertension1999;17:1647‐55. RodgersA , ChapmanN , WoodwardM , LiuLS , ColmanS , LeeA , et al. Perindopril‐based blood pressure lowering in individuals with cerebrovascular disease: consistency of benefits by age, sex and region. Journal of Hypertension2004;22:653‐9. TzourioC , AndersonC , ChapmanN , WoodwardM , NealB , MacMahonS , et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Archives of Internal Medicine2003;163:1069‐75. ">PROGRESS 2001</a>; <a href="./references#CD007858-bbs2-0008" title="BathPM , MartinRH , PaleschY , CottonD , YusufS , SaccoR , et al. Effect of telmisartan on functional outcome, recurrence, and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke2009;40:3541‐6. DienerHC , SaccoR , YusufS , Steering Committee, PRoFESS Study Group. Rationale, design and baseline data of a randomized, double‐blind, controlled trial comparing two antithrombotic regimens (a fixed‐dose combination of extended‐release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovascular Diseases2007;23:368‐80. DienerHC , SaccoRL , YusufS , CottonD , OunpuuS , LawtonWA , et al. Effects of aspirin plus extended‐release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double‐blind, active and placebo‐controlled study. Lancet Neurology2008;7:875‐84. YusufS , DienerHC , SaccoRL , CottonD , OunpuuS , LawtonWA , et al. Telmisartan to prevent recurrent stroke and cardiovascular events. New England Journal of Medicine2008;359:1225‐37. ">PRoFESS 2008</a>; <a href="./references#CD007858-bbs2-0011" title="ErikssonS , OlofssonBO , WesterPO , for the TEST study group. Atenolol in secondary prevention after stroke. Cerebrovascular Diseases1995;5:21‐5. ">TEST 1995</a>). The pooled RR of BPLDs for myocardial infarction was 0.90 (95% CI 0.72 to 1.11; high‐quality evidence; <a href="./references#CD007858-fig-0009" title="">Analysis 1.6</a>). </p> </section> <section id="CD007858-sec-0096"> <h5 class="title">Vascular death</h5> <p>Data from six trials (34,747 participants) were available (<a href="./references#CD007858-bbs2-0002" title="BauerRB . Effect of antihypertensive treatment on stroke recurrence: results of the hypertension‐stroke cooperative study. Cerebral Vascular Diseases: Transactions of the Ninth Princeton Conference. 1975:137‐54. HooblerSW . Antihypertensive therapy for stroke patients. Hypertension and Stroke Control in the Community: Proceedings of a WHO Meeting, March 1974. 1976. Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. Journal of the American Medical Association1974;229:409‐18. ">Co‐operative Study 1975</a>; <a href="./references#CD007858-bbs2-0003" title="The Dutch TIA Study Group. The Dutch TIA trial: protective effects of low‐dose aspirin and atenolol in patients with transient ischemic attacks or nondisabling stroke. Stroke1988;19:512‐7. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. New England Journal of Medicine1991;325:1261‐6. The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke1993;24:543‐8. ">Dutch TIA Trial 1993</a>; <a href="./references#CD007858-bbs2-0006" title="LiuL , GongL , Guang WangJ . Blood pressure lowering in patients with cerebrovascular disease: results of the randomized Post‐stroke Antihypertensive Treatment Study (PATS). Journal of the American College of Cardiology1998;31 (Suppl 2A):211A. LiuL , WangZ , GongL , ZhangY , ThijsL , StaessenJA , et al. Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertension Research2009;32:1032‐40. PATS Collaborating Group. Post‐stroke antihypertensive treatment study. A preliminary result. Chinese Medical Journal1995;108:710‐7. ">PATS 1995</a>; <a href="./references#CD007858-bbs2-0009" title="ArimaH , AndersonC , OmaeT , LiuL , TzourioC , WoodwardM , et al. Perindopril‐based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial. Journal of Hypertension2010;28:395‐400. ArimaH , ChalmersJ , WoodwardM , AndersonC , RodgersA , DavisS , et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. Journal of Hypertension2006;24:1201‐8. ArimaH , TzourioC , AndersonC , WoodwardM , BousserMG , MacMahonS , et al. Effects of perindopril‐based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke2010;41:394‐6. ChapmanN , HuxleyR , AndersonC , BousserMG , ChalmersJ , ColmanS , et al. Effects of a perindopril‐based blood pressure‐lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke2004;35:116‐21. NealB , MacMahonS . The PROGRESS study: rationale and design. Journal of Hypertension1995;13:1869‐73. NinomiyaT , DonnanG , AndersonN , BladinC , ChambersB , GordonG , et al. Effects of the end point adjudication process on the results of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS). Stroke2009;40:2111‐5. PROGRESS Collaborative Group. Randomised trial of a perindopril‐based blood‐pressure‐lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet2001;358:1033‐41. PROGRESS Management Committee. PROGRESS: Perindopril pROtection aGainst REcurrent Stroke Study: status in March 1997. Journal of Human Hypertension1998;12:627‐9. Progress Management Committee. PROGRESS ‐ Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline. Journal of Hypertension1999;17:1647‐55. RodgersA , ChapmanN , WoodwardM , LiuLS , ColmanS , LeeA , et al. Perindopril‐based blood pressure lowering in individuals with cerebrovascular disease: consistency of benefits by age, sex and region. Journal of Hypertension2004;22:653‐9. TzourioC , AndersonC , ChapmanN , WoodwardM , NealB , MacMahonS , et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Archives of Internal Medicine2003;163:1069‐75. ">PROGRESS 2001</a>; <a href="./references#CD007858-bbs2-0008" title="BathPM , MartinRH , PaleschY , CottonD , YusufS , SaccoR , et al. Effect of telmisartan on functional outcome, recurrence, and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke2009;40:3541‐6. DienerHC , SaccoR , YusufS , Steering Committee, PRoFESS Study Group. Rationale, design and baseline data of a randomized, double‐blind, controlled trial comparing two antithrombotic regimens (a fixed‐dose combination of extended‐release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovascular Diseases2007;23:368‐80. DienerHC , SaccoRL , YusufS , CottonD , OunpuuS , LawtonWA , et al. Effects of aspirin plus extended‐release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double‐blind, active and placebo‐controlled study. Lancet Neurology2008;7:875‐84. YusufS , DienerHC , SaccoRL , CottonD , OunpuuS , LawtonWA , et al. Telmisartan to prevent recurrent stroke and cardiovascular events. New England Journal of Medicine2008;359:1225‐37. ">PRoFESS 2008</a>; <a href="./references#CD007858-bbs2-0011" title="ErikssonS , OlofssonBO , WesterPO , for the TEST study group. Atenolol in secondary prevention after stroke. Cerebrovascular Diseases1995;5:21‐5. ">TEST 1995</a>). The pooled RR of BPLDs for vascular death was 0.85 (95% CI 0.76 to 0.95; high‐quality evidence; <a href="./references#CD007858-fig-0010" title="">Analysis 1.7</a>). </p> </section> <section id="CD007858-sec-0097"> <h5 class="title">Death by any cause</h5> <p>Data from eight trials (35,110 participants) were available (<a href="./references#CD007858-bbs2-0001" title="CarterAB . Hypotensive therapy in stroke survivors. Lancet1970;1:485‐9. ">Carter 1970</a>; <a href="./references#CD007858-bbs2-0002" title="BauerRB . Effect of antihypertensive treatment on stroke recurrence: results of the hypertension‐stroke cooperative study. Cerebral Vascular Diseases: Transactions of the Ninth Princeton Conference. 1975:137‐54. HooblerSW . Antihypertensive therapy for stroke patients. Hypertension and Stroke Control in the Community: Proceedings of a WHO Meeting, March 1974. 1976. Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. Journal of the American Medical Association1974;229:409‐18. ">Co‐operative Study 1975</a>; <a href="./references#CD007858-bbs2-0004" title="Marti MassoJF , LozanoR . Nicardipine in the prevention of cerebral infarction. Clinical Therapeutics1990;12:344‐51. ">Marti Masso 1990</a>; <a href="./references#CD007858-bbs2-0003" title="The Dutch TIA Study Group. The Dutch TIA trial: protective effects of low‐dose aspirin and atenolol in patients with transient ischemic attacks or nondisabling stroke. Stroke1988;19:512‐7. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. New England Journal of Medicine1991;325:1261‐6. The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke1993;24:543‐8. ">Dutch TIA Trial 1993</a>; <a href="./references#CD007858-bbs2-0006" title="LiuL , GongL , Guang WangJ . Blood pressure lowering in patients with cerebrovascular disease: results of the randomized Post‐stroke Antihypertensive Treatment Study (PATS). Journal of the American College of Cardiology1998;31 (Suppl 2A):211A. LiuL , WangZ , GongL , ZhangY , ThijsL , StaessenJA , et al. Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertension Research2009;32:1032‐40. PATS Collaborating Group. Post‐stroke antihypertensive treatment study. A preliminary result. Chinese Medical Journal1995;108:710‐7. ">PATS 1995</a>; <a href="./references#CD007858-bbs2-0009" title="ArimaH , AndersonC , OmaeT , LiuL , TzourioC , WoodwardM , et al. Perindopril‐based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial. Journal of Hypertension2010;28:395‐400. ArimaH , ChalmersJ , WoodwardM , AndersonC , RodgersA , DavisS , et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. Journal of Hypertension2006;24:1201‐8. ArimaH , TzourioC , AndersonC , WoodwardM , BousserMG , MacMahonS , et al. Effects of perindopril‐based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke2010;41:394‐6. ChapmanN , HuxleyR , AndersonC , BousserMG , ChalmersJ , ColmanS , et al. Effects of a perindopril‐based blood pressure‐lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke2004;35:116‐21. NealB , MacMahonS . The PROGRESS study: rationale and design. Journal of Hypertension1995;13:1869‐73. NinomiyaT , DonnanG , AndersonN , BladinC , ChambersB , GordonG , et al. Effects of the end point adjudication process on the results of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS). Stroke2009;40:2111‐5. PROGRESS Collaborative Group. Randomised trial of a perindopril‐based blood‐pressure‐lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet2001;358:1033‐41. PROGRESS Management Committee. PROGRESS: Perindopril pROtection aGainst REcurrent Stroke Study: status in March 1997. Journal of Human Hypertension1998;12:627‐9. Progress Management Committee. PROGRESS ‐ Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline. Journal of Hypertension1999;17:1647‐55. RodgersA , ChapmanN , WoodwardM , LiuLS , ColmanS , LeeA , et al. Perindopril‐based blood pressure lowering in individuals with cerebrovascular disease: consistency of benefits by age, sex and region. Journal of Hypertension2004;22:653‐9. TzourioC , AndersonC , ChapmanN , WoodwardM , NealB , MacMahonS , et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Archives of Internal Medicine2003;163:1069‐75. ">PROGRESS 2001</a>; <a href="./references#CD007858-bbs2-0008" title="BathPM , MartinRH , PaleschY , CottonD , YusufS , SaccoR , et al. Effect of telmisartan on functional outcome, recurrence, and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke2009;40:3541‐6. DienerHC , SaccoR , YusufS , Steering Committee, PRoFESS Study Group. Rationale, design and baseline data of a randomized, double‐blind, controlled trial comparing two antithrombotic regimens (a fixed‐dose combination of extended‐release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovascular Diseases2007;23:368‐80. DienerHC , SaccoRL , YusufS , CottonD , OunpuuS , LawtonWA , et al. Effects of aspirin plus extended‐release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double‐blind, active and placebo‐controlled study. Lancet Neurology2008;7:875‐84. YusufS , DienerHC , SaccoRL , CottonD , OunpuuS , LawtonWA , et al. Telmisartan to prevent recurrent stroke and cardiovascular events. New England Journal of Medicine2008;359:1225‐37. ">PRoFESS 2008</a>; <a href="./references#CD007858-bbs2-0011" title="ErikssonS , OlofssonBO , WesterPO , for the TEST study group. Atenolol in secondary prevention after stroke. Cerebrovascular Diseases1995;5:21‐5. ">TEST 1995</a>). The pooled RR of BPLDs for death by any cause was 0.98 (95% CI 0.91 to 1.05; moderate‐quality evidence; <a href="./references#CD007858-fig-0011" title="">Analysis 1.8</a>). </p> </section> <section id="CD007858-sec-0098"> <h5 class="title">Dementia</h5> <p>Data from two trials (6671 participants) were available (<a href="./references#CD007858-bbs2-0009" title="ArimaH , AndersonC , OmaeT , LiuL , TzourioC , WoodwardM , et al. Perindopril‐based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial. Journal of Hypertension2010;28:395‐400. ArimaH , ChalmersJ , WoodwardM , AndersonC , RodgersA , DavisS , et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. Journal of Hypertension2006;24:1201‐8. ArimaH , TzourioC , AndersonC , WoodwardM , BousserMG , MacMahonS , et al. Effects of perindopril‐based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke2010;41:394‐6. ChapmanN , HuxleyR , AndersonC , BousserMG , ChalmersJ , ColmanS , et al. Effects of a perindopril‐based blood pressure‐lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke2004;35:116‐21. NealB , MacMahonS . The PROGRESS study: rationale and design. Journal of Hypertension1995;13:1869‐73. NinomiyaT , DonnanG , AndersonN , BladinC , ChambersB , GordonG , et al. Effects of the end point adjudication process on the results of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS). Stroke2009;40:2111‐5. PROGRESS Collaborative Group. Randomised trial of a perindopril‐based blood‐pressure‐lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet2001;358:1033‐41. PROGRESS Management Committee. PROGRESS: Perindopril pROtection aGainst REcurrent Stroke Study: status in March 1997. Journal of Human Hypertension1998;12:627‐9. Progress Management Committee. PROGRESS ‐ Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline. Journal of Hypertension1999;17:1647‐55. RodgersA , ChapmanN , WoodwardM , LiuLS , ColmanS , LeeA , et al. Perindopril‐based blood pressure lowering in individuals with cerebrovascular disease: consistency of benefits by age, sex and region. Journal of Hypertension2004;22:653‐9. TzourioC , AndersonC , ChapmanN , WoodwardM , NealB , MacMahonS , et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Archives of Internal Medicine2003;163:1069‐75. ">PROGRESS 2001</a>; <a href="./references#CD007858-bbs2-0008" title="BathPM , MartinRH , PaleschY , CottonD , YusufS , SaccoR , et al. Effect of telmisartan on functional outcome, recurrence, and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke2009;40:3541‐6. DienerHC , SaccoR , YusufS , Steering Committee, PRoFESS Study Group. Rationale, design and baseline data of a randomized, double‐blind, controlled trial comparing two antithrombotic regimens (a fixed‐dose combination of extended‐release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovascular Diseases2007;23:368‐80. DienerHC , SaccoRL , YusufS , CottonD , OunpuuS , LawtonWA , et al. Effects of aspirin plus extended‐release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double‐blind, active and placebo‐controlled study. Lancet Neurology2008;7:875‐84. YusufS , DienerHC , SaccoRL , CottonD , OunpuuS , LawtonWA , et al. Telmisartan to prevent recurrent stroke and cardiovascular events. New England Journal of Medicine2008;359:1225‐37. ">PRoFESS 2008</a>). The pooled RR of BPLDs for dementia was 0.88 (95% CI 0.73 to 1.06; high‐quality evidence; <a href="./references#CD007858-fig-0012" title="">Analysis 1.9</a>). </p> <p>We did not perform subgroup analyses based on baseline blood pressure, self‐reported ethnicity, prior history of hypertension, age, index stroke event, and sex, because of insufficient studies reporting estimates for these subgroups. </p> </section> </section> <section id="CD007858-sec-0099"> <h4 class="title">Intensive versus standard blood pressure‐lowering</h4> <p>One trial classified their outcome event 'intracranial haemorrhage' as either 'intracerebral', 'subdural or epidural' or 'other' (<a href="./references#CD007858-bbs2-0010" title="BenaventeOR , WhiteCL , PearceL , PergolaP , RoldanA , BenaventeMF , et al. The Secondary Prevention of Small Subcortical Strokes (SPS3) study. International Journal of Stroke2011;6:164‐75. The SPS3 Study Group. Blood‐pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet2013;382:507‐15. WhiteCL , SzychowskiJM , RoldanA , BenaventeMF , PretellEJ , DelBruttoOH , et al. Clinical features and racial/ethnic differences among the 3020 participants in the Secondary Prevention of Small Subcortical Strokes (SPS3) trial. Journal of Stroke and Cerebrovascular Diseases2013;22:764‐74. ">SPS3 2013</a>). We did not count 'subdural or epidural' and 'other' as 'stroke of any type' or 'haemorrhagic stroke'. However, we included these outcome events in the 'time to recurrent stroke' analyses, as only summary estimates (hazard ratio and 95% CI) were reported for these time‐to‐event data. </p> <p>Data from three trials (3632 participants) were available for recurrent stroke of any type, major vascular event, myocardial infarction, and death by any cause (<a href="./references#CD007858-bbs2-0005" title="FletcherK , MantJ , McManusR , CampbellS , BettsJ , TaylorC , et al. Protocol for Past BP: a randomised controlled trial of different blood pressure targets for people with a history of stroke or transient ischaemic attack (TIA) in primary care. BMC Cardiovascular Disorders2010;10:37. MantJ , McManusRJ , RoalfeA , FletcherK , TaylorCJ , MartinU , et al. Different systolic blood pressure targets for people with history of stroke or transient ischaemic attack: PAST‐BP (Prevention After Stroke‐Blood Pressure) randomised controlled trial. BMJ2016;352:i708. ">PAST‐BP 2016</a>; <a href="./references#CD007858-bbs2-0007" title="BlackburnDJ , KrishnanK , FoxL , BallardC , BurnsA , FordGA , et al. Prevention Of Decline in Cognition After Stroke Trial (PODCAST): a study protocol for a factorial randomised controlled trial of intensive versus guideline lowering of blood pressure and lipids. Trials2013;14:401. ">PODCAST 2017</a>; <a href="./references#CD007858-bbs2-0010" title="BenaventeOR , WhiteCL , PearceL , PergolaP , RoldanA , BenaventeMF , et al. The Secondary Prevention of Small Subcortical Strokes (SPS3) study. International Journal of Stroke2011;6:164‐75. The SPS3 Study Group. Blood‐pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet2013;382:507‐15. WhiteCL , SzychowskiJM , RoldanA , BenaventeMF , PretellEJ , DelBruttoOH , et al. Clinical features and racial/ethnic differences among the 3020 participants in the Secondary Prevention of Small Subcortical Strokes (SPS3) trial. Journal of Stroke and Cerebrovascular Diseases2013;22:764‐74. ">SPS3 2013</a>). The pooled RRs of intensive blood pressure‐lowering were 0.80 (95% CI 0.63 to 1.00) for recurrent stroke (<a href="./references#CD007858-fig-0023" title="">Analysis 4.1</a>), 0.58 (95% CI 0.23 to 1.46) for major vascular event (<a href="./references#CD007858-fig-0025" title="">Analysis 4.3</a>), 0.90 (95% CI 0.58 to 1.38) for myocardial infarction (<a href="./references#CD007858-fig-0028" title="">Analysis 4.6</a>), and 1.08 (95% CI 0.83 to 1.39) for death by any cause (<a href="./references#CD007858-fig-0030" title="">Analysis 4.8</a>). </p> <p>Data from two trials (3549 participants) were available for vascular death (<a href="./references#CD007858-bbs2-0005" title="FletcherK , MantJ , McManusR , CampbellS , BettsJ , TaylorC , et al. Protocol for Past BP: a randomised controlled trial of different blood pressure targets for people with a history of stroke or transient ischaemic attack (TIA) in primary care. BMC Cardiovascular Disorders2010;10:37. MantJ , McManusRJ , RoalfeA , FletcherK , TaylorCJ , MartinU , et al. Different systolic blood pressure targets for people with history of stroke or transient ischaemic attack: PAST‐BP (Prevention After Stroke‐Blood Pressure) randomised controlled trial. BMJ2016;352:i708. ">PAST‐BP 2016</a>; <a href="./references#CD007858-bbs2-0010" title="BenaventeOR , WhiteCL , PearceL , PergolaP , RoldanA , BenaventeMF , et al. The Secondary Prevention of Small Subcortical Strokes (SPS3) study. International Journal of Stroke2011;6:164‐75. The SPS3 Study Group. Blood‐pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet2013;382:507‐15. WhiteCL , SzychowskiJM , RoldanA , BenaventeMF , PretellEJ , DelBruttoOH , et al. Clinical features and racial/ethnic differences among the 3020 participants in the Secondary Prevention of Small Subcortical Strokes (SPS3) trial. Journal of Stroke and Cerebrovascular Diseases2013;22:764‐74. ">SPS3 2013</a>). The pooled RR of intensive blood pressure‐lowering was 0.87 (95% CI 0.56 to 1.35) (<a href="./references#CD007858-fig-0029" title="">Analysis 4.7</a>). </p> <p>Data from two trials (3103 participants) were available for ischaemic and haemorrhagic stroke (<a href="./references#CD007858-bbs2-0007" title="BlackburnDJ , KrishnanK , FoxL , BallardC , BurnsA , FordGA , et al. Prevention Of Decline in Cognition After Stroke Trial (PODCAST): a study protocol for a factorial randomised controlled trial of intensive versus guideline lowering of blood pressure and lipids. Trials2013;14:401. ">PODCAST 2017</a>; <a href="./references#CD007858-bbs2-0010" title="BenaventeOR , WhiteCL , PearceL , PergolaP , RoldanA , BenaventeMF , et al. The Secondary Prevention of Small Subcortical Strokes (SPS3) study. International Journal of Stroke2011;6:164‐75. The SPS3 Study Group. Blood‐pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet2013;382:507‐15. WhiteCL , SzychowskiJM , RoldanA , BenaventeMF , PretellEJ , DelBruttoOH , et al. Clinical features and racial/ethnic differences among the 3020 participants in the Secondary Prevention of Small Subcortical Strokes (SPS3) trial. Journal of Stroke and Cerebrovascular Diseases2013;22:764‐74. ">SPS3 2013</a>). The pooled RR of intensive blood pressure‐lowering was 0.86 (95% CI 0.67 to 1.09) for ischaemic stroke (<a href="./references#CD007858-fig-0026" title="">Analysis 4.4</a>), and 0.42 (95% CI 0.17 to 1.02) for haemorrhagic stroke (<a href="./references#CD007858-fig-0027" title="">Analysis 4.5</a>). </p> <p>Data from one trial (3020 participants) were available for time to recurrent stroke (<a href="./references#CD007858-bbs2-0010" title="BenaventeOR , WhiteCL , PearceL , PergolaP , RoldanA , BenaventeMF , et al. The Secondary Prevention of Small Subcortical Strokes (SPS3) study. International Journal of Stroke2011;6:164‐75. The SPS3 Study Group. Blood‐pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet2013;382:507‐15. WhiteCL , SzychowskiJM , RoldanA , BenaventeMF , PretellEJ , DelBruttoOH , et al. Clinical features and racial/ethnic differences among the 3020 participants in the Secondary Prevention of Small Subcortical Strokes (SPS3) trial. Journal of Stroke and Cerebrovascular Diseases2013;22:764‐74. ">SPS3 2013</a>). The hazard ratio of intensive blood pressure‐lowering for time to recurrent stroke was 0.81 (95% CI 0.64 to 1.03; <a href="./references#CD007858-fig-0024" title="">Analysis 4.2</a>). </p> <p>Data from one trial (83 participants) were available for dementia (<a href="./references#CD007858-bbs2-0007" title="BlackburnDJ , KrishnanK , FoxL , BallardC , BurnsA , FordGA , et al. Prevention Of Decline in Cognition After Stroke Trial (PODCAST): a study protocol for a factorial randomised controlled trial of intensive versus guideline lowering of blood pressure and lipids. Trials2013;14:401. ">PODCAST 2017</a>). The RR of intensive blood pressure‐lowering for dementia was 5.12 (95% CI 0.25 to 103.48; Analysis 4.9). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007858-sec-0100" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007858-sec-0100">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007858-sec-0158">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007858-sec-0100"></div> <section id="CD007858-sec-0101"> <h3 class="title" id="CD007858-sec-0101">Summary of main results</h3> <section id="CD007858-sec-0102"> <h4 class="title">Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment</h4> <p>Blood pressure‐lowering drugs (BPLDs) initiated at least 48 hours after stroke or transient ischaemic attack (TIA) reduced the risk of recurrent stroke. We observed substantial heterogeneity, and predefined subgroup analyses were hampered by lack of trials assessing these specific subgroups. </p> <p>BPLDs also reduced the risk of vascular death but did not reduce time to recurrent stroke, and risk of major vascular event, ischaemic stroke, haemorrhagic stroke, myocardial infarction, death by any cause, or dementia. However, point estimates for all secondary outcome measures were in favour of treatment with BPLDs. </p> </section> <section id="CD007858-sec-0103"> <h4 class="title">Intensive versus standard blood pressure‐lowering</h4> <p>Intensive blood pressure‐lowering did not reduce the risk of recurrent stroke, time to recurrent stroke, risk of major vascular event, ischaemic stroke, myocardial infarction, vascular death, death by any cause, and dementia, whereas it did reduce the risk of haemorrhagic stroke. However, we observed a favourable trend for intensive blood pressure‐lowering in the outcomes recurrent stroke, time to recurrent stroke, and major vascular events. </p> </section> </section> <section id="CD007858-sec-0104"> <h3 class="title" id="CD007858-sec-0104">Overall completeness and applicability of evidence</h3> <p>Our primary analysis is based on 35,110 participants, and we assessed secondary outcome measures in a large subset of these participants, except for dementia, which was only assessed in a relatively small number of participants (n = 6671). </p> <p>We included only three studies (3632 participants) comparing different blood pressure targets, and the largest of these studies only included participants with a lacunar stroke as index event. Therefore, many questions regarding the optimal blood pressure target after TIA or stroke remain unanswered. </p> </section> <section id="CD007858-sec-0105"> <h3 class="title" id="CD007858-sec-0105">Quality of the evidence</h3> <p>Overall, the trials included in our main analyses ranged from low to substantial risk of bias. In a sensitivity analysis based on high risk of bias, we excluded three trials. Two of these trials mainly suffered from insufficient blinding and lack of description of their randomisation procedures, whereas the third suffered from significant numbers of loss to follow‐up and differing numbers of outcome events between different reports. </p> <p>The resulting quality of the evidence, as assessed in the GRADE format, was moderate for our primary outcome measure, 'recurrent stroke of any type'. The quality of evidence was high for most of our secondary outcome measures, except for 'death by any cause', which we also downgraded to moderate. </p> </section> <section id="CD007858-sec-0106"> <h3 class="title" id="CD007858-sec-0106">Potential biases in the review process</h3> <p>We conducted an extensive literature search according to current Cochrane standards, without language restrictions. Therefore, we consider it unlikely that we missed potentially relevant studies. </p> <p>We did not use individual participant data. Therefore, we did not include participants from trials that investigated BPLDs in a more general population, as none of these trials reported a subgroup analysis of people with a history of TIA or stroke. </p> <p>We included one trial that also included 2.0% of participants with subarachnoid haemorrhage (<a href="./references#CD007858-bbs2-0006" title="LiuL , GongL , Guang WangJ . Blood pressure lowering in patients with cerebrovascular disease: results of the randomized Post‐stroke Antihypertensive Treatment Study (PATS). Journal of the American College of Cardiology1998;31 (Suppl 2A):211A. LiuL , WangZ , GongL , ZhangY , ThijsL , StaessenJA , et al. Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertension Research2009;32:1032‐40. PATS Collaborating Group. Post‐stroke antihypertensive treatment study. A preliminary result. Chinese Medical Journal1995;108:710‐7. ">PATS 1995</a>). Therefore, we performed an additional sensitivity analysis, in which we excluded patients with subarachnoid haemorrhage as possible index event. </p> </section> <section id="CD007858-sec-0107"> <h3 class="title" id="CD007858-sec-0107">Agreements and disagreements with other studies or reviews</h3> <p>Two similar meta‐analyses on the effect of BPLDs in the secondary prevention of stroke were performed previously (<a href="./references#CD007858-bbs2-0025" title="LakhanSE , SapkoTS . Blood pressure lowering treatment for preventing stroke recurrence: a systematic review and meta‐analysis. International Archives of Medicine2009;2:30. ">Lakhan 2009</a>; <a href="./references#CD007858-bbs2-0027" title="LiuL , WangZ , GongL , ZhangY , ThijsL , StaessenJA , et al. Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertension Research2009;32:1032‐40. ">Liu 2009</a>), which also found a positive effect of BPLDs on reducing recurrent stroke (pooled odds ratios 0.71 (95% confidence interval (CI) 0.59 to 0.86) and 0.78 (95% CI 0.68 to 0.90) respectively). Due to differences in inclusion criteria, the previous meta‐analyses included three and two additional studies (respectively) in comparison with our meta‐analysis, which resulted in the slight differences in effect estimates and CIs between all meta‐analyses. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007858-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/urn:x-wiley:14651858:media:CD007858:CD007858-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_t/tCD007858-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD007858-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/full#CD007858-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007858-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/urn:x-wiley:14651858:media:CD007858:CD007858-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_t/tCD007858-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD007858-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/full#CD007858-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007858-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/urn:x-wiley:14651858:media:CD007858:CD007858-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_t/tCD007858-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD007858-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/full#CD007858-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007858-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/urn:x-wiley:14651858:media:CD007858:CD007858-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_t/tCD007858-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment, Outcome 1 Recurrent stroke of any type." data-id="CD007858-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment, Outcome 1 Recurrent stroke of any type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/references#CD007858-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007858-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/urn:x-wiley:14651858:media:CD007858:CD007858-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_t/tCD007858-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment, Outcome 2 Time to recurrent stroke." data-id="CD007858-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment, Outcome 2 Time to recurrent stroke. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/references#CD007858-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007858-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/urn:x-wiley:14651858:media:CD007858:CD007858-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_t/tCD007858-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment, Outcome 3 Major vascular event (composite of non‐fatal stroke, non‐fatal myocardial infarction, or death from any vascular cause." data-id="CD007858-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment, Outcome 3 Major vascular event (composite of non‐fatal stroke, non‐fatal myocardial infarction, or death from any vascular cause. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/references#CD007858-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007858-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/urn:x-wiley:14651858:media:CD007858:CD007858-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_t/tCD007858-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment, Outcome 4 Ischaemic stroke." data-id="CD007858-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment, Outcome 4 Ischaemic stroke. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/references#CD007858-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007858-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/urn:x-wiley:14651858:media:CD007858:CD007858-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_t/tCD007858-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment, Outcome 5 Haemorrhagic stroke." data-id="CD007858-fig-0008" src="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment, Outcome 5 Haemorrhagic stroke. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/references#CD007858-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007858-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/urn:x-wiley:14651858:media:CD007858:CD007858-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_t/tCD007858-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment, Outcome 6 Myocardial infarction." data-id="CD007858-fig-0009" src="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment, Outcome 6 Myocardial infarction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/references#CD007858-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007858-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/urn:x-wiley:14651858:media:CD007858:CD007858-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_t/tCD007858-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment, Outcome 7 Vascular death." data-id="CD007858-fig-0010" src="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment, Outcome 7 Vascular death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/references#CD007858-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007858-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/urn:x-wiley:14651858:media:CD007858:CD007858-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_t/tCD007858-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment, Outcome 8 Death by any cause." data-id="CD007858-fig-0011" src="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment, Outcome 8 Death by any cause. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/references#CD007858-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007858-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/urn:x-wiley:14651858:media:CD007858:CD007858-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_t/tCD007858-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment, Outcome 9 Dementia." data-id="CD007858-fig-0012" src="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment, Outcome 9 Dementia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/references#CD007858-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007858-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/urn:x-wiley:14651858:media:CD007858:CD007858-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_t/tCD007858-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment, Outcome 10 Blood pressure baseline (systolic)." data-id="CD007858-fig-0013" src="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment, Outcome 10 Blood pressure baseline (systolic). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/references#CD007858-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007858-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/urn:x-wiley:14651858:media:CD007858:CD007858-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_t/tCD007858-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment, Outcome 11 Blood pressure baseline (diastolic)." data-id="CD007858-fig-0014" src="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment, Outcome 11 Blood pressure baseline (diastolic). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/references#CD007858-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007858-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/urn:x-wiley:14651858:media:CD007858:CD007858-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_t/tCD007858-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment (subgroups), Outcome 1 Recurrent stroke of any type by baseline systolic blood pressure (SBP)." data-id="CD007858-fig-0015" src="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment (subgroups), Outcome 1 Recurrent stroke of any type by baseline systolic blood pressure (SBP). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/references#CD007858-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007858-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/urn:x-wiley:14651858:media:CD007858:CD007858-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_t/tCD007858-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment (subgroups), Outcome 2 Recurrent stroke of any type by intervention." data-id="CD007858-fig-0016" src="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment (subgroups), Outcome 2 Recurrent stroke of any type by intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/references#CD007858-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007858-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/urn:x-wiley:14651858:media:CD007858:CD007858-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_t/tCD007858-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment (subgroups), Outcome 3 Recurrent stroke of any type by type of index event." data-id="CD007858-fig-0017" src="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment (subgroups), Outcome 3 Recurrent stroke of any type by type of index event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/references#CD007858-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007858-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/urn:x-wiley:14651858:media:CD007858:CD007858-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_t/tCD007858-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment (subgroups), Outcome 4 Major vascular event by intervention." data-id="CD007858-fig-0018" src="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment (subgroups), Outcome 4 Major vascular event by intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/references#CD007858-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007858-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/urn:x-wiley:14651858:media:CD007858:CD007858-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_t/tCD007858-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment (sensitivity analyses), Outcome 1 Recurrent stroke of any type, methodological quality." data-id="CD007858-fig-0019" src="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment (sensitivity analyses), Outcome 1 Recurrent stroke of any type, methodological quality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/references#CD007858-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007858-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/urn:x-wiley:14651858:media:CD007858:CD007858-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_t/tCD007858-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment (sensitivity analyses), Outcome 2 Recurrent stroke of any type, minimum 5 mmHg systolic blood pressure (SBP) reduction." data-id="CD007858-fig-0020" src="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment (sensitivity analyses), Outcome 2 Recurrent stroke of any type, minimum 5 mmHg systolic blood pressure (SBP) reduction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/references#CD007858-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007858-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/urn:x-wiley:14651858:media:CD007858:CD007858-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_t/tCD007858-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment (sensitivity analyses), Outcome 3 Recurrent stroke of any type, minimum 3 mmHg diastolic blood pressure (DBP) reduction." data-id="CD007858-fig-0021" src="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment (sensitivity analyses), Outcome 3 Recurrent stroke of any type, minimum 3 mmHg diastolic blood pressure (DBP) reduction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/references#CD007858-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007858-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/urn:x-wiley:14651858:media:CD007858:CD007858-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_t/tCD007858-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment (sensitivity analyses), Outcome 4 Recurrent stroke of any type, excluding patients with subarachnoid haemorrhage as possible index event." data-id="CD007858-fig-0022" src="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment (sensitivity analyses), Outcome 4 Recurrent stroke of any type, excluding patients with subarachnoid haemorrhage as possible index event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/references#CD007858-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007858-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/urn:x-wiley:14651858:media:CD007858:CD007858-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_t/tCD007858-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Intensive versus standard blood pressure‐lowering, Outcome 1 Stroke of any type (fatal and non‐fatal)." data-id="CD007858-fig-0023" src="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Intensive versus standard blood pressure‐lowering, Outcome 1 Stroke of any type (fatal and non‐fatal). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/references#CD007858-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007858-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/urn:x-wiley:14651858:media:CD007858:CD007858-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_t/tCD007858-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Intensive versus standard blood pressure‐lowering, Outcome 2 Time to recurrent stroke." data-id="CD007858-fig-0024" src="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Intensive versus standard blood pressure‐lowering, Outcome 2 Time to recurrent stroke. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/references#CD007858-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007858-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/urn:x-wiley:14651858:media:CD007858:CD007858-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_t/tCD007858-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Intensive versus standard blood pressure‐lowering, Outcome 3 Major vascular event (composite of non‐fatal stroke, non‐fatal myocardial infarction, or death from any vascular cause." data-id="CD007858-fig-0025" src="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Intensive versus standard blood pressure‐lowering, Outcome 3 Major vascular event (composite of non‐fatal stroke, non‐fatal myocardial infarction, or death from any vascular cause. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/references#CD007858-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007858-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/urn:x-wiley:14651858:media:CD007858:CD007858-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_t/tCD007858-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Intensive versus standard blood pressure‐lowering, Outcome 4 Ischaemic stroke." data-id="CD007858-fig-0026" src="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Intensive versus standard blood pressure‐lowering, Outcome 4 Ischaemic stroke. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/references#CD007858-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007858-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/urn:x-wiley:14651858:media:CD007858:CD007858-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_t/tCD007858-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Intensive versus standard blood pressure‐lowering, Outcome 5 Haemorrhagic stroke." data-id="CD007858-fig-0027" src="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Intensive versus standard blood pressure‐lowering, Outcome 5 Haemorrhagic stroke. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/references#CD007858-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007858-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/urn:x-wiley:14651858:media:CD007858:CD007858-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_t/tCD007858-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Intensive versus standard blood pressure‐lowering, Outcome 6 Myocardial infarction." data-id="CD007858-fig-0028" src="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Intensive versus standard blood pressure‐lowering, Outcome 6 Myocardial infarction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/references#CD007858-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007858-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/urn:x-wiley:14651858:media:CD007858:CD007858-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_t/tCD007858-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Intensive versus standard blood pressure‐lowering, Outcome 7 Vascular death." data-id="CD007858-fig-0029" src="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Intensive versus standard blood pressure‐lowering, Outcome 7 Vascular death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/references#CD007858-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007858-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/urn:x-wiley:14651858:media:CD007858:CD007858-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_t/tCD007858-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Intensive versus standard blood pressure‐lowering, Outcome 8 Death by any cause." data-id="CD007858-fig-0030" src="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 Intensive versus standard blood pressure‐lowering, Outcome 8 Death by any cause. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/references#CD007858-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/media/CDSR/CD007858/image_n/nCD007858-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD007858-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Blood pressure‐lowering drugs (BPLDs) compared to placebo or no treatment for preventing recurrent stroke, major vascular events, and dementia in patients with a history of TIA or stroke</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Blood pressure‐lowering drugs (BPLDs) compared to placebo or no treatment for preventing recurrent stroke, major vascular events, and dementia in patients with a history of TIA or stroke</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with a history of TIA or stroke </p> <p><b>Settings:</b> in hospital or community </p> <p><b>Intervention:</b> BPLDs </p> <p><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)<br/> Follow‐up</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo or no treatment</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with BPLDs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrent stroke of any type</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>35,110<br/> (8 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.81<br/> (0.70 to 0.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 fewer per 1000<br/> (30 fewer to 7 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Time to recurrent stroke</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>26,889<br/> (3 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.82<br/> (0.65 to 1.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not available</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not available</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major vascular event (composite of non‐fatal stroke, non‐fatal myocardial infarction, or death from any vascular cause) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>28,630<br/> (4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.90<br/> (0.78 to 1.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>151 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 fewer per 1000<br/> (33 fewer to 6 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Myocardial infarction</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>34,747<br/> (6 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.90<br/> (0.72 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 fewer per 1000<br/> (6 fewer to 2 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Vascular death</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>34,747<br/> (6 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.85<br/> (0.76 to 0.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47 per 1.000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 fewer per 1000<br/> (11 fewer to 2 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Death by any cause</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>35,110<br/> (8 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.98<br/> (0.91 to 1.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 fewer per 1000<br/> (7 fewer to 4 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Dementia</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>6671<br/> (2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.88<br/> (0.73 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 fewer per 1000<br/> (18 fewer to 4 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>BPLDs</b> : blood pressure‐lowering drugs; <b>CI:</b> confidence interval; <b>HR</b> : hazard ratio; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>We downgraded the quality of evidence for the outcomes 'recurrent stroke of any type', and 'death by any cause' because multiple studies with a high or unclear risk of bias were included for these outcomes. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Blood pressure‐lowering drugs (BPLDs) compared to placebo or no treatment for preventing recurrent stroke, major vascular events, and dementia in patients with a history of TIA or stroke</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/full#CD007858-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007858-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Recurrent stroke of any type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.70, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Time to recurrent stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26889</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.65, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Major vascular event (composite of non‐fatal stroke, non‐fatal myocardial infarction, or death from any vascular cause <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.78, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Ischaemic stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26701</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.70, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Haemorrhagic stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26437</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.39, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34747</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.72, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Vascular death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34747</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.76, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Death by any cause <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.91, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Dementia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6671</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.73, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Blood pressure baseline (systolic) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.39, 0.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Blood pressure baseline (diastolic) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.22, 0.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/references#CD007858-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007858-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment (subgroups)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Recurrent stroke of any type by baseline systolic blood pressure (SBP) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6656</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.64, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 SBP &lt; 120 mmHg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.47, 2.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 SBP 120 ‐ 139 mmHg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.67, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 SBP 140 ‐ 159 mmHg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2565</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.57, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 SBP &gt; 160 mmHg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1954</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.51, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Recurrent stroke of any type by intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.70, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 ACE inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.64, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Angiotensin receptor antagonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.87, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Beta‐blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.75, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.18, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Diuretics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.59, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Recurrent stroke of any type by type of index event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5854</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.64, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 TIA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.50, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Ischaemic stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.64, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Intracerebral haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>611</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.39, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Combined Ischaemic stroke and Intracerebral haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Major vascular event by intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.78, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 ACE inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.68, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Angiotensin receptor antagonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.88, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Beta‐blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.84, 1.21]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment (subgroups)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/references#CD007858-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007858-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment (sensitivity analyses)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Recurrent stroke of any type, methodological quality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29082</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.75, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Recurrent stroke of any type, minimum 5 mmHg systolic blood pressure (SBP) reduction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33575</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.68, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Recurrent stroke of any type, minimum 3 mmHg diastolic blood pressure (DBP) reduction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.72, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Recurrent stroke of any type, excluding patients with subarachnoid haemorrhage as possible index event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.70, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Blood pressure‐lowering drugs (BPLDs) versus placebo or no treatment (sensitivity analyses)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/references#CD007858-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007858-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Intensive versus standard blood pressure‐lowering</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Stroke of any type (fatal and non‐fatal) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3632</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.63, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Time to recurrent stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.64, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Major vascular event (composite of non‐fatal stroke, non‐fatal myocardial infarction, or death from any vascular cause <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3632</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.23, 1.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Ischaemic stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.67, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Haemorrhagic stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.17, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3632</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.58, 1.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Vascular death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3549</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.56, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Death by any cause <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3632</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.83, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9 Dementia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Intensive versus standard blood pressure‐lowering</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007858.pub2/references#CD007858-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007858.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD007858-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD007858-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007858-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD007858-note-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD007858-note-0005">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD007858-note-0003">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD007858-note-0002">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007858\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007858\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007858\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007858\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007858\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007858\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007858\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007858\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007858\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007858\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007858\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007858\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007858\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007858\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007858\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007858\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007858\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007858\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=cdmLYOAV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007858.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007858.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007858.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007858.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007858.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724413738"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007858.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724413742"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007858.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e62383ecaf3fd',t:'MTc0MDcyNDQxNC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 